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The Policy Research Unit in Economic Evaluation of Health and Care interventions is funded by the 
Department of Health Policy Research Programme. It is a collaboration between researchers from 
the University of Sheffield and the University of York.  
The Department of Health's Policy Research Unit in Economic Evaluation of Health and Care 
Interventions is a 7 year programme of work that started in January 2011.  The unit is led by 
Professor John Brazier (Director, University of Sheffield) and Professor Mark Sculpher (Deputy 
Director, University of York) with the aim of assisting policy makers in the Department of Health to 
improve the allocation of resources in health and social care. 
This is an independent report commissioned and funded by the Policy Research Programme in the 
Department of Health. The views expressed are not necessarily those of the Department. 
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Acronym Definition 
ACS Acute coronary syndrome 
AE Adverse events 
AF Atrial Fibrillation 
AFTEQ Atrial Fibrillation Effect on Quality Of Life questionnaire 
AIC Academic in confidence 
AVB Atrioventricular block 
BI Barthel Index 
BP Blood pressure 
CABG Coronary artery bypass graft 
CCAD Central Cardiac Audit Database  
CCSC Canadian Cardiovascular Society grading scale 
CES-D Center for Epidemiological Studies depression scale 
CHD Coronary heart disease 
CHF Congestive heart failure 
CRM Cardiac rhythm management 
CRT Cardiac resynchronisation therapy 
CRT-D Cardiac resynchronisation therapy defibrillator 
CRT-P Cardiac resynchronisation therapy pacemaker 
CVD Cardiovascular disease 
DES Discrete event simulation model 
DH Department of Health 
ECG Electrocardiogram 
EQ-5D EuroQol 5 dimensions 
EQ-5D-5L EuroQol 5 dimensions 5 Levels 
ES Effect size(s) 
FR Future research 
GMC General Medical Council 
GP General practitioner 
GRACE Global Registry of Acute Cardiac Events 
IC Intra-cranial 
ICC Intraclass correlation 
ICD Implantable cardioverter defibrillators 
HRQoL Health related quality of life   
HR Hazard Rate 
HS Health states 
HTA(s) Health technology assessment(s) 
HUI2 Health Utility Index mark 2 
HUI3 Health Utility Index mark 3 
KCCQ Kansas City Cardiomyopathy Questionnaire 
LVEF Left ventricular ejection force 
LVSD Left ventricular systolic dysfunction 
MA Meta-analysis 
MCS Mental component summary 
MCT Mixed treatment comparison 
MLHF Minnesota Living with Heart Failure questionnaire 
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MRS Modified Rankin scale 
MTA Multiple technology assessment 
MI Myocardial infarction 
MINAP Myocardial ischaemia national audit project 
NACRM National audit of cardiac rhythm management 
NACSA National adult cardiac surgery audit 
NAPCI National Audit of Percutaneous Coronary Interventional Procedures 
NCA National Clinical Audit 
NHFA National Heart Failure Audit 
NHS National Health Service 
NICE National Institute for Health and Care Excellence 
NSTEMI Non- ST elevation myocardial infarction 
NVAF Non-Valvular Atrial Fibrillation 
NYHA New York Heart Association classification 
ONS Office of National Statistics 
OPT Optimal pharmacologic therapy 
OR Odds ratio 
PCI Percutaneous  coronary intervention 
PCS Physical component summary 
PCT Primary care trust 
PR Potential recommendations 
PROM(s) Patient reported outcome measure(s) 
QALY(s) Quality adjusted life year(s) 
QLMI Quality of life after myocardial infarction 
R&D Research and development 
RCT Randomised controlled trial 
SCD Sudden cardiac death 
SF-36 Short form 36 Health Survey 
SF-6D Short form 6 dimensions 
SF-12D Short form 12 dimensions 
SG Standard gamble 
SR Systematic review 
SRM Standardised response mean(s) 
SSS Sick sinus syndrome 
STEMI ST elevation myocardial infarction 
STA Single technology assessment 
TA(s) Technology Appraisal(s) 
TAG Technology Assessment group 
TIA Transient ischaemic attack 
TIMI Thrombolysis in Myocardial Infarction 
TLR Target lesion revascularisation 
TVR Target vessel revascularisation 
TTO Time trade off 
UK United Kingdom 
US United States 
VAS Visual analogue scale 
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WP Work package 
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1. BACKGROUND 
EEPRU was approached by Jason Cox (R&D Division) to prepare a programme of research to support 
the appropriateness of, and use of, patient reported outcome measures (PROMs) collected for the 
National Clinical Audit (NCA).  The EEPRU programme was informed by a R&D template prepared by 
Simon Bennett, Steve Fairman and Keith Willett at NHS England. 
 
The purpose of introducing PROMs into the NCA programme is to be able to 1) compare 
performance between providers and commissioners in the National Health Service (NHS), 2) 
compare the cost-effectiveness of alternative providers in delivering the specific services (i.e. linking 
outcomes and resource use), and 3) assess the cost-effectiveness of alternative interventions and 
other changes in the NHS.  The intention is to introduce PROMs across a range of conditions over the 
next 3 years commencing with 13 conditions in the 2014/15 NCA programme.  
 
The agreed research programme consists of 3 concurrent work packages (WP) as described in the 
document submitted to the DH (8
th
 November 2013).  The current document provides details on the 
objectives, methodology and results for Work Package 1 (WP1): to determine what PROMS should 
be used in the 13 health conditions specified in the 2014/15 NCA programme. 
 
2. OVERVIEW 
WP1 is split into three separate components consisting of: 
WP1.1 To examine whether the EQ-5D is appropriate in the 13 health conditions specified in the 
2013/14 NCA programme.  
WP1.2 To identify what measure could be used when the EQ-5D is not appropriate in the 13 health 
conditions, taking into account that the proposed measure would be used to generate 
preference-based utility measures (either directly through existing preference-based weights, 
or indirectly through existing mapping functions suitable for the proposed measure). 
WP1.3 To identify the evidence required to address questions of cost-effectiveness using the NCA 
data. 
 
Each component consists of a series of reviews of the literature. 
 
This Appendix provides the detailed results for the cardiovascular disease (CVD), which include 
cardiac arrhythmia, heart failure (HF), coronary angioplasty, cardiac surgery and acute coronary 
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syndrome (ACS), and should be read in conjunction with both the main report and the 
methods/search strategy appendices. 
 
3. METHOD 
The full detailed methodology used is provided in Appendix A, including the search strategy, 
selection criteria for studies included, and data extraction etc.  In summary, for each included 
cardiovascular condition a review of the literature was undertaken to assess the appropriateness of 
the EQ-5D in terms of classic psychometric criteria (WP1.1); where the EQ-5D was not considered 
appropriate, additional searches were undertaken to identify alternative measures (WP1.2); and 
finally, existing health technology appraisals were reviewed and data requirements were compared 
with variables currently collected in the CVD audits (WP1.3).   
 
3.1 Psychometric properties (WP1.1) 
Assessments reported in the included studies were categorised according to the following 
definitions: 
 
Acceptability 
Data relating to how acceptable the measure was to the person completing it, expressed as the 
proportion of completed surveys, or the proportion of missing data. 
 
Reliability 
There are two main definitions for reliability, a) the degree to which a measure reproduces the same 
results in an unchanged population and b) the degree to which a measure reproduces the same 
results when completed by different assessors (e.g. patient and proxy report). In both cases, 
reliability can be assessed by re-testing, and calculating the correlations or difference between tests. 
In case a) the comparison may be between the same populations separated by time, where no 
change in health state was observed (as compared to using an alternative condition specific or 
generic measure). In case b) the measure may be completed by multiple people (proxies) on the 
ƉĂƚŝĞŶƚ ?Ɛ ďĞŚĂůĨ ĂŶĚ ƚŚĞŝƌ ƌĞƐƉŽŶƐĞƐ ĐŽŵƉĂƌĞĚ ǁŝƚŚ ƚŚŽƐĞ ŽĨ ƚŚĞ ƉĂƚŝĞŶƚ ? tŚĞƌĞ ƚŚĞ ŽƵƚĐŽŵĞ
measure is specifically designed for self-report by patients, this test of reliability may be expected to 
produce less agreement.  
 
Construct validity 
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This is an assessment of how well an instrument measures what it intends to measure. Two main 
definitions are used in this review.  
a) Known group validity, where estimates for groups that are known to differ in a concept of interest 
are compared either qualitatively or statistically. The known groups may be defined using other 
measures, according to clinical categorisation.  
b) Convergent validity assesses the extent to which a measure correlates with other measures of the 
same or similar concepts. Correlation coefficients were considered low if <0.3, moderate if between 
0.3 and 0.5, and strong when >0.5.  
 
Responsiveness 
a) Change over time. This is an assessment of whether measurements using the instrument can 
detect a change over time, where a change is expected. This may be before and after an 
intervention, or through progression of a disease. Evidence was considered to be good where a t-
test was significant, though weaker evidence to support responsiveness was considered where there 
was a change in the expected direction, but was not statistically significant or not tested. Effect size 
and standardised response mean were also acceptable assessments of responsiveness.  
b) Ceiling and floor effects were also considered to be indicators of responsiveness. Assessments of 
ceiling effects include the proportion of patients who score full health within a group of patients 
with known health detriments. A ceiling or floor effect can affect the sensitivity of the measure in 
detecting changes over time in patients at the extremes of the measure (for example those with 
severe disease activity and those with just minor symptoms of the condition). 
 
3.2 Alternative measures (WP1.2) 
As the EQ-5D was found to be acceptable for CVD conditions, no additional searches for alternative 
measures were conducted. 
 
3.3 Evidence required for economic evaluations (WP1.3) 
The existing Health technology assessments (HTAs) were reviewed by CVD condition alongside the 
variables currently collected for each relevant NCA to determine if clinical or PROM data routinely 
collected in the NCAs would suffice to address questions of cost-effectiveness, and to identify any 
gaps in the evidence that would be required to compare providers, or the cost-effectiveness of 
interventions or policies. 
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4.  RESULTS FOR CARDIAC ARRHYTHMIA 
4.1 Evidence of appropriateness of EQ-5D in cardiac arrhythmia (WP1.1) 
Evidence of the appropriateness of the EQ-5D is presented jointly for all CVD conditions considered 
in this Appendix. This was considered to be an appropriate way to present results, given i) the 
paucity of evidence available for each individual cardiovascular condition, and ii) the existence of 
some overlap of the study populations as defined by the CVD conditions (e.g. acute coronary 
syndrome (ACS)) patients can be treated with coronary angioplasty or cardiac surgery, such as 
coronary artery bypass graft (CABG). Evidence relevant to each individual cardiovascular condition is 
discussed in Section 4.1.5.  
 
4.1.1 Selection of systematic review for CVD conditions 
Two systematic reviews were identified through expert sources (1;2), and one (3) from the 
Longworth et al. review.(4)  The process of selection of the most appropriate review is documented 
in Table 1. 
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Table 1: Selection of most appropriate review for cardiovascular conditions  
Review Search date Relevance of 
review 
Quality of 
search 
Quality of 
review 
Selection 
Oxford (2009)(1) August 2008 Question 
relevant, but 
too little data 
provided 
Reliance on 
pre-existing 
database, with 
additional 
searches, but 
full strategy 
not provided 
(available on 
request).  
No QA; search 
numbers 
provided; 
unclear 
reviewers SS, 
and DE; 
synthesis 
unclear 
Exclude  W less 
recent than 
Dyer; less 
psychometric 
detail than 
Dyer 
Oxford (2010)(2) July 2009 Question 
relevant, some 
detail provided 
Reliance on 
pre-existing 
database, with 
additional 
searches. Full 
strategy 
provided in 
appendix. 
No QA; details 
of search 
numbers 
provided; 
unclear 
reviewers SS, 
and DE, but at 
least 2 
reviewers; 
synthesis 
unclear 
Exclude  Wless 
psychometric 
detail than 
Dyer 
Dyer et al(2010)(3) October 2008 Question 
relevant, some 
detail provided 
EMBASE, 
MEDLINE, And 
EuroQoL site 
searched, 
reference lists 
also searched. 
Search strategy 
described 
briefly (full 
search strategy 
NR) but 
available from 
authors. 
No QA; details 
of search 
numbers 
provided; 
unclear SS and 
DE by 
reviewers, 
limited 
reporting of 
results and 
discrepant 
results not 
explained. 
Include  
QA, quality assessment; DE, data extraction; SS, study selection; NR, Not reported 
 
4.1.2 Structured abstract for Dyer et al 2010 (3) 
Purpose of review 
Amongst other aims that are not relevant to WP1.1, the review aimed to synthesise the evidence on 
the validity and reliability of the EQ-5D in studies in CVD. The considerations in this abstract focus on 
the sections of the review that relate to WP1.1 only.(3) 
 
Methods of review 
Search and study selection: EMBASE and MEDLINE (database host platform used was unclear), the 
EuroQoL website. Electronic searches were conducted from January 1988 to October 2008, and 
combined, exploded or used medical subject headings relating to the CVD field and the EQ-5D as 
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follows:  ? ?ĐĂƌĚŝŽǀĂƐĐƵůĂƌ ? ?ĞǆƉ OR  ‘ĐĂƌĚŝŽǀĂƐĐƵůĂƌ ? ?OR  ? ?ĐĂƌĚŝĂĐ ? ?exp OR  ‘ĐĂƌĚŝĂĐ ? ?OR 
 ? ?ĐĂƌĚŝŽůŽŐǇ ? ?ĞǆƉ OR  ‘ĐĂƌĚŝŽůŽŐǇ ? ?AND  ‘ĞƵƌŽƋŽů ? OR  ‘Y  ? ?OR  ‘Y ? ? ? However, the full search 
strategies were not reported and exact terms used in the research database searches were not 
provided. The EuroQol website was also used to identify unique references, including working 
papers and conference proceedings that may not have been captured in the initial literature search. 
The review included studies that presented original research and reported EQ-5D scores specific to 
cardiovascular disease or reported psychometric properties of the EQ-5D in a population with 
cardiovascular disease. Studies presented as abstracts only were excluded. The psychometric 
properties of EQ-5D examined in the review were validity (construct, convergent and discriminative), 
reliability and responsiveness. Studies that only reported EQ-5D (index or visual analogue scale 
(VAS)) scores graphically in terms of change over time were explicitly excluded from the review. In 
terms of disease area, all CVDs were included in the review.(3)  
 
Data extraction and synthesis: Data was extracted (unclear whether double data extraction or data 
checking performed) using a standard data abstraction form developed for the review. The 
psychometric properties were summarised according to the type of property assessed (namely 
validity, reliability and responsiveness), the comparison performed, the statistical test result, and 
included in tabular form in the Appendix. A narrative synthesis was performed according to the 
psychometric qualities mentioned above. The authors did not provide a conceptual description of 
each psychometric property, other than indicating that construct validity included convergent and 
discriminative validity. 
 
Results of the review   
Dyer et al. (2010)(3) included 10 articles which reported evidence on the measurement properties of 
the EQ-5D in CVD and included the following disease subgroups: ischaemic heart diseases (three 
studies), cerebrovascular diseases (three studies), HF (two studies), arterial embolism and 
thrombosis (one study) and peripheral vascular disease (one study). The review results were 
presented according to psychometric properties of the EQ-5D instrument, rather than by disease 
subgroup. In the included studies the EQ-5D index and VAS scores and dimensions were compared 
against generic health related quality of life  (HRQoL) measures, namely the Health Utility Index 
mark 2 (HUI2), Health Utility Index mark 3 (HUI3), Short form 36 Health Survey (SF-36), Short form 
12 dimensions (SF-12) and Short form 12 dimensions preference-measure (SF-6D) (Appendix). The 
EQ-5D was also compared against disease specific HRQoL measures, such as the MacNew quality of 
life questionnaire, Kansas City Cardiomyopathy Questionnaire (KCCQ) and VascuQol. In addition, the 
EEPRU NCA Appendix K: Cardiovascular Disease 
Page 14 
 
studies also included the following clinical measurements of disease severity: the Barthel Index (BI), 
modified Rankin scale (MRS), the Center for Epidemiological Studies depression scale (CES-D), the 
New York Heart Association classification (NYHA) and the Canadian Cardiovascular Society grading 
scale (CCSC). 
 
The narrative synthesis was brief, and the level of detail of tabulated study results was limited. The 
authors report that three studies found moderate to strong agreement between the EQ-5D index 
and VAS and other generic HRQoL measures, demonstrating construct (convergent) validity of the 
EQ-5D.(5-7) For discriminative validity, the EQ-5D was reported to be less sensitive to the detection 
of clinical change than disease specific measures, namely the KCCQ and NYHA, and to perform better 
at detecting larger compared to smaller clinical changes, based on the findings of one study.(8) The 
review also indicated that there was evidence of strong ceiling effects for EQ-5D domains and index 
values, based on two studies.(5;9) Finally, it was reported that the EQ-5D showed good reliability 
and responsiveness compared to other generic measures, namely the SF-12, but was less responsive 
than disease specific measures such as the KCCQ, according to two studies.(10;11) 
 
Review ĂƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ 
The authors of the review concluded that the assessment of the validity and reliability of the EQ-5D 
suggested fairly strong convergent validity with other HRQoL measures and good discriminative 
abilities in detecting patients whose health status changed by a given clinical magnitude. They also 
concluded that there was evidence of strong ceiling effects across each health dimension and for the 
index values. Finally, they concluded that EQ-5D could be used by clinicians to evaluate the impact of 
cardiovascular disease on patients and to inform decision making and resource allocation. 
 
4.1.3 Assessment of review in relation to objectives of WP1.1 
Relevance of review question: One of the aims of Dyer et al, namely to synthesise the evidence on 
the validity and reliability of EQ-5D in studies in CVD, is consistent with the aims of WP1.1.(3) 
However, CVD is a wider disease group than the individual CVD conditions considered within this 
ǁŽƌŬ ƉĂĐŬĂŐĞ ? ĂŶĚ ǇĞƌ Ğƚ Ăů ?Ɛ ĐĂƚĞŐŽƌŝĞƐ ǁĞƌĞ ŶŽƚ ĂůǁĂǇƐ ĐŽŵƉĂƚŝďůĞ ǁŝƚŚ ƚŚŽƐĞ ŽĨ tW ? ? ? ?ACS 
would be included within the ischaemic diseases subgroup and there was direct correspondence in 
the case of HF. However, it was unclear whether coronary angioplasty and adult cardiac surgery 
were captured within the ischaemic heart disease subgroup. The remaining subgroups in the review 
(cerebrovascular diseases, arterial embolism and thrombosis, and peripheral vascular disease) did 
not correspond to any of the CVD conditions in WP 1.1. 
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Assessment of review quality: Dyer et al. (2010)(3) scored poorly against the relevant AMSTAR 
criteria. It was unclear whether an a priori design was used, as no reference was made to it within 
the review. The studies included in the review do not appear to have been subjected to quality 
assessment, and therefore, this was not taken into account when formulating conclusions. 
Furthermore, it was not stated how data extraction and data checking were conducted, and the 
number of reviewers involved in the process. 
 
Acceptability of the search: Overall, the reported approach, combination of cardiovascular keywords 
with EQ-5D, and sources searched by the review authors was considered appropriate for the 
purpose of the review.  It was not possible to comment on the database search strategy given that 
full strategies were not provided in the review. 
 
Acceptability of study selection: The selection criteria were well described and were in accordance 
with the aims of WP1.1. In a small deviation from the selection criteria of WP1.1, studies published 
as abstracts only were excluded, as were studies that only presented data graphically. However, 
overall, the included studies were in accordance with the inclusion criteria of WP1.1, and there is 
only a small risk of having missed studies.  
 
Adequacy of available data and synthesis:  The data reported in the review was insufficient to 
adequately inform W.P1.1, as not all relevant results from the included studies were reported or 
discussed in the review.  Moreover, the main text of the review referred mostly to favourable 
evidence on the performance of the EQ-5D. The authors did not discuss seemingly discrepant results 
or the reasons why results might be in disagreement. The review authors did not comment on the 
amount of evidence available to assess each of the psychometric properties of EQ-5D under analysis, 
other than to state that most studies assessed convergent validity. As the number of patients in each 
study was not reported in the review, it was not possible to make strong statements regarding the 
amount of evidence available. Nevertheless, based on the number of studies used it would appear 
that less evidence was available to assess the reliability and responsiveness of EQ-5D, which may 
limit the robustness of conclusions regarding these characteristics. Another limitation of this review, 
given the wider objective of work package 1.1, is that the available evidence was not examined in 
terms of the individual cardiovascular conditions. Examining the results across the CVD subgroups in 
the review, and with the caveat that the number of patients in each study was unknown, the 
amount of evidence seems to differ considerably. There were no studies examining convergent 
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validity in HF, with only discriminative validity and responsiveness being assessed for this condition. 
Ischaemic heart diseases and cerebrovascular diseases were the disease subgroups with more 
psychometric properties of EQ-5D assessed, and also with more included studies. One of the 
cardiovascular conditions for WP 1.1, cardiac arrhythmia was not covered by the studies included in 
the review. This appeared to be due to a lack of available evidence on psychometric properties of 
EQ-5D in cardiac arrhythmia, given that studies in this condition were included for the other 
objectives of the review.  Other conditions, such as adult cardiac surgery and coronary angioplasty 
may have been included and grouped under the ischaemic heart diseases subgroup, but the 
information in the review was too limited to be sure of their inclusion within wider disease 
subgroups (e.g. ischaemic diseases). Similarly to cardiac arrhythmias, studies on adult cardiac 
surgery and coronary angioplasty were included for the other objectives of the review, thus it was 
anticipated that the potential non-inclusion of studies on the psychometric properties of EQ-5D in 
these conditions was due to lack of available evidence. The studies on cerebrovascular diseases, 
arterial embolism and thrombosis, and peripheral vascular diseases would not have been included 
according to the WP1.1 inclusion criteria, as they did not correspond to any of the CVD conditions of 
interest. Thus, the number of included studies would have been reduced to five, which reduced 
considerably the amount of evidence that was available for the purposes of WP1.1. Finally, the 
review did not aim to assess the acceptability of the EQ-5D in patients with CVD, which was a 
psychometric property of interest for WP 1.1.  
 
The above mentioned limitations of the review in terms of data reporting, formulation of 
conclusions and lack of absolute correspondence between included CVD conditions determined the 
need for remedial action. Thus, all studies were re-considered for inclusion, and a search was 
conducted for the period between 2008 to March 2013, so as to update the review with any other 
primary studies that might provide relevant data to the review.  A detailed data extraction and 
synthesis of all studies was also performed.  All related tables are provided in the Appendix. 
 
4.1.4 Reanalysis and update of Dyer et al. 2010(3) 
Of the 10 studies initially included in the review, 5 met the inclusion criteria of WP1.1.(5;6;8-10) The 
updated search identified 18 studies of potential relevance to the review for which the full text was 
obtained.  Only 7 of these studies met the criteria for inclusion in this review.(12-18) As such, a total 
of twelve studies were included in this reanalysis and update. The excluded articles are listed in 
Appendix B with reasons for exclusion.  
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Given the paucity of evidence available for each individual CVD condition, as well as the existence of 
some overlap of the study populations as defined by the CVD conditions (e.g. ACS patients can be 
treated with coronary angioplasty or cardiac surgery, such as CABG), the results were presented for 
CVD, and the overall evidence was discussed. Notwithstanding, the available evidence by each 
individual conditions is also discussed in Section 4.1.5.  
 
Five of the studies assessed the psychometric properties of the EQ-5D in ACS.(5;6;13;18;19)   The 
studies were conducted in Germany,(5) United States (US),(6) several European countries(18;19), 
and Turkey.(13) Different tariffs were applied to estimate the EQ-5D index score across the studies. 
Schweikert et al (2006) applied the Greiner et al (2003) European tariff,(20) Nowels et al (2005),  De 
Smedt et al (2013) and De Smedt et al (2014) applied the UK standard tariff,(21) and it was not 
reported which tariff was applied in Sut et al. (2011). The European tariff is not comparable to UK 
tariff as the former has values in a considerably different range (0-100).(20) Therefore, only results 
referring to the health dimensions of EQ-5D, and not to the index were reported for Schweikert et al 
(2006) in this review. 
 
Five of the studies assessed the psychometric properties of the EQ-5D in HF.(8;10;14-16) The studies 
were conducted in the US and Canada,(8;10;14;16) and Greece.(15) Most of these studies(8;10;15) 
applied  the UK standard tariff(21) to estimate the EQ-5D utility score, whereas one study(16) 
applied the US specific tariff(22) and another did not report which tariff was applied.(14)  
 
One of the studies examined the acceptability of EuroQol 5 dimensions 5 Levels (EQ-5D-5L) in 
cardiac arrhythmia.(17) The study was conducted in the UK, and the EuroQoL EQ-5D-5L crosswalk 
was used to estimate the utility score (but it was unclear which country tariff was applied). 
 
Four of the studies assessed the psychometric properties of the EQ-5D in a patient population that 
included more than one CVD condition in WP1.1. There were three studies that included ACS, 
coronary angioplasty and cardiac surgery, and one study that included coronary angioplasty and 
cardiac surgery.(9) The van Stel et al (2006) was conducted in the Netherlands, and applied the UK 
tariff to estimate EQ-5D index scores.(21) 
 
The results for analyses conducted on the EQ-5D health dimensions and EQ-5D index scores are 
reported below by psychometric property assessed, with considerations regarding individual 
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conditions presented in Section 4.1.5.  Study characteristics and results are tabulated in the 
Appendix.  
 
Acceptability: One study assessed the acceptability of EQ-5D(5) by estimating the proportion of 
missing and invalid responses, which ranged between 0.6 to 2.9% within the study follow-up (up to 
three months after discharge from the hospital), and performed slightly better on this property than 
SF-36 (missing range 1.5 to 6.5%) (Appendix). Withers et al,(17) assessed the acceptability of a PROM 
tool that included the EQ-5D-5L questionnaire, as well as two other disease-specific HRQoL 
questionnaires. The initial return rate of complete responses for the PROM tool ranged from 45 to 
50%, across centers in the study. Following reminders to non-responders, the response rate went up 
to 71.2% for the full sample.(17) In another study,(9) acceptability was not formally assessed, but 
the percentage of missing data by instrument was reported (Appendix), with EQ-5D having less 
missing data than SF-6D at both time points (baseline 9.1% vs. 15.9%; post-intervention 15.9% vs. 
22.6%). Acceptability could not be assessed from the data reported in the remaining studies, as 
analyses were mostly based on patients that completed the different questionnaires.  
 
Reliability: One study reported results for test/retest reliability for patients who reported no change 
in health status by estimating the proportion of agreement and kappa statistics within two time 
periods (period 1 from admission to discharge, and period 2 from discharge to three months 
afterwards).  Patients were identified as not having experienced change within periods according to 
Ă ‘ƚƌĂŶƐŝƚŝŽŶƋƵĞƐƚŝŽŶ ?ŝŶƚŚĞƋƵĞƐƚŝŽŶŶĂŝƌĞƵƐĞĚĂƚĚŝƐĐŚĂƌŐĞĂŶĚƚŚƌĞĞŵŽŶƚŚƐƉŽƐƚ-discharge which 
explicitly asked whether patients felt better, worse, or unchanged compared with their previous 
situation. The mean duration of period 1 was not reported in the study. The proportion of 
agreement in patients who reported no change in period 1 (n=11/106) ranged from 55% for the 
health dimension usual care (kappa=0.17, p-value not reported) to 100% for the health dimension 
self-care (kappa=1.0), and for period 2 (n=32 to 34/106) ranged from 65% for the health dimension 
anxiety/depression (kappa=0.24, p-value not reported) to 88% for the health dimension self-care 
(kappa=0.53) (Appendix).(5) 
 
 
Construct validity (Convergent):  Seven studies reported results that provided some support for the 
convergent validity of the EQ-5D. One study compared the proportion of patients citing no problems 
in each EQ-5D health dimension in two subgroups (Myocardial infarction (MI) vs. CABG patients) for 
which quality of life was expected to be higher for MI patients.(5) With the exception of the health 
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ĚŝŵĞŶƐŝŽŶĂŶǆŝĞƚǇ ?ĚĞƉƌĞƐƐŝŽŶ ?ƉA? ? ? ? ? ? ? ?ƚŚĞƉĞƌĐĞŶƚĂŐĞŽĨƉĂƚŝĞŶƚƐŝŶĚŝĐĂƚŝŶŐ ?ŶŽƉƌŽďůĞŵƐ ?ĨŽƌƚŚĞ
EQ-5D health dimensions was significantly higher for MI than for CABG patients (p<0.05) (Appendix). 
Another study assessed the construct validity of the Turkish version of the EQ-5D by estimating the 
Spearman rank correlations of EQ-5D index with the MacNew questionnaire subscales (r: 0.557-
0.721, p<0.001) and global score (r=0.688, p<0.001) and considered the strong and significant 
correlations to be evidence of the validity of the instrument (Appendix).(13) van Stel et al (2006) 
estimated Spearman rank correlations between dimensions of the SF-6D and EQ-5D, and found 
moderate to strong correlations in related domains (r=0.31-0.47, p<0.0001) (Appendix).(9) De Smedt 
et al (2014) also found moderate to strong correlations in related health dimensions of EQ-5D and 
SF-6D (r=0.390-0.630, p<0.0001), as well as a strong correlation and moderate agreement between 
utility scores of both instruments (r=0.695, p<0.01; intraclass correlation (ICC)=0.536, p<0.01) 
(Appendix)(19). Nowels et al (1995) estimated the Spearman rank correlations between health 
dimensions of EQ-5D and the domains of two instruments, the SF-36 and the disease specific Quality 
of Life after Myocardial Infarction (QLMI). The correlations between similar health dimensions of the 
EQ-5D and SF-36 were strong (r=0.5-0.75), but significance was not reported. The correlations 
between EQ-5D and QLMI ranged from weak to strong (r= 0.01-0.64) across the comparison 
(Appendix), but were in general high for related dimensions with some exceptions (e.g. restriction 
and self-care; r=0.07).(6) The studies also assessed the convergence of the EQ-5D index with overall 
scores of other measures. Van Stel et al. (2006) reported the ICC between the EQ-5D and SF-6D 
utility scores (ICC=0.45) which was considered poor by the authors.(9) Kontodimopoulos et al (2011) 
found a similar ICC (0.484, p<0.0001), but a strong correlation between the two scores as estimated 
by the Pearson correlation coefficient (r=0.647, p<0.001).(15) In the Nowels et al (2005) study, the 
correlation between the EQ-5D index and the QLMI total score was strong (r=0.57), although 
significance was not reported.(6) The correlation between the EQ-5D index and SF-12 summary 
scores was also found to be strong (Physical component summary (PCS): r=0.64; Mental component 
summary (MCS): r=0.47; p<0.05) (Appendix)(18).  Garster et al (2009) examined the partial 
correlation (partial on age, race, and sex) between the EQ-5D utility scores and the CVD proxy scores 
described above for the coronary heart disease (CHD) subsample of the study. The correlation was 
negative (the CVD score decreased with increased HRQoL as expected) and strong (r=-0.65), but 
significance was not reported.(14) One study examined the association between EQ-5D health 
dimensions response level (no problems, moderate problems, severe problems) and median SF-36 
and McNew subscales at admission, i.e. by estimating median scores of comparable subscales by 
response levels of corresponding EQ-5D health dimensions.(5) The authors found that for all EQ-5D 
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dimension levels the median SF-36 and McNew subscales were ranked as expected and significantly 
different between groups (p<0.001, Kruskal-Wallis H test).(5) 
 
Construct validity (known group): One study examined known-group validity by assessing the 
relationship of EQ-5D with age, gender and education, using the Kruskall-Wallis test.  EQ-5D mean 
scores were found to be significantly different (p<0.001) for each category within age, gender and 
education level, and it confirmed the hypothesis that quality of life decreased with age, and lower 
education, and was lower for females (Appendix).(18)  Known-group validity was also assessed as 
discriminative ability by comparing subgroups of patients of different clinical severity. Nowels et al 
(2005) compared differences in EQ-5D index scores between two groups based on their CCSC scores 
(I vs. II, III, or IV), using Mann-Whitney rank-sum testing, which showed evidence of excellent 
discriminative ability between the two groups (p<0.001). The difference in means for the subgroups 
categorised as  CCSC I or CCSC II were also compared, and statistical difference was found using the 
Mann-Whitney rank-sum testing (p<0.05), but not with a t-test (p=0.1).(6) Garster et al (2009) 
examined the ability of EQ-5D to differentiate between subgroups classified by disease severity (no 
CHD, CHD no chest pain medication, and CHD plus chest pain medication).(14) The corresponding 
effect sizes (ES) were compared to a CVD proxy score derived from the Minnesota Living with Heart 
Failure questionnaire (MLHF). Significant differences in unadjusted mean EQ-5D scores (p<0.001, F-
ƚĞƐƚ ?ǁĞƌĞ ĨŽƵŶĚĨŽƌ  ‘EŽ, ?ǀƐ ?  ‘,ŶŽŵĞĚŝĐĂƚŝŽŶ ?  ?ĚŝĨĨĞƌĞŶĐĞA?-0.055 ?ĂŶĚ  ‘EŽ, ?ǀƐ ?  ‘,
ƉůƵƐŵĞĚŝĐĂƚŝŽŶ ? ?ĚŝĨĨĞƌĞŶĐĞA?-0.14). Similar results were found for mean scores adjusted by baseline 
characteristics.  ES for EQ-5D scores were lower (moderate to large ES: 0.32-0.84) than for the CVD 
proxy score (large ES: 0.51- ? ? ? ? ?ĂĐƌŽƐƐ ƐƵďŐƌŽƵƉĐŽŵƉĂƌŝƐŽŶƐ ?dŚĞĐŽŵƉĂƌŝƐŽŶďĞƚǁĞ Ŷ  ‘,ŶŽ
ŵĞĚŝĐĂƚŝŽŶ ?ǀƐ ? ‘,ƉůƵƐŵĞĚŝĐĂƚŝŽŶ ? yielded large ES for the CVD proxy score (0.62) and for EQ-5D 
(0.52). The authors considered that ES were in general of the same magnitude as for the CVD proxy 
score, and that generic indexes (which included other HRQoL instruments besides EQ-5D) could 
capture differences in HRQoL between populations with and without CHD.(14) 
 
Responsiveness (change over time): Spertus et al. (2005) examined groups with different degrees of 
clinical change over a 6 week period (mean 6.7 weeks, standard deviation 2.6) as assessed by a 
cardiologist (large (n=5), moderate (n=13), or small deterioration (n=35), no change (n=320), small 
(n=65), moderate (n=34), or large improvement (n=4)). The differences in mean changes in EQ-5D 
scores for subgroups of patients whose condition had changed were compared to stable patients 
using t-tests. The results were presented graphically for all measures (KCCQ, 6-minute walk test, EQ-
5D index, EQ-5D VAS, NYHA, SF-12 PCS and MCS, figure weight change, and B-type natriuretic 
EEPRU NCA Appendix K: Cardiovascular Disease 
Page 21 
 
peptide), and level of significance was indicated. Mean changes in EQ-5D scores for all change 
categories, except large deterioration, were small (absolute change smaller than 0.1) and not 
significant. The mean change score for the large deterioration category was significant (p<0.001) 
between minus 0.4 and minus 0.3 (graphical depiction). In the same study, responsiveness to clinical 
change was also compared between the measures by estimating c-statistics, which represent the  
percentage  of  times that the measure correctly identified patients with clinical change for all 
possible pairs of patients, one experiencing clinical change and one not. This was estimated for four 
categories (moderate to large deterioration, small deterioration, small improvement, moderate to 
large improvement), and results were presented graphically with only estimates for KCCQ and 6-
minute walk text being mentioned in the main text. From the graph, c-statistics for the EQ-5D index 
appeared to range from approximately 0.56 (for small clinical improvements) to approximately 0.69 
(for moderate to large clinical deterioration). The authors concluded that KCCQ and NYHA have 
better discriminative abilities than the EQ-5D index.(8) It is worth noting that it would have been 
more appropriate to estimate ES or standardised response means (SRM) for each of the change 
groups (and provide more comparable evidence) to assess responsiveness to clinical change than the 
methods used by the authors. Furthermore, the data is presented in a way that hinders comparison 
between measurements. Eurich et al (2006) assessed EQ- ? ?ƐƌĞƐƉŽŶƐŝǀĞŶĞƐƐƚŽĐůŝŶŝĐĂůĐŚĂŶŐĞŽǀĞƌ
a period of six weeks as defined by three separate criteria (change in NYHA classification, validated 
global rating of change assessment, and change in distance travelled in the 6-minute walk test), by 
estimating mean change scores in ES and SRM, amongst other statistics, for each degree of clinical 
change considered.(10) In this study, the same statistics were also estimated for KCCQ, EQ-5D VAS 
and RAND-12. The mean changes (statistical significance was not reported) in EQ-5D index over time 
across measures for individuals who had suffered clinical deterioration appeared to be smaller in 
general, when compared to those who improved their clinical status (Appendix).  However, 
differences in change scores for EQ-5D were small for all degrees of clinical change and across all 
clinical change criteria, and corresponding standard deviations were relatively large.  The EQ-5D 
appeared to be more responsive to higher degrees of clinical improvement, than to smaller clinical 
changes (both improvement and deterioration), according to NYHA and global rating of change, but 
this was less evident for the 6-minute walk test (Appendix). Nevertheless, the number of patients for 
the categories of larger improvement were very small (NYHA criteria, n=2; global rating of change 
criteria, n=7; 6-minute walk test, n=7) (Appendix), so results should be interpreted cautiously. The 
^ZDĞƐƚŝŵĂƚĞĚĨŽƌƚŚĞ  “ŶŽĐŚĂŶŐĞƐ ?ĐĂƚĞŐŽƌŝĞƐĂĐĐŽƌĚŝŶŐƚŽƚŚĞ NYHA criteria (SRM: 0.25, n=206) 
and the global rating of change criteria (SRM: 0.21, n=206) were all higher than for the 
corresponding estimates for moderate improvement (NHYA SRM: 0.11, n=50; global rating of change 
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SRM: 0.15, n=53), which seems counterintuitive (Appendix). The authors concluded that the HRQoL 
measures were more responsive to improvement than to deterioration in clinical status, and that 
responsiveness varied for the same generic HRQoL depending on which responsiveness indices and 
external criterion were used to identify clinical change.(10) 
 
Responsiveness of EQ-5D was also assessed in one study by comparing the degree of agreement in 
ĐůĂƐƐŝĨǇŝŶŐ ƉĂƚŝĞŶƚƐ ? ĐŚĂŶŐĞƐ ŝŶ ,ZYŽ> ĂƐ Ă ĐůŝŶŝĐĂůůǇ ƐŝŐŶŝĨŝĐĂŶƚ ŝŵƉƌŽǀĞŵĞŶƚ ? ĚĞƚĞƌŝŽƌĂƚŝŽŶ Žƌ
stability over a time period of 6 months compared with the MLHF.(16) The percentage of overall 
agreement was low (19%), and the k statistics also indicated lack of agreement (k=-0.25; weighted 
k=-0.3; n=86; p<0.05) (Appendix). The authors also compared the number of patients identified 
through EQ-5D as experiencing each type of change (improvement, no change, deterioration) in 
HRQoL by each type of change according to MLHF. The agreement was found to be low across 
similar categories (deterioration:  n=11 (EQ-5D) vs. n=46 (MHLF); stable: n=2 (EQ-5D) vs. n=13 
(MHLF); improvement: n=3 (EQ-5D) vs. n=27 (MHLF)), and there was also considerable disagreement 
in classifying changes in HRQoL with 16 patients experiencing a deterioration in HRQoL according to 
EQ-5D out of 27 patients being classified as showing improvement (Appendix).(16) Although this 
comparison can be considered methodologically naïve, and some of the sample sizes were extremely 
small, it provided some evidence against the responsiveness of EQ-5D that should not be ignored. 
 
Responsiveness (ceiling effects): van Stel et al (2006) examined the existence of potential ceiling 
effects in the health dimensions and index scores for the EQ-5D and SF-6D at baseline.(9) Despite 
ƚŚĞ ĐŽŶƐŝĚĞƌĂďůĞ ƉĞƌĐĞŶƚĂŐĞ ŽĨ ƉĂƚŝĞŶƚƐ ƌĞƉůǇŝŶŐ  ‘ŶŽ ƉƌŽďůĞŵƐ ? ƚŽ ŝŶĚŝǀŝĚƵĂů Y-5D health 
dimensions (ranging between 30.5% in usual activities to 93.1% in self-care), only 13.5% of patients 
scored full health on the EQ-5D compared to 0.4% on the SF-6D (Appendix). The authors considered 
that there was evidence of a ceiling effect for EQ-5D.(9) Another study, also found evidence of 
ceiling effects for EQ-5D, with 28.8% of patients reporting full health with this instrument compared 
to 4.2% with SF-6D (Appendix).(19)  
 
4.1.5 Conclusion of appropriateness of EQ-5D in CVD conditions  
Overall, the evidence base assessing the performance of the EQ-5D in CVD conditions is mostly 
positive, although relatively small with only twelve studies complying with the inclusion criteria for 
this review.  The acceptability of EQ-5D was fair to good in the three studies that assessed this 
property. Evidence regarding reliability was very limited and indicated poor performance.  
Nevertheless, reliability was examined in one study alone and only at health dimension level. 
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Construct validity (convergent) between EQ-5D was generally good, and more evident at the index 
than at the health dimension level. This was the psychometric property for which there was more 
robust evidence, given the amount of evidence available and its general concordance. The available 
evidence in terms of construct validity also reinforced that the EQ-5D can distinguish between 
subgroups of patients of varying HRQoL, namely between MI and CABG patients.  There was 
considerable positive evidence of known-group validity across groups defined by age, gender and 
educational level, provided by a large European study that included more than 8,000 patients from 
22 countries.(18)  The ability of EQ-5D to distinguish between groups of different disease severity 
(according to cardiologist assessment or based on self-report) was found to be good. Finally, 
evidence on responsiveness as change over time was poor across the three studies that assessed it, 
but it should be noted that the methodology used to assess it, and in one case the reporting of 
results, was not the most adequate. It was concluded that the evidence on responsiveness is mostly 
uncertain, but studies so far suggest that EQ-5D may perform poorly in this characteristic. 
Importantly, the studies that assessed responsiveness as change over time were all conducted in a 
single disease condition, HF, so there is also a question of whether the poor performance in this 
condition is likely to extend to other CVD conditions. One study detected a ceiling effect, i.e. a 
tendency towards single level response, that was considerably more pronounced for individual 
health domains of EQ-5D (especially for self-care), than for the utility score.(9) Evidence of ceiling 
effects for EQ-5D utility scores was also found in a large European study.(19) This may translate into 
less discriminative ability of EQ-5D for patients at lower levels of disease severity. 
 
Six studies included in the review assessed the psychometric properties of EQ-5D in HF, and 
provided evidence of construct (both convergent and known-group) validity, but poor 
responsiveness. No other psychometric properties of EQ-5D were examined in HF. For ACS and 
cardiac surgery there was some evidence of the majority of all reported psychometric properties 
(with the exception of responsiveness), taken from five and four studies respectively. EQ-5D 
performed well in terms of acceptability and validity, but showed poor reliability. In the five studies 
in coronary angioplasty, EQ-5D performed similarly to what was found for ACS and cardiac surgery in 
the same properties. The only evidence found for cardiac arrhythmia refered to acceptability of EQ-
5D, which was considered good. The number of studies available and conclusions on evidence by 
condition and psychometric property assessed are summarised below in Tables 2 and 3. 
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Table 2: Number of studies reporting psychometric properties of EQ-5D in CVD 
Condition Acceptability Reliability 
Construct validity 
(Convergent) 
Construct validity 
(Known group) 
Responsiveness  
(Change over time) 
Responsiveness  
(Ceiling effects) 
Cardiac arrhythmia 1(17) 0 0 0 0 0 
Heart failure 0 0 3(13-15) 1(14) 3(8;10;16) 0 
Coronary angioplasty 1(9) 0 3 (23) (12;18) 1(18) 0 2 (19;23) 
Cardiac surgery 2(5;9) 1(5) 4 (18;19;23;24)  1(18) 0 2 (19;23) 
Acute coronary syndrome 1(5) 1(5) 5 (13;18;19;24;25) 2(18;25) 0 2(19;23)  
 
 
Table 3: Conclusions on evidence on psychometric properties of EQ-5D in CVD 
Condition Acceptability Reliability 
Construct validity 
(Convergent) 
Construct validity 
(Known group 
validity) 
Responsiveness 
 (Change over time) 
Responsiveness 
 (Ceiling effects) 
Cardiac arrhythmia Good NE NE NE NE  NE 
Heart failure NE NE Good Good  Poor NE 
Coronary angioplasty Fair  NE Fair/Good Good NE Potential ceiling effects 
Adult cardiac surgery Fair/Good Poor Fair/Good Good NE Potential ceiling effects 
Acute coronary syndrome Good Poor Good Good NE Potential ceiling effects 
NE
25 
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4.2 Routinely collected proxy measures in cardiac arrhythmia (WP1.2) 
As the EQ-5D was found to be acceptable for CVD conditions, no additional searches for alternative 
measures were conducted. 
 
4.3 Evidence for economic evaluations in cardiac arrhythmia (WP1.3) 
4.3.1 Cost-effectiveness modelling approach used in recent HTAs in cardiac arrhythmia 
Eight Technology appraisals (TAs) relating to cardiac arrhythmia were identified from the searches. 
One of the TAs was withdrawn,(26), and one of them is currently in development with anticipated 
issue date of June 2014.(27) Four of the TAs examined the clinical and cost-effectiveness of a 
pharmaceutical intervention in atrial fibrillation (AF),(28-31) while the other three assessed devices 
to manage cardiac arrhythmia.(27;32;33)  Three of TAs compared anti-coagulant drugs in the 
prevention of stroke and systemic embolism in atrial fibrillation (AF) patients,(28-30) and one 
compared anti-arrhythmic drugs for the treatment of AF and atrial flutter.  One of the TAs examined 
the clinical and cost-effectiveness of implantable cardioverter defibrillators (ICD) or cardiac 
resynchronisation therapy (CRT), in addition to optimal pharmacologic therapy (OPT) compared to 
OPT alone for the treatment of three patient populations: i) people with an increased risk of sudden 
cardiac death (SCD) as a result of ventricular arrhythmias: ii) people with HF (due to left ventricular 
systolic dysfunction (LVSD) and cardiac dyssynchrony); and iii) people with both conditions.(27) 
Another TA examined the clinical and cost-effectiveness of CRT for people with HF and evidence of 
dyssynchrony by comparing CRT pacemaker (CRT-P) and CRT defibrillator (CRT-D) devices each with 
OPT, and with each other.(32)  TA88 examined the clinical and cost-effectiveness of dual-chamber 
pacemakers compared to single chamber pacemakers for bradycardia due to atrioventricular block 
(AVB) or sick sinus syndrome (SSS).(33)  
 
All TAs except one used Markov models to examine the cost-effectiveness of the interventions under 
appraisal; the exception was TA197, which used a discrete event simulation model (DES).(31)  The 
Markov models used to assess anticoagulant therapy comprised of discrete health states 
representing the clinical pathway for AF patients at the point of intervention.  The number of health 
states varied across models from 4 to 23 discrete health states, corresponding mostly to the 
occurrence of thromboembolic, ischaemic and bleeding events, as well as stable states and 
death.(28;29)  One of the models defined the health states based on the level of disability (as 
measured by the MRS), with probabilities of future clinical events conditioned by disability level.(30)  
In three TAs transitions between states were modelled based on data from clinical trials (single trial 
data or estimates resulting from meta-analyses). All cause mortality was modelled based on UK 
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specific life tables, usually adjusted for CHADS2 score, which is a predictor of stroke risk. 
Cardiovascular mortality was generally informed by clinical trial data (baseline and relative risks).(28-
30) 
 
The DES model had 4 discrete health states (normal sinus rhythm, permanent AF with uncontrolled 
symptoms, permanent AF with controlled symptoms, and death), and clinical events included AF 
recurrence, ACS, stroke, congestive HF and changes in AF symptoms. Occurrence of events within 
the model was informed by survival analysis from clinical trial data. Treatment effects and adverse 
events rates were estimated through evidence synthesis of trial data.  All cause mortality was also 
based on UK life-tables, adjusted by CHADS2 scores. (31) 
 
Two of the models used to assess the cost-effectiveness of devices in cardiac rhythm management 
included discrete health states and key clinical events which represented the clinical pathway for 
people with HF (or with HF and increased risk of SCD) at the point of the intervention.  The number 
of health states varied across models from 4 to 28 discrete health states, depending on if the 
occurrence of clinical events was modelled as individual health states or grouped within health 
states.  Cardiovascular mortality (due to worsening of HF or SDC) was generally modelled using 
survival data from clinical trials (survival curves and hazard ratios). Other key clinical events 
encompassed hospitalisations, surgical complications, device related procedures (in TAs on CRT) and 
heart transplants, and their occurrence was generally modelled using trial data (relative risks). When 
trial data was not used, relative risks were estimated based on individual studies in the published 
literature or on evidence synthesis of trial estimates conducted within the TAs.(27;32)   Another TA 
used two separate Markov models to examine the cost-effectiveness of dual-chamber pacemakers 
compared to single chamber pacemakers for bradycardia. The clinical pathway was considered to 
differ according to underlying aetiology (SSS or AVB), hence the need for two separate models. Each 
model included numerous discrete health states that reflect main outcomes in each pathway 
following pacemaker insertion, and comprised of complications of insertion, remaining well with the 
pacemaker, developing  pacemaker syndrome (mild or severe), upgrade to dual chamber 
pacemaker, atrial fibrillation, HF, stroke generator expiry or death. The clinical event rates were 
sourced from clinical trial data (single trials and meta-analysis), and cardiovascular mortality was 
assumed to be constant in time and cause specific. (33) 
 
All of the studies quality adjusted survival by assigning mean utility values to the discrete health 
states. In the models in HF populations the utilities were sourced from the published literature, and 
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differed according to the NYHA classification for HF severity.(27;32)  The majority of TAs used EQ-5D 
data taken from the published literature as the main source of HRQoL estimates,(27-31) although 
one TA also used time trade-off and standard gamble elicited utility values to inform the model.(32) 
Another used mostly time trade-off elicited utilities from patients within a clinical trial.(33)  Across 
the TAs, HRQoL in patients with cardiac arrhythmia has been assumed to depend mostly on 
underlying coronary disease and its severity, complications subsequent to surgical procedures, 
symptoms, and adverse effects of anticoagulant drugs.(27-33)  Disability following stroke is another 
important aspect of HRQoL, especially in patients at increased risk of stroke, i.e. patients with AF, 
with assigned utility weights varying by level of disability. (28-30) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
28 
EEPRU NCA Appendix K: Cardiovascular Conditions 
Page 28 
 
Table 4: Summary of existing models in cardiac arrhythmia 
 Model approach Method used to model utilities  
MTA (ID:481): Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac 
resynchronisation therapy for the treatment of heart failure (review of TA95 and TA120); 2014(27)  
 TAG de-novo Markov model  
4 separate health states: stable, 
hospitalisation, transplanted and dead. 
Key clinical events: hospitalisation due to 
heart failure or arrhythmia, transplant, 
device failure, death, peri-operative 
complications of implant procedure, routine 
device replacements, lead displacement, 
infections, and device upgrades. 
Effectiveness: Survival curves for cardiac 
mortality (SCD and HF) RR risk for other key 
clinical events, treatment effects applied as 
RR reductions.  
Source: clinical RCTs , MA, published 
literature   
Utility: EQ-5D; mean values assigned to health 
states according to NYHA classes. 
Source: published literature, observational analysis 
of RCT data, assumptions
 
 
STA (TA275): Apixaban for the prevention of stroke and systemic embolism in people with non-valvular 
atrial fibrillation; 2012(28) 
 DĂŶƵĨĂĐƚƵƌĞƌ ?ƐDĂƌŬŽǀŵŽĚĞů ? ? ?separate 
health states: NVAF, ischaemic stroke 
(mild/moderate/severe/fatal); haemorrhagic 
stroke (mild/moderate/severe/fatal); non-
fatal or fatal other intracranial haemorrhage 
(i.e non-haemorrhagic stroke); non-fatal or 
fatal systemic embolism; non-fatal or fatal 
other major bleeds; clinically relevant non-
major bleeds; non-fatal or fatal MI; other 
cardiovascular hospitalisations. 
Effectiveness: HR of events applied to 
baseline risk (CHADS2 score adjusted); risk 
modified by HR of treatment effect; stroke 
severity distribution; type of bleed 
distribution. 
Source: Clinical RCT 
Utility: Mean EQ-5D; TTO elicitation; SG elicitation; 
assumptions. Applied to separate health states. 
Source: Published literature. 
STA (TA256 ): Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial 
fibrillation; 2012 (29) 
 DĂŶƵĨĂĐƚƵƌĞƌ ?ƐDĂƌŬŽǀŵŽĚĞů ?22 separate 
health states: stable AF; therapy initiation; 
off therapy stable, on therapy stable; 
systemic embolism; on therapy minor bleed; 
on therapy major bleed; on therapy minor 
stroke; on therapy major stroke; on therapy 
post-minor stroke; on therapy post-major 
stroke; on therapy minor bleed; on therapy 
major bleed; off therapy minor stroke; off 
therapy major stroke; off therapy post-minor 
stroke; off therapy post-major stroke; IC 
bleed; Post-IC bleed; MI; post-MI; death. 
Effectiveness: RR of events 
^ŽƵƌĐĞ PĐůŝŶŝĐĂůZdƐĂŶĚŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ
network MA 
Mean utilities: EQ-5D; TTO elicitation; Median 
utilities: SG elicitation- Utilities applied to stable 
states and stroke related events 
Source: published literature  
AE: Marginal decrement from major bleeding to 
utility (EQ-5D) associated with bleeding  events 
Source:  Published literature 
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STA (TA249):  Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation; 
2012 (30) 
 DĂŶƵĨĂĐƚƵƌĞƌ ?ƐDĂƌŬŽǀŵŽĚĞů ?4 separate 
health states: independent disability, 
moderate disability; dependent; death 
Key: clinical events: ischemic stroke; intra 
cranial haemorrhage; haemorrhagic stroke; 
extra cranial bleeds; systemic embolism; 
transient ischemic attack; and acute MI.  
Effectiveness: Baseline death risk 
 ?ĚĞƉĞŶĚĞŶƚŽŶ,^ ?ƐĐŽƌĞ ? ?ĞǀĞŶƚƐZZ ?
ĂŶĚƚƌĞĂƚŵĞŶƚĞĨĨĞĐƚƐ ?ZZ ?ůůĐĂƵƐĞ
mortality estimated from UK life tables 
adjusted for CHADS2 score 
^ŽƵƌĐĞ PĐůŝŶŝĐĂůZd ?ŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐDd ?
published literature. 
Utility: Mean EQ-5D values; TTO elicitation; 
assumptions. Applied to separate health states. 
Source: clinical RCT and published literature from 
RCT. 
AE: Marginal decrement from major bleeding to 
utility (EQ-5D) associated with bleeding  events 
Source:  Published literature and assumptions 
STA (TA197): Dronedarone for atrial fibrillation and atrial flutter; 2010 (31) 
 DĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ^ŵŽĚĞů ? ?ŵĂŝŶhealth 
states(normal sinus rhythm, permanent AF 
with uncontrolled symptoms, permanent AF 
with controlled symptoms and death) and 7 
events (AF recurrence, ACS, stroke, CHF, 
treatment discontinuation for any cause, AF 
symptoms change for permanent patient 
and death) 
Effectiveness: Survival analysis risk equations 
for clinical events. All cause mortality 
estimated from UK life tables adjusted for 
CHADS2 score. Treatment effects applied as 
ORs. 
Source:  clinical RCT, published literature, 
ŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐDd  
Utility: mean EQ-5D values assigned to health states 
Source: Observational study  
AE: utility decrements elicited by TTO in general 
public 
Source: AIC study conducted by manufacturer in 
127 subjects 
 
 
MTA (TA120): The effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) 
for heart failure; 2007(32)  
 TAG de-novo Markov model, with submodels 
for each device and OPT. 
28 separate health states reflecting the 
occurrence of the key clinical events: routine 
device replacements, peri-operative 
complications, infections, device upgrades, 
left lead dislodgments, hospitalisation due to 
heart failure, hospitalisation due to 
arrhythmia, heart transplant, surgical failure 
and death. 
Each health state in the model has a 
corresponding probability tree to model 
transition probabilities according to clinical 
events. 
Effectiveness: Survival curves for 
cardiovascular mortality (SCD and worsening 
of HF) by treatment, RR risk for other key 
clinical events with treatment effects applied 
as RR reductions.  
Source: clinical RCTs, published literature, 
expert opinion, assumptions. 
Utility: EQ-5D and TTO (elicited); mean values 
assigned according to NYHA classes; Utility on 
hospitalisation due to heart failure: SG (elicited) 
Source: published literature
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MTA (TA88):  The effectiveness and cost effectiveness of dual chamber pacemakers compared to single 
chamber pacemakers for bradycardia due to atrioventricular block or sick sinus syndrome: systematic 
review and economic evaluation; 2005(33)  
 2 TAG Markov models, according to the 
underlying cause of bradycardia (AVB or 
SSS);  numerous discrete health states that 
reflect main outcomes following pacemaker 
insertion, and include: complications of 
insertion, remaining well with the 
pacemaker; pacemaker syndrome (mild or 
severe); upgrade to dual chamber 
pacemaker; atrial fibrillation; heart failure; 
stroke; generator expiry or death. 
Effectiveness: Time-constant cardiovascular 
mortality rates, Events RR 
Source: clinical RCTs, MTC, published 
literature 
Utility: Mean utilities elicited through TTO and 
applied to health states; mean EQ-5D values; clinical 
expert elicitation. 
 
Source: clinical RCT, published literature. 
 
AE: Adverse Events; MTA: Multiple Technology Appraisal; STA: Single Technology Appraisal; MA: Meta-
analysis TAG: Technology Appraisal Group; TTO: Time trade-off; SG: Standard Gamble, RCT: randomised 
controlled trial; CHF: congestive heart failure; MTC: mixed treatment comparison; AIC: Academic in 
confidence; NVAF: Non-Valvular Atrial Fibrillation; IC: intra-cranial; ONS: Office of national statistics; BP: 
Blood pressure; LVEF: Left ventricular ejection force; RR: Relative risk; HR: Hazard rate; OR: Odds ratio; SR: 
Systematic review. 
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In summary, the following evidence would be required to compare providers or the cost-
effectiveness of interventions for cardiac arrhythmia: 
x Device interventions (type of device,  new or repair/substitution) 
x Pharmaceutical interventions (type of intervention, treatment discontinuation, adverse 
events) 
x Clinical variables that characterise disease severity in heart failure patients (NYHA) 
x Surgical rates (type of intervention, success rate, peri and post-surgical complications)  
x Cerebrovascular, bleeding and  thromboembolic  events (type of event, rates, disability level 
following event) 
x Hospitalisation (rates, cause,  length of stay) 
x HRQoL data (prior to surgical procedure and at follow-up) 
x Death rates (cardiac and surgical related, all cause) 
 
The majority of this evidence would need to be dated and linked through timings of collection.  
    
4.3.2 Fields collected in National Audit of Cardiac Rhythm Management 
The national audit of cardiac rhythm management (NACRM) is composed of two questionnaires for 
two distinct types of clinical interventions in cardiac arrhythmia: implantation of cardiac devices 
(collected in the spreadsheet Device-dataset-5502n-14032014); and interventional procedures for 
management of cardiac rhythm disorders, namely ablation procedures (collected in the spreadsheet 
eps-dataset-v305-26032014). The ablation dataset also collects PROM data through two 
questionnaires, namely EQ-5D and the Atrial Fibrillation Effect on Quality Of Life questionnaire 
(AFTEQ), with both questionnaires being applied prior to the ablation procedure, and at 6 and 12 
months of follow-up. There are only three mandatory fields in the devices and ablation datasets 
(hospital identifier, patient case record number, procedure date).  However, there are a minimum 
number of fields that are part of the cardiac rhythm management (CRM Minimum Data Standard) 
(on which hospitals are assessed for completeness). The Minimum Data Standard fields, and the 
remaining fields are provided in the Appendix.   
 
For cardiac devices the data provide information on patient demographics (hospital identifier, 
patient case record number, NHS number, age, sex, postcode); baseline data (date of first implant, 
pre-device aetiology, pre-device symptom, Electrocardiogram (ECG) indication for device, functional 
status (NYHA), left ventricular ejection fraction, ICD Indication, pre-device/Ablation QRS duration); 
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procedure (Procedure date, first operator (name, General Medical Council (GMC) number), 
consultant (name, GMC number), intervention category, generator mode (or maximum system 
capability)); procedure details related to the generator/device (generator mode, generator/device 
procedure, reason for generator change, generator model, generator serial number); lead extraction 
(indication for lead extraction); complications (acute complications).  For interventional procedures 
the data provide information on demographics (same as for devices dataset); baseline data (pre 
procedure aetiology,  pre procedure symptom (ablation Indication), other documented arrhythmia, 
pre procedure arrhythmia); procedure (procedure date, first operator (name, GMC number), 
consultant (name, GMC number), procedure type, ablation procedure, ablation attempted, success, 
acute complications); atrial fibrillation ablation details (European Heart Rhythm Association atrial 
fibrillation classification, NYHA functional status); follow-up for atrial fibrillation ablation 
(complications (post discharge), frequency of palpitations, duration of palpitations).  
 
4.3.3 Comparing fields in the NACRM with variables used in existing HTAs 
The existing models either use survival curves to model mortality, (all cause, cardiovascular and non-
cardiovascular) or assume time-constant mortality rates.  There is information in the NACRM on 
clinical interventions (date of procedure/device implantation, generator mode (identifies the type of 
device), procedure type, ablation success) which would provide some of the information required to 
compare alternative treatments.  The mortality data could be used to model survival, as death 
related to procedure is collected in the acute and late complications fields. However, this would still 
be insufficient to distinguish between cardiovascular and non-cardiovascular death, as not all causes 
of death are collected within the audit. The field late complications captures key clinical events, 
namely complications (including death) related to either device implantation or ablation procedures 
occurring within one year of the procedure, but is not included in the minimum data standard of the 
audit. Furthermore, there are other key clinical events that would not be captured by this audit, such 
as readmissions to hospital due to clinical deterioration (e.g. hospitalisation due to HF worsening).  
The NACRM only collects data on antiarrhythmic drugs on patients with AF, with no other 
medication data being collected in the two datasets of the audit. 
 
Clinical variables such as NHYA functional status (no limitation of physical activity, slight limitation of 
ordinary physical activity, marked limitation of ordinary physical activity, symptoms at rest or 
minimal activity), European Heart Rhythm Association AF classification (no symptoms, mild 
symptoms, severe symptoms, disabling symptoms), and Left ventricular ejection force (LVEF) 
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(measure of severity of left ventricular disfunction), as well as pre-device aetiology (apparently 
normal heart, ischaemic heart disease, congenital, cardiac surgery, catheter ablation, percutaneous 
structural cardiac intervention, cardiomyopathy, endocarditis, myocarditis, valve disease - 
operated/intervened, cardiac transplant, channelopathy, myotonic dystrophy), and pre-procedure 
aetiology (apparently normal heart, pre-excitation (delta wave), ischaemic heart disease, valve 
disease, hypertensive heart disease, hypertrophic cardiomyopathy, dilated cardiomyopathy, 
arrhythmogenic right ventricular cardiomyopathy, myocarditis, channelopathy), could be used to 
case-mix patients when comparing performance or cost-effectiveness of interventions. Pre-device/ 
pre-procedure aetiology could also be used to inform the clinical pathway(s) relevant to structure 
the model. Furthermore, the audit collects data on the type of procedures, device implanted (where 
applicable) and success rates of surgical procedures (implantation or ablation), which would provide 
information required to compare interventions.  
 
Patient related outcome measures are already collected in the NACRM, the EQ-5D and AFTEQ, 
although only for patients undergoing ablation procedures. The extension of the collection of PROM 
data to all patients in the NACRM (preferably the EQ-5D), could improve the ability of the audit to 
inform cost-effectiveness analysis of interventions. The value of collecting PROM data in cardiac 
arrhythmias may be greater than in other conditions where it is possible to map clinical variables to 
a preference-based measure. In this particular case, mapping from clinical variables could be very 
challenging, given that these variables are usually disease specific and there are several underlying 
cardiovascular diseases that can be the cause of cardiac arrhythmia.  
 
The mandatory fields in the NACRM are insufficient to inform cost-effectiveness analysis of 
interventions and policies in cardiac arrhythmia. However, the minimum data standard subdataset 
has considerably more information that would be useful to model decision problems in this 
cardiovascular condition. Nevertheless, there are a number of fields that are not included in the 
minimum data standard, and that would provide valuable information in this context. For example, 
the PROM data collected in the audit is not currently part of the minimum data standard dataset and 
is only collected for atrial fibrillation dataset. The late complications fields would also provide 
important follow-up data, and would be especially relevant to model survival within models, as it 
reports cardiovascular related causes of death. It is worth noting that the complications that are 
collected are mostly directly related to the procedure, and do not capture adverse events of 
medication. As mentioned above, the NACRM collects limited data on medication, with only data 
related to anti-arrhythmic drugs in patients with AF being collected. Given that these patients may 
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also be prescribed anticoagulant drugs that can impact on HRQoL through adverse events (e.g. 
bleeding), and by potentially modifying the rate of thromboembolic events leading to disability, 
information on AEs would be worth including in the audit fields related to anticoagulant medication.  
Alternatively, these data could be retrieved by linking the NACRM dataset to other national audit 
datasets that collect data on related conditions (e.g. the National Heart Failure Audit (NHFA)) which 
could be done via NHS number. The limitation here would be that not all patients would be 
registered in both datasets. This would also be the case for clinical events leading to hospital 
readmission, which are also not collected in the audit.  
 
Depending on the completion rates of non-mandatory fields in the audit, with additional fields 
added or linkage to other datasets, it is possible that the NACRM could be used to compare the cost-
effectiveness of interventions or policies. 
 
4.4 Recommendations for cardiac arrhythmia 
In summary, no evidence was identified on the validity and responsiveness of the EQ-5D in cardiac 
arrhythmia, although the instrument was considered to have good acceptability (Section 4.1). 
Nevertheless, the validity of EQ-5D has been demonstrated in other related conditions, such as heart 
failure, as well as more generally in the cardiovascular area. Furthermore, EQ-5D derived utility 
weights have been widely used in cost-effectiveness studies in cardiac arrhythmia, and NACRM 
already collects EQ-5D data in patients with atrial fibrillation who undergo atrial ablation 
procedures. In addition, and although many variables of importance are already collected in the 
audit, there are concerns about the completion rates of fields not included in the CRM Minimum 
Data Standard and that not all relevant fields to perform robust economic evaluations are collected 
in the audit.  Potential recommendations (PR) and areas for future research (FR) are discussed 
below.  All suggested future research areas are indicative and would require a discussion and 
detailed proposal if required. 
 
As the EQ-5D questionnaire is already collected in the NACRM for ablation procedures, it would be 
of value to extend the collection of the questionnaire to the devices implantation dataset (PR.1). 
Furthermore, as there is a dearth of evidence on the psychometric properties of EQ-5D, the data 
collected in the audit could be used to examine these properties, so as to validate the use of EQ-5D 
in this condition (FR.1).  Research on this topic is already being conducted by the National Institute 
for Cardiovascular Outcomes Research.(17) 
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There are concerns whether the NACRM collects suffiently detailed information to compare 
providers or perform economic evaluations.  The inclusion of mandatory information on the use of 
anticoagulant drugs and the occurrence of adverse events associated with these drugs, with special 
attention to bleeding and cerebrovascular events, would increase the flexibility of the secondary use 
of the data (PR.2).  Depending on the completion rates of the Minimum Data Standard Dataset 
consideration should be given to making these fields mandatory (PR.3). 
 
Table 5: Recommendations and associated future research for cardiac arrhythmia 
PR.1 Extend EQ-5D-5L collection so that it is conducted for both elements of the NACRM, i.e. the 
device and the ablation procedures dataset. implantation of cardiac devices (collected in 
the spreadsheet Device-dataset-5502n-14032014) 
FR.1 Assess the psychometric properties of the EQ-5D-5L in patients with cardiac arrhythmias 
using data collected in the audit 
PR.2 Collect mandatory information on the use of anticoagulant drugs and the occurrence of 
adverse events associated with these drugs, with special attention to bleeding and 
cerebrovascular events 
PR.3 Depending on completion rates of Minimum Data Standard Dataset, consider making these 
fields mandatory 
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5. RESULTS FOR HEART FAILURE 
5.1 Evidence of appropriateness of EQ-5D in heart failure (WP1.1) 
Six studies included in the updated review in CVD conditions (Section 4.1.4) assessed the 
psychometric properties of EQ-5D in heart failure, and provided positive evidence of construct (both 
convergent and known-group) validity, but poor responsiveness. Full details on the assessment of 
the appropriateness of EQ-5D in heart failure are presented in Section 4.1.5. 
 
5.2 Routinely collected proxy measures in heart failure (WP1.2) 
As the EQ-5D was found to be acceptable for CVD conditions, no additional searches for alternative 
measures were conducted. 
 
5.3 Evidence for economic evaluations in heart failure (WP1.3) 
5.3.1 Cost-effectiveness modelling approach used in recent HTAs in heart failure 
Three TAs relating to heart failure were identified from the searches, one of these is currently in 
development with anticipated issue date of June 2014.(27)  One of the TAs examined the clinical and 
cost-effectiveness of CRT in addition to optimal OPT compared to OPT alone for the treatment of 
people with heart failure (due to LVSD and cardiac dyssynchrony) or people with both an increased 
risk of SCD as a result of ventricular arrhythmias and heart failure.(27) Another TA examined the 
clinical and cost-effectiveness of CRT for people with heart failure and evidence of dyssynchrony by 
comparing CRT-P and CRT-D devices each with OPT, and with each other.(32) The third TA examined 
the clinical and cost-effectiveness of ivabadrine in addition to standard care compared to standard 
care alone for the treatment of chronic heart failure.(34)  
 
All TAs used Markov models to examine the cost-effectiveness of the interventions under appraisal.  
The models comprised of discrete health states and key clinical events which represented the clinical 
pathway for people with heart failure (or with heart failure and increased risk of SCD) at the point of 
the intervention.  The number of health states varied across models from two to 28 discrete health 
states, depending on if the occurrence of clinical events was modelled as individual health states or 
grouped within health states.  Cardiovascular mortality (due to worsening of heart failure or SCD) 
was modelled mostly by using survival data from clinical trials (survival curves and hazard ratios). 
Other key clinical events encompassed hospitalisations, surgical complications, device related 
procedures (in TAs on CRT) and heart transplants, and their occurrence was modelled based mostly 
on trial data (relative risks). When trial data were not used, relative risks were estimated based on 
individual studies in the published literature or on evidence synthesis of trial estimates conducted 
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within the TAs. Disease severity in the model was based on the NYHA classification for heart failure 
severity. In two of the TAs, the distribution of patients by NYHA classes at model entry was derived 
from trial data, and changes over time were assumed to occur as observed on trial or not to occur at 
all (if evidence did not suggest disease severity changes post-intervention).(27;32)  In another TA, 
the NYHA distribution was predicted by a regression model that estimated the likelihood of changing 
NYHA class given treatment and time spent in a particular severity class.(34) 
 
Two of the studies quality adjusted survival by assigning mean utility values to the discrete health 
states. These utilities were sourced from the published literature, and weighted according to NYHA 
distribution in the health state.(27;32)  One study used a regression model to predict utilities within 
the alive health state, according to predicted NYHA distribution over time. The regression model also 
allowed predicting utility decrements from hospitalisations (from heart failure, cardiovascular causes 
and all causes) and utility benefit from interventions. This regression model relied on patient level 
data taken from the study used to provide the primary clinical evidence.(34) The majority of utility 
estimates in the three TAs used EQ-5D data,(27;32) although one TA also used time trade-off and 
standard gamble elicited utility values from published literature to inform the model.(32) 
 
Table 6: Summary of existing models in heart failure  
 Model approach Method used to model utilities  
MTA (ID:481): Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac 
resynchronisation therapy for the treatment of heart failure (review of TA95 and TA120); 2014(27)  
 TAG de-novo Markov model  
4 separate health states: stable, 
hospitalisation, transplanted and dead. 
Key clinical events: hospitalisation due to 
heart failure or arrhythmia, transplant, 
device failure, death, peri-operative 
complications of implant procedure, routine 
device replacements, lead displacement, 
infections, and device upgrades. 
Effectiveness: Survival curves for cardiac 
mortality (SCD and HF) RR risk for other key 
clinical events, treatment effects applied as 
RR reductions.  
Source: clinical RCTs , MA, published 
literature   
Utility: EQ-5D; mean values assigned to health 
states according to NYHA classes. 
Source: published literature, observational analysis 
of RCT data, assumptions
 
 
STA (TA267): Ivabradine for the treatment of chronic heart failure; 2012 (34) 
 Markov model  
2 separate health states: alive, dead. 
Key clinical events: hospitalisation due to HF, 
cardiovascular causes and all causes; 
changes in NYHA class; and death (non-
cardiovascular, and cardiovascular HF 
Utility: EQ-5D; mean values assigned to NYHA 
classes at model entry; Utility decrements from 
hospitalisations (from hearth failure, cardiovascular 
causes and all causes) and utility benefit from 
intervention predicted by mixed regression models.  
Source: sub-study of RCT  
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related and non HF related).   
Effectiveness: Regression models applied to 
estimate events occurrence with the 
exception of non-cardiovascular mortality, 
which was estimated from UK life tables.  
Source: clinical RCT, published literature.  
 
MTA (TA120): The effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) 
for heart failure; 2007(32)  
 TAG de-novo Markov model, with submodels 
for each device and OPT. 
28 separate health states reflecting the 
occurrence of the key clinical events: routine 
device replacements, peri-operative 
complications, infections, device upgrades, 
left lead dislodgments, hospitalisation due to 
heart failure, hospitalisation due to 
arrhythmia, heart transplant, surgical failure 
and death. 
Each health state in the model has a 
corresponding probability tree to model 
transition probabilities according to clinical 
events. 
Effectiveness: Survival curves for 
cardiovascular mortality (SCD and worsening 
of HF) by treatment, RR risk for other key 
clinical events with treatment effects applied 
as RR reductions.  
Source: clinical RCTs, published literature, 
expert opinion, assumptions. 
Utility: EQ-5D and TTO (elicited); mean values 
assigned to separate health states according to 
NYHA classes; Utility on hospitalisation due to heart 
failure: SG (elicited) 
Source: published literature
 
 
AE: Adverse Events; MTA: Multiple Technology Appraisal; STA: Single Technology Appraisal; MA: Meta-
analysis TAG: Technology Appraisal Group; TA: Technology Appraisal; TTO: Time trade-off; SG: Standard 
Gamble, RCT: randomised controlled trialBP: Blood pressure; LVEF: Left ventricular ejection force; RR: 
Relative risk; HR: Hazard rate, SR: Systematic review. 
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In summary, the following evidence would be required to compare providers or the cost-
effectiveness of interventions for heart failure: 
x Device interventions (type of device,  new or repair/substitution) 
x Pharmaceutical interventions (type of intervention, treatment discontinuation, adverse 
events) 
x Clinical variables that characterise disease severity in heart failure patients (NYHA) 
x Surgical rates (type of intervention, success rate, peri and post-surgical complications)  
x Hospitalisation (rates, cause,  length of stay) 
x HRQoL data (prior to surgical procedure and at follow-up) 
x Death rates (cardiac and surgical related, all cause) 
 
The majority of this evidence would need to be dated and linked through timings of collection. 
 
5.3.2 Fields collected in National Heart Failure Audit 
The fields in the NHFA are collected through a questionnaire (the spreadsheet Dataset version 4.2.1).  
Items in the datasets can be labelled core mandatory, core or non-core. The difference between 
core mandatory and core is that for the former a value must be included in the corresponding field, 
whereas for core fields, records can be included even without a value (although it is expected that 
such data is included), and still generate a record. Non-core includes all fields that are not expected 
to be included (but can be recorded for specific projects). The core mandatory fields, the remaining 
core and non-core fields are provided in the Appendix.  The data provide information on patient 
registration (hospital identifier, local patient identifier, patient name, age, sex and postcode); 
admission details (date of admission, main place of care, specialist input, breathlessness, peripheral 
oedema); medical history (ischaemic heart disease, device therapy, valve disease, hypertension, 
diabetes, asthma, chronic obstructive pulmonary disease), physical examination (weight, heart rate, 
systolic blood pressure); investigations on discharge (haemoglobin, urea, creatinine, serum sodium, 
serum potassium, electrocardiogram, echo); treatment on discharge (angiotensin-converting-
enzyme inhibitor, angiotensin receptor blocker, beta blocker, loop diuretic, thiazide or metolazone, 
mineralocorticoid receptor antagonist, digoxin); discharge and referral (confirmed diagnosis of heart 
failure, heart failure management plan, stable on oral therapy after discharge planning, review 
appointment with the heart failure multidisciplinary team, date of review appointment, referral to 
heart failure nurse follow-up, referral to cardiac rehabilitation, referral to cardiology follow-up, date 
of discharge, stable on oral therapy after discharge planning, death in hospital). 
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5.3.3 Comparing fields in the National Heart Failure Audit with variables used in existing HTAs 
The existing models use survival curves to model mortality, (all cause, cardiovascular and non-
cardiovascular).  There is some information in the NHFA on clinical interventions (main place of care, 
specialist input, device therapy, treatment on discharge) which would provide some of the 
information required to compare alternative treatments.  The mortality data could be used to model 
overall mortality, but it will not allow distinction between cardiovascular and non-cardiovascular 
death, as cause of death is not collected within the audit. Furthermore, the NHFA will only provide 
data on death occurring at the hospital. Relative risks of hospitalisation due to heart failure 
worsening could potentially be estimated by using readmission data (date and breathlessness). 
Transitions to stable state could also be modelled based on discharge data (stable on oral therapy 
after discharge planning). 
 
The NHFA collects referral data (referral to cardiothoracic surgery, referral to transplant) that can be 
used to inform the occurrence of further clinical events, but these items are not mandatory. 
Furthermore, the audit does not provide data on surgical complications and device related 
procedures, which are relevant for those patients requiring CRT or heart transplant.  
 
Breathlessness (no limitation of physical activity, slight limitation of ordinary physical activity, 
marked limitation of ordinary physical activity, symptoms at rest or minimal activity) and 
investigations such as electrocardiogram or echocardiogram (allow detecting LVSD and AF) could be 
used to case-mix patients when comparing performance or cost-effectiveness of interventions. 
 
Patient related outcome measures are not currently collected in the NHFA.  The inclusion of a 
preference-based HRQoL questionnaire (preferably the EQ-5D), could improve the ability of the 
NHFA to inform cost-effectiveness analysis of interventions. An alternative might be to map from a 
clinical variable currently collected in the NHFA, breathlessness (corresponding to NYHA 
classification for severity), to a preference-based measure, which would be compatible with the 
modelling approaches used in previous TAs. This alternative would have the disadvantage of 
potentially underestimating the impact of interventions for which effects in HRQoL are not 
exclusively mediated through improvement in clinical severity defined according to changes in NYHA 
class. Furthermore, the NYHA is only collected at admission and readmission, and for mapping 
purposes it would be valuable to collect this measure at discharge too to capture potential benefits 
of interventions. 
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Assuming the mandatory fields have relatively high completion rates, with the exception of HRQoL, 
the information currently collected in the existing NHFA would provide the majority of information 
required to model the cost-effectiveness of interventions and policies in heart failure.  The identified 
gaps in mortality data could potentially be overcome by using external data (e.g. Office of National 
Statistics data). Similarly, data on events related to surgical complications and device related 
procedures could be obtained by linking the NHFA dataset to other national audit datasets, namely 
the CRM datasets.  
 
As shown in Section 4.1.5 there is positive evidence of the validity of EQ-5D in heart failure, but the 
evidence base regarding responsiveness could be improved by methodologically sound research in 
the area. To our best knowledge the collection of PROMs within the NHFA is not currently being 
considered. 
 
5.4 Recommendations for heart failure  
In summary, the EQ-5D appears to be appropriate in patients with HF, and the current heart failure 
audit collects much of the information required to conduct economic evaluations.  Nevertheless, the 
audit does not collect any HRQoL data, and death rates by cause are not collected. The issues and 
corresponding PR and areas for FR are discussed below.  All suggested FR areas are indicative and 
would require a discussion and detailed proposal if required. 
 
In section 4.1, it was concluded tha EQ-5D is appropriate to use in cardiovascular conditions, 
including in heart failure. Considering that the NHFA does not currently collect any preference-based 
measure that can inform economic evaluation, it is recommended that EQ-5D (EQ-5D-5L) is collected 
as part of the audit (PR.4).  Nevertheless, there was very limited data on the responsiveness to 
change of EQ-5D across cardiovascular conditions, and existing evidence suggested that this was 
poor for the particular case of heart failure. As the methods used to assess responsiveness of EQ-5D 
were not without flaws, future research could aim to examine this property in heart failure patients 
using the NHFA data (FR.2). 
 
The NHFA already collects a wealth of information on the clinical status of patients admitted to 
hospital for treatment of their condition, and the associated interventions and care received whilst 
in hospital and on discharge.  However, cause of death is not currently collected. This field would be 
of importance for longer term extrapolation of survival and should be considered for mandatory 
collection (PR.5). More detailed research on analyses of fields currently collected in the NHFA is 
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currently being undertaken under a separate research project within this programme of work (WP3) 
(FR.3). 
 
Table 7: Recommendations and associated future research for heart failure 
PR.4 Collect the EQ-5D (EQ-5D-5L) in the NCA 
FR.2 Assess the responsiveness of the EQ-5D-5L to changes in NYHA (already collected in the 
NCA)using data collected in the audit 
PR.5 Collect mandatory information on cause of death 
FR.3 Analyses of fields currently collected in the heart failure NCA is currently being undertaken 
under a separate research project within this programme of work (WP3)   
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6. RESULTS FOR CORONARY ANGIOPLASTY 
6.1 Evidence of appropriateness of EQ-5D in coronary angioplasty (WP1.1) 
Five studies included in the updated review in CVD conditions (Section 4.1.4) assessed the 
psychometric properties of EQ-5D in coronary angioplasty, and provided positive evidence of 
acceptability, and construct (both convergent and known-group) validity, but showed poor 
reliability. Full details on the assessment of the appropriateness of EQ-5D in coronary angioplasty 
are presented in Section 4.1.5. 
 
6.2 Routinely collected proxy measures in coronary angioplasty (WP1.2) 
As the EQ-5D was found to be acceptable for CVD conditions, no additional searches for alternative 
measures were conducted. 
 
6.3 Evidence for economic evaluations in coronary angioplasty (WP1.3) 
6.3.1 Cost-effectiveness modelling approach used in recent HTAs in coronary angioplasty 
Five TAs relating to coronary angioplasty were identified from the searches, one of these is currently 
in development with an anticipated issue date of July 2014,(35) and corresponds to the review of a 
previous TA.(36)  Three of the TAs examined the clinical and cost-effectiveness of platelet 
aggregation inhibitors for the treatment of people who have suffered an ACS and are medically 
managed or underwent revascularisation (namely percutaneous coronary intervention (PCI) and 
CABG).(35-37)  Another TA examined the clinical and cost-effectiveness of a direct thrombin 
inhibitor, bivalirudin, compared to heparin in addition to glycoproteins inhibitors for patients with ST 
elevation myocardial infarction (STEMI) intended for PCI.(38) Although these four TAs did not assess 
coronary angioplasty procedures, they assessed the cost-effectiveness of alternative adjunctive 
pharmacological interventions in patient populations that included patients intended for or 
undergoing revascularisation.  On TA152, the clinical and cost-effectiveness of drug-eluting stents vs. 
bare metal stents was compared in patients with coronary heart disease. (39) 
 
All TAs on ACS patient populations used two-part models to examine the cost-effectiveness of the 
interventions under appraisal.  The models comprised a short-term element that included a decision 
tree to model clinical events following an ACS (between three days to one year after the episode), 
and a long-term Markov model (15 months to lifetime) that modelled the subsequent clinical 
pathway and prognosis for those patients that survived within the short-term model.(35-38)  The 
most common reason for employing a two-part model was to separately characterise the impact of 
treatments over the initial acute period and the post-acute period (or trial follow-up period vs, 
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longer term). Often an assumption was made that relative effectiveness of particular treatment 
would be confined to the acute or trial period (e.g. TA182, TA236) but that the longer term 
consequences associated with particular events incurred during this period would be different. It is 
worth noting that in other cardiovascular conditions, such as cardiac arrhythmias and heart failure 
(Sections 4.3 and 5.3), the flexibility provided by the two-part models is not as relevant, given that 
the longer-term chronic nature of these conditions can be adequately reflected by a single Markov 
model. In these conditions, wŚŝůĞƌŝƐŬŽĨĞǀĞŶƚŵĂǇǀĂƌǇŽǀĞƌ ƚŝŵĞ ?ƚŚĞĐŽŶĐĞƉƚŽĨ ƚŚĞ  ‘ĂĐƵƚĞ ?ĂŶĚ
 ‘ƉŽƐƚ-ĂĐƵƚĞ ?ƉĞƌŝŽĚƐŝƐůĞƐƐĂƉƉůŝĐĂďůĞ, and hence a Markov process is used throughout as opposed to 
essentially dichotomising the period of risk. 
 
The main clinical events incorporated in the models reflected the occurrence of further ACS (fatal 
and non-fatal), stroke (fatal, and non-fatal, with different types and subsequent level of disability 
considered for the latter), revascularisation procedures (PCI and CABG), bleeding and other-
cardiovascular and non-cardiovascular mortality. Baseline risks and relative risks of clinical events in 
the short-term model were modelled based mostly on trial data (survival analysis), while risks and 
relative risks of clinical events on the longer-term element of the models were sourced from the 
published literature.(35-38)  In one TA, observational data from the Myocardial Ischaemia National 
Audit Project (MINAP) and General Practitioner Research Database was used to estimate risk of non-
fatal events in the long-term Markov model.(37)  The only TA that was not specific to an ACS patient 
population did not provide a detailed description of the model, which hinders the assessment of 
how effectiveness was modelled. Nevertheless, the authors state that there was no evidence of 
differences in mortality and myocardial infarction rates between patients in whom bare metal stents 
were implanted vs. those with drug-eluting stents, and thus effectiveness measures were limited to 
rates of repeat vascularisation, namely target lesion revascularisation (TLR) and target vessel 
revascularisation (TVR), and reductions in number of lesions treated for patients who had undergone 
repeat revascularisations in the 12 months following the index PCI. Rates of TLR and TVR, and 
number of lesions treated in repeat revascularisations for the different interventions were estimated 
from meta-analyses of published clinical trials, and adjusted using observational UK data that 
provided estimates of the proportion of patients likely to benefit from the interventions (i.e. patients 
for whom revascularisation was performed for at least one lesion that had been previously treated) 
across risk subgroups. The authors considered this adjustment to be necessary to convert trial 
efficacy data into estimates that reflected expected effectiveness in UK patients. This model also 
incorporated estimates of waiting times for different revascularisation procedures (PCI or CABG) to 
adjust the duration of benefits in the model.(39) 
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All studies quality adjusted survival by assigning mean utility values to the separate health states. 
The majority of utilities were derived from mean EQ-5D estimates sourced from external estimates 
reported in the published literature,(35-38) or from trial and observational UK data.(37;39)  In some 
models, utilities were gender and/or age specific (35;36), and one model weighted utilities according 
to the level of subsequent disability in the stroke health states (although it was unclear what 
instrument or assumption was used to classify stroke severity.(35) 
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Table 8: Summary of existing models in coronary angioplasty 
 Model approach Method used to model utilities  
MTA (ID:648): Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes 
(review of TA182); 2013 (35) 
 TAG two part model; short term trial-based 
model plus long-term extrapolation Markov 
model.   
Short-term model composed of decision tree 
for the first three days followed by a Markov 
model. Clinical events in the model are: 
primary endpoint events (non-fatal MI, Non-
fatal stroke), bleed endpoint event, 
cardiovascular or bleed death, other death. 
Long-term de-novo Markov model: 
Ten initial health states defined by a 
combination of 1) worst event (none, MI, 
stroke), 2) Prior events (0, 1, 2, 3+) and 3) 
Disabled (yes or no).  
Further health states are defined by the 
occurrence of clinical events (and dependent 
on previous health state): Fatal MI, Nonfatal 
MI, Fatal HS, Nonfatal HS not disabling, 
Nonfatal HS disabling, Fatal ischaemic 
stroke/transient ischaemic, Nonfatal 
ischaemic stroke/transient ischaemic not 
disabling, Nonfatal ischaemic 
stroke/transient ischaemic disabling, other 
vascular death, non-vascular death. 
Effectiveness: Risk equations for primary 
endpoints and bleeding events (active 
treatment period) on short term model; 
gender specific event incidence risks and 
event fatality risks (age adjusted) for long-
term model; RR of MI, stroke, vascular and 
non-vascular death for patients with 
diabetes vs. no diabetes were applied to 
reflect differences between populations. 
Source: clinical RCTs, published literature 
Utility: mean EQ-5D utility values (gender specific 
and disability weighted for stroke states) applied to 
separate health states; disutilities from clinical 
events applied as decrements for year following 
event.  
 
 
Source: clinical RCTs, assumptions. 
 
STA (TA236): Ticagrelor for the treatment of acute coronary syndromes; 2011 (37) 
 DĂŶƵĨĂĐƚƵƌĞƌ ?ƐƚǁŽ-part model: one-year 
decision tree plus long-term extrapolation 
Markov model.  
Decision tree: 4 separate health states (no 
further event, non-fatal MI, non-fatal stroke 
and death from any cause). 
Markov model: 6 separate health states; no 
further event, non-fatal MI, post MI, non-
fatal stroke, post stroke and dead. Non-fatal 
MI and non-fatal stroke health states are 
tunnel states that allow for a worse 
prognosis for patients in the year in which a 
non-fatal event occurs compared to 
subsequent years. 
Effectiveness: Survival analysis to estimate 
Utility: mean EQ5D values assigned to each 
separate health state  
Source: clinical RCT, assumptions(Published 
literature utility estimates applied in sensitivity 
analysis) 
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baseline risk and HR of clinical events on 
short term model. In the long-term model 
fatal events RRs are applied to mortality 
estimates from UK life tables, and non-fatal 
event rates were estimated from an 
observational database. 
Sources: clinical RCTs, published literature, 
manufacturer study based on MINAP and 
General Practice Research Database.  
STA (TA230): Bivalirudin for the treatment of ST-segment elevation myocardial infarction; 2011 (38) 
 DĂŶƵĨĂĐƚƵƌĞƌ ?ƐƚǁŽ-part model: one-year 
decision tree plus long-term extrapolation 
Markov model.  
Decision tree: Initial angiography and 
reperfusion therapy, after which they can 
experience 7 possible subsequent events: no 
relevant complications, minor bleed, major 
bleed, stroke, repeat MI, repeat 
revascularisation and death. 
Markov model: 2 separate health states; 
alive and dead 
Effectiveness: RR of clinical events for 
patients treated with bivalirudin applied to 
baseline risks on the comparator arm, 
independent of index treatment (PCI, CABG 
or conservative treatment) in the short-term 
model; long term model assumes that life-
expectancy for those surviving the initial 
period was identical for both bivalirudin and 
heparin with GPI, and based on UK register 
data.  
Source: clinical RCT, published literature 
Utility: mean EQ5D values from a single 
observational UK study were assigned to patients in 
the initial period (0.683) and in the long-term model 
(0.718), from a cohort study that followed up 
patients for 1-year after being diagnosed with acute 
MI. 
Source: Published literature 
 
STA (TA182): Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary 
intervention; 2009(36)  
 DĂŶƵĨĂĐƚƵƌĞƌ ?ƐƚǁŽ-part Markov model: 
short term trial-based model plus long-term 
extrapolation Markov model.   
Short-term model is composed of a decision 
tree for the first three days followed by a 
Markov model (15 months). Clinical events in 
the model are: primary endpoint events 
(non-fatal MI, non-fatal stroke), bleed 
endpoint event, cardiovascular or bleed 
death, other death. 
Long-term Markov model; same structure as 
for trial-based Markov model. 
Effectiveness: Risk equations for primary 
endpoints  and bleeding events (active 
treatment period) on short term model; 
mortality RRs in revascularised STEMI and 
unstable angina/NSTEMI compared to 
general coronary heart disease population, 
applied to UK age and gender adjusted life 
tables for long term model. 
Source: Clinical RCTs; published literature 
Utility: Baseline utility (mean EQ-5D age and sex 
specific) taken from UK population norms;  ongoing 
utility EQ-5D decrements for ACS and stroke/MI 
from single study; Major bleeding assumed to 
impose 25% utility decrement during 14 days. 
 
Source: Published literature; assumptions 
 
TAG critiqued the use of utility values as they were 
not directly measured on the population of interest 
(heart disease). The TAG applied a condition specific 
long-term utility decrement based on a US survey 
study. Limitations of this approach were recognised 
by the TAG. 
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MTA (TA152): Coronary artery disease - drug-eluting stents (review TA71); 2008 (39) 
 Model is not described within the report, but 
it is said that the modelling approach is the 
same as for the previous appraisal (TA71) 
with minor modifications.  
Previous TAG projected survival model: 
Surviving patients can suffer the following 
events: fatal and non-fatal acute MI, fatal 
and non-fatal stroke, repeat 
revascularisations, acute renal failure and 
severe bleeding.
(39)
 
Effectiveness: 
As model structure is not described, and 
differences from TA71 are not clear, it is 
difficult to assess how effectiveness was 
modelled. Nevertheless, the emphasis was 
on assessing the reduction in 
revascularisation rates and number of 
lesions treated in revascularisation 
procedures, as no differences in mortality or 
acute MI incidence were found between 
interventions. Authors state that they have 
adjusted trial efficacy data by combining MA 
estimates with prevalence rates of 
revascularisation by subgroup (defined 
according to the presence of risk factors). 
Risk factors for non-elective patients were 
previous CABG and small vessels, and for 
elective patients, calcification, angulation, 
restenotic lesion, and triple vessel disease. 
Source: MA of published clinical RCTs, 
observational data 
Utility: 
The authors used EQ-5D values from a UK survey 
study for symptomatic angina, after PCI and after 
CABG health states. For the remaining health states 
(which were not described) the utility estimates 
applied were as for TA71, which were mainly 
sourced from a clinical trial. 
HS: health states; AE: Adverse Events; MTA: Multiple Technology Appraisal; GPI: Glycoproteins inhibitors; 
STA: Single Technology Appraisal; MI: Myocardial Infarction; HS: Haemorrhagic stroke; TAG: Technology 
Appraisal Group; TIA: Transient ischaemic attack; TA: Technology Appraisal; RCT: randomised controlled 
trial; RR: Relative risk. 
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In summary, the following evidence would be required to compare providers or the cost-
effectiveness of interventions for coronary angioplasty patients: 
x Pharmaceutical interventions (type of intervention, treatment discontinuation, adverse 
events) 
x Aetiology requiring angioplasty 
x Procedure rates (type of intervention, success rate, peri and post-procedure complications)  
x Hospitalisation (rates, cause,  length of stay) 
x Further cardiovascular events (ACS, revascularisation, stroke) 
x HRQoL data (prior to surgical procedure and at follow-up) 
x Death rates (cardiac and procedure related, all cause) 
 
 
6.3.2 Fields collected in National Audit of Percutaneous Coronary Interventional Procedures 
The fields in the National Audit of Percutaneous Coronary Interventional Procedures (NAPCI) are 
collected via a questionnaire (the spreadsheet BCISversion5_6_1). Although there is an expectation 
that all fields are completed, there are a minimum number of fields that are part of the NAPCI 
Minimum Data Standard, [personal communication with Tracy Whittaker, National Audit Project 
Manager for the PCI and Congenital Heart Disease Audits, 5
th
 June 2014] and that are involved with 
risk stratified outcome assessment.(40)  The Minimum Data Standard fields and remaining fields are 
provided in the Appendix.  The data provide information on patient demographics (NHS number, age 
and gender); pre-procedure details (indication for intervention, procedure urgency, cardiogenic 
shock, date/time of symptom onset, date/time arrival at first hospital, date/time arrival at PCI 
hospital); procedure details (vessels attempted, date/time of first balloon inflation, PCI hospital 
outcome); previous medical history (diabetes, medical history, history of renal disease); and 
discharge details (status at discharge, discharge date). 
 
6.3.3 Comparing fields in the National Audit of Percutaneous Coronary Interventional Procedures 
with variables used in existing HTAs 
Survival analysis was used in previous TAs to model mortality, and the data collected in the NAPCI 
ĂƵĚŝƚƚŚƌŽƵŐŚƚŚĞǀĂƌŝĂďůĞ ‘ƐƚĂƚƵƐĂƚĚŝƐĐŚĂƌŐĞ ?could be used to model all cause mortality. However, 
cause of death is not collected within the audit, and therefore it is not possible to distinguish 
between cardiovascular and non-cardiovascular mortality. Furthermore, the audit only collects data 
on death occurring at the hospital, which can be a limitation. The NAPCI provides data on clinical 
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interventions (drug therapy before intervention, glycoproteins used during number of stents, 
number of drug eluting stents, drug(s) eluted by stents, arterial access (femoral, brachial or radial) 
which would provide some of the information required to compare alternative treatments, but none 
of these data are part of the minimum data standard and its completeness may be limited compared 
to other fields in the audit. The NAPCI collects data on PCI outcomes that include complications 
(haemorrhagic and embolic cerebrovascular events, transient ischaemic attack/reversible ischemic 
neurologic deficit, reinfarction), as well as revascularisation procedures (CABG and PCI) following 
initial PCI that can be used to inform the occurrence of further clinical events occurring within the 
same hospital episode. There are other fields that also collect data related to complications 
(procedural complications, arterial complications, bleeding up to discharge), but these are not part 
of the minimum standard data. Importantly, the audit does not collect data on all types of stroke 
(thrombotic stroke is not specifically considered on the PCI outcomes field) or data related to 
severity of disability following cerebrovascular events, which is anticipated to impact on HRQoL, as 
well as costs. 
 
Previous models have defined patient subgroups or adjusted effectiveness and utility estimates 
based on sex, age, comorbidities (namely diabetes), underlying disease (ACS, stable angina), type of 
admission (elective, non-elective). These data are collected in the audit and could be used to case-
mix patients when comparing performance or cost-effectiveness of interventions.  
 
The NAPCI does not currently collect patient related outcome measures.  The inclusion of a 
preference-based HRQoL questionnaire (preferably the EQ-5D), could improve the ability of the 
audit to inform cost-effectiveness analysis of interventions. An alternative would be to apply values 
from the published literature to clinical events, as has been done in previous models. However, as 
mentioned before, the audit only collects data on those events that occur during the time spent in 
hospital following the initial PCI.There is a very important limitation to this approach, as it may fail to 
capture the impact on HRQoL of the interventions, given that it may not be related to the 
occurrence of clinical events alone, but also to any beneficial effect on symptoms (e.g. relief of chest 
pain caused by myocardial ischaemia). It is worth noting that in previous TAs, the focus was not on 
HRQoL differences driven by improvement in symptoms as they aimed to examine adjunctive 
therapies or different types of stents, rather than the surgical procedure which was the same for 
every comparison. Collection of a PROM would have a greater potential value to this particular audit, 
as it would allow HRQoL considerations to be related to events, but also to symptomatic differences 
that may be evident and are not fully accounted for by events. As it is, it may be difficult to 
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demonstrate the full symptomatic benefits of interventions over just the hospitalisation period 
following coronary angioplasty, and PROMs collection should not be limited to this period. It would 
be preferable that it was performed as for ablation patients in the NACRM, i.e. prior to the 
procedure, and at longer follow-up time points (6 and 12 months in this particular case), so as to 
ensure that any symptomatic impact of treatments that is not limited to the hospitalisation period is 
captured.  
 
Assuming that the audit fields in general have relatively high completion rates, with the exception of 
HRQoL, the information currently collected in the existing NAPCI would provide a considerable 
amount of the information required to model the cost-effectiveness of interventions and policies in 
coronary angiography. Limitations on the collection of mortality data could be partially overcome by 
incorporating external data, namely by linkage to mortality registers, or by using estimates from the 
published literature. Linking the PCI audit to other datasets could not only allow the calculation of 
longer term mortality rates, but also the distribution of patients between cardiovascular and non-
cardiovascular deaths. Even if mortality registers do not allow identifying cause of death, this can be 
ascertained through linkage to other audits or registers (e.g. Hospital Episode Statistics).  For 
example, if there is a record of a previous coronary heart disease or cerebrovascular disease 
hospitalisation recorded in the 30-day period which precedes a patient ?ƐĚĞĂƚŚ ?ƚŚĞŶƚŚŝƐŵŝŐŚƚďĞ
used to inform cause of death. As illustrated by previous models, cause of death is important for the 
purposes of extrapolation, since it may not be reasonable to assume that a single mortality function 
can be applied to both short and longer term parts of the model. A potential alternative approach to 
overcome gaps in mortality data might be to use external evidence on the expected rate of non-
cardiovascular mortality and remove this from the mortality estimates reported in the audit, and 
then to model non-cardiovascular mortality separately (e.g. using cause-exclusion life table data). 
Clinical events occurring after hospital discharge or not recorded in the audit (e.g. thrombotic 
strokes) could also be sourced from the published literature with the exception of further PCI 
ŝŶƚĞƌǀĞŶƚŝŽŶƐ ? ƐŝŶĐĞ ƉĂƚŝĞŶƚƐ ? E,^ ŶƵŵďĞƌ ĐŽƵůĚ ďĞ ƵƐĞĚƚŽ ƚƌĂĐŬ ƌĞĂĚŵŝƐƐŝŽŶƐ ? ^ŝŵŝůĂƌůǇ ? ƚŚĞ
distribution of patients according to disability severity following cerebrovascular events could also 
be sourced from the published literature. An alternative to inform the occurrence of clinical events 
would be to use the NHS number to link the PCI audit to other audits which collect data related to 
cardiovascular events (e.g. the MINAP for ACS, and the national adult cardiac surgery audit (NACSA) 
for revascularisations with CABG).  
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6.4 Recommendations for coronary angioplasty 
In summary, the EQ-5D appears to be appropriate in patients undergoing coronary angioplasty, and 
the current PCI audit collects some of the information required to conduct economic evaluations.  
Nevertheless, the audit does not collect any HRQoL data, and could be improved by the inclusion of 
more fields and or making their collection mandatory. The issues and corresponding PR and areas for 
FR are discussed below.  All suggested FR areas are indicative and would require a discussion and 
detailed proposal if required. 
 
As shown in Section 4.1 there is positive evidence of the validity of EQ-5D in coronary angioplasty, 
most specifically for known-group and convergent validity, although no evidence was available on 
reliability and responsiveness. There was also some evidence that EQ-5D exhibits ceiling effects in 
this condition. Nevertheless, EQ-5D was considered an appropriate measure to estimate HRQoL in 
ĐŽƌŽŶĂƌǇĂŶŐŝŽƉůĂƐƚǇ ?ĂŶĚŝƚƐ ŝŶĐůƵƐŝŽŶ ŝŶ ƚŚĞW/ĂƵĚŝƚǁŽƵůĚ ŝŵƉƌŽǀĞƚŚĞĂƵĚŝƚ ?ƐĂďŝůŝƚǇ ƚŽ ŝŶĨŽƌŵ
cost-effectiveness analysis in coronary angioplasty especially if its collection also encompasses time 
points beyond the initial hospitalisation period.  To our best knowledge the collection of PROMs 
within the PCI audit is not currently being considered, so it is recommended that EQ-5D (EQ-5D-5L) is 
collected within the audit (PR.6). The use of the EQ-5D-5L, could potentially reduce any ceiling 
effects (86) in patients in less severe stages of cardiovascular disease. As no available evidence was 
available on reliability and responsiveness of the EQ-5D, future research could aim to examine these 
properties in coronary angioplasty patients using the NAOCI data (FR.4). 
 
The PCI audit already collects considerable information of relevance for the economic evaluation of 
interventions in coronary angioplasty (described in Section 6.3.3).  However, fields such as cause of 
death, type of stroke and severity of disability following stroke are not currently collected. The 
importance of these fields has been highlighted in Section 6.3.3, and should be considered for 
mandatory collection (PR.7). Furthermore, it is also recommended that fields regarding 
pharmacological and surgical interventions in coronary angioplasty patients (drug therapy, number 
and type of stents and type of arterial access), which are already collected in the audit, are 
considered for mandatory collection or inclusion in the Minimum Data Standard dataset to ensure 
high completion rates (PR.8). 
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Table 9: Recommendations and associated future research for coronary angioplasty 
PR.6 Collect the EQ-5D (EQ-5D-5L) in the NCA prior to procedure, after procedure and at least 
one longer follow-up time point 
FR.4 Assess the psychometric properties of the EQ-5D-5L using data collected in the audit 
PR.7 Collect mandatory information on cause of death, type of stroke and severity of disability 
following stroke 
PR.8 Make collection of data on drug therapy, number and type of stents and type of 
arterialaccess mandatory or at least part of the Minimum Data Standard dataset 
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7. RESULTS FOR CARDIAC SURGERY 
7.1 Evidence of appropriateness of EQ-5D in cardiac surgery (WP1.1) 
Four studies included in the updated review in CVD conditions (Section 4.1.4) assessed the 
psychometric properties of EQ-5D in cardiac surgery, and provided positive evidence of acceptability 
and construct (both convergent and known-group) validity, but showed poor reliability. 
Furthermore, there was evidence of potential ceiling effects for the EQ-5D in this condition. Full 
details on the assessment of the appropriateness of EQ-5D in cardiac surgery are presented in 
Section 4.1.5. 
 
7.2 Routinely collected proxy measures in Cardiac Surgery (WP1.2) 
As the EQ-5D was found to be acceptable for CVD conditions, no additional searches for alternative 
measures were conducted. 
 
7.3 Evidence for economic evaluations in cardiac surgery (WP1.3) 
7.3.1 Cost-effectiveness modelling approach used in recent HTAs in cardiac surgery  
The searches identified two TAs relating to cardiac surgery. One of the TAs examined the clinical and 
cost-effectiveness of ticagrelor compared to clopidogrel for the treatment of ACS in patients 
managed medically, and those who are managed with PCI or CABG.(37) Another TA examined the 
clinical and cost-effectiveness of a direct thrombin inhibitor, bivalirudin compared to heparin in 
addition to glycoproteins inhibitors for patients with STEMI intended for PCI. The modelling 
approach in this TA assumes that all patients receive an initial angiography for diagnostic purposes, 
and are then allocated to a primary treatment intervention with the majority of patients undergoing 
PCI.(38)  None of these TAs assessed cardiac surgery procedures; they assessed the cost-
effectiveness of alternative adjunctive pharmacological interventions in patient populations that 
included patients intended for or undergoing revascularisation. Furthermore, they only include one 
type of procedure collected in the NACSA, namely CABG. Nevertheless, CABG is the most frequent 
procedure for which data is collected in the NACSA. (41)  Other types of surgery included in the audit 
are heart valve replacement or repair and aortic surgery. 
 
The two TAs used two-part models to examine the cost-effectiveness of the interventions under 
appraisal.  The models comprised a short-term element that included a decision tree to model 
clinical events within one year following an ACS, and a 39 years long-term Markov model (assumed 
to be lifetime) that modelled subsequent clinical pathway and prognosis for those patients that 
survived within the short-term model. The rationale for employing a two-part model has been 
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described previously in Section 6.3, and mostly this modelling approach allows the impact of 
treatments over the initial acute period and the post-acute period (or trial follow-up period vs longer 
term) to be characterised separately. The main clinical events incorporated in the models reflected 
the occurrence of further ACS (fatal and non-fatal), stroke (fatal, and non-fatal, with different types 
and subsequent level of disability considered for the latter), revascularisation procedures (PCI and 
CABG), bleeding and other-cardiovascular and non-cardiovascular mortality. Baseline risks and 
relative risks of clinical events in the short-term model were modelled based mostly on trial data 
(survival analysis), while relative risks of clinical events on the longer-term element of the models 
were sourced from the published literature.(37;38)  In one TA, observational data from the MINAP 
and General Practitioner Research Database was used to estimate risk of non-fatal events in the 
long-term Markov model.(37)  
 
All studies quality adjusted survival by assigning mean utility values to the discrete health states. 
These mean utilities were derived from EQ-5D data sourced from external published 
literature(37;38) and from the clinical trial that also informed the effectiveness estimates in the 
short-term element of the model.(37) Unlike other models used to examine the cost-effectiveness of 
pharmacological interventions in patients revascularised with PCI,(35) these models did not explicitly 
weight utilities according to disability in the stroke health states.   
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Table 10: Summary of existing models in cardiac surgery 
 Model approach Method used to model utilities  
STA (TA236): Ticagrelor for the treatment of acute coronary syndromes; 2011 (37) 
 DĂŶƵĨĂĐƚƵƌĞƌ ?ƐƚǁŽ-part model: one-year 
decision tree plus long-term extrapolation 
Markov model.  
Decision tree: 4 discrete health states (no 
further event, non-fatal MI, non-fatal stroke 
and death from any cause). 
Markov model: 6 separate health states; no 
further event, non-fatal MI, post MI, non-
fatal stroke, post stroke and dead. Non-fatal 
MI and non-fatal stroke health states are 
tunnel states that allow for a worse 
prognosis for patients in the year in which a 
non-fatal event occurs compared to 
subsequent years. 
Effectiveness: Survival analysis to estimate 
baseline risk and HR of clinical events on 
short term model. In the long-term model 
fatal events RRs are applied to UK life tables 
mortality estimates, and non-fatal event 
rates were estimated from an observational 
database. 
Sources: clinical RCTs, published literature, 
manufacturer study based on MINAP and 
General Practice Research Database.  
Utility: mean EQ-5D values assigned to each 
separate health state  
Source: clinical RCT, assumptions(Published 
literature utility estimates applied in sensitivity 
analysis) 
 
STA (TA230): Bivalirudin for the treatment of ST-segment elevation myocardial infarction; 2011(38)  
 DĂŶƵĨĂĐƚƵƌĞƌ ?ƐƚǁŽ-part model: one-year 
decision tree plus long-term extrapolation 
Markov model.  
Decision tree: Initial angiography and 
reperfusion therapy, after which they can 
experience 7 possible subsequent events: no 
relevant complications, minor bleed, major 
bleed, stroke, repeat MI, repeat 
revascularisation and death. 
Markov model: 2 discrete health states; alive 
and dead 
Effectiveness: RR of clinical events for 
patients treated with bivalirudin applied to 
baseline risks on the comparator arm, 
independent of index treatment (PCI, CABG 
or conservative treatment) in the short-term 
model; long term model assumes that life-
expectancy for those surviving the initial 
period was identical for both bivalirudin and 
heparin with GPI, and based on UK register 
data.  
Source: clinical RCT, published literature 
Utility: mean EQ-5D values from a single 
observational UK study were assigned to patients in 
the initial period (0.683) and in the long-term model 
(0.718), from a cohort study that followed up 
patients for 1-year after being diagnosed with acute 
MI. 
Source: Published literature 
 
AE: Adverse Events; MTA: Multiple Technology Appraisal; STA: Single Technology Appraisal; MI: 
Myocardial Infarction; GPI: Glycoproteins inhibitors; TAG: Technology Appraisal Group; TIA: Transient 
ischaemic attack; TA: Technology Appraisal; RCT: randomised controlled trial; RR: Relative risk. 
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In summary, the following evidence would be required to compare providers or the cost-
effectiveness of interventions for cardiac surgery patients: 
x Pharmaceutical interventions (type of intervention, treatment discontinuation, adverse 
events) 
x Aetiology requiring cardiac surgery 
x Procedure rates (type of intervention, success rate, peri and post-procedure complications)  
x Hospitalisation (rates, cause, length of stay) 
x Further cardiovascular events (ACS, revascularisation, stroke, level of disability following 
stroke) 
x HRQoL data (prior to surgical procedure and at follow-up) 
x Death rates (cardiac and procedure related, all cause) 
The majority of this evidence would need to be dated and linked through timings of collection. 
 
7.3.2 Fields collected in National Adult Cardiac Surgery Audit 
The fields in the NACSA are collected via a questionnaire (the spreadsheet NACSAdatasetV4.1). 
Similarly to the PCI audit, there is an expectation that all fields are completed, but a Minimum Data 
Standard is still in development. Nevertheless, a record cannot be submitted to the audit without 
the completion of the fields: date of birth, procedure type, procedure date, height and weight. 
Mandatory fields and fields on which hospitals are assessed for completeness and the remaining 
fields are provided in the Appendix.  The data provide information on: patient demographics (age 
and gender); cardiac history (recent MI); previous interventions (previous cardiac surgery, date of 
last cardiac operation); additional medical history and risk factors (creatinine at time of surgery, 
renal function/dialysis, history of pulmonary disease, history of neurological dysfunction, 
extracardiac arteriopathy, pre-operative heart rhythm); cardiac investigations (left ventricular 
function ejection fraction category, pulmonary artery systolic pressure); pre-operative status and 
support (intravenous nitrates or any heparin, intravenous inotropes prior to anaesthesia, ventilated 
(pre-operation), cardiogenic shock, date and time of operation, operative urgency, number of 
previous heart operations, responsible consultant surgeon, responsible consultant anaesthetist); 
procedures classified by group (CABG, valve, major aortic, other cardiac procedures); other cardiac 
procedures; valve surgery (reason for repeat aortic valve  operation, native mitral valve pathology, 
reason for repeat mitral valve operation, native tricuspid valve pathology, reason for repeat tricuspid 
valve operation, native pulmonary valve pathology, reason for repeat pulmonary valve operation); 
pre-operative, intra-operative and post-operative cardiac support devices (reason for repeat aortic 
58 
EEPRU NCA Appendix K: Cardiovascular Conditions 
Page 58 
 
valve  operation, native mitral valve pathology, reason for repeat mitral valve operation, native 
tricuspid valve pathology, reason for repeat tricuspid valve operation, native pulmonary valve 
pathology, reason for repeat pulmonary valve operation); cardiopulmonary bypass data (height and 
weight); and post-operative course (patient status at discharge, date of discharge/ date of death in 
hospital). Although the patient NHS number is not mandatory, whenever this field is not completed 
the Central Cardiac Audit Database (CCAD) will attempt to obtain it from the National Strategic 
Tracing Service using the patient's name, date of birth and postcode.   
 
7.3.3 Comparing fields in the National Cardiac Surgery Audit with variables used in existing HTAs 
Survival analysis was used in previous TAs to model mortality, and therefore the data collected in 
NACSA audit through the variables  ‘ƐƚĂƚƵƐ Ăƚ ĚŝƐĐŚĂƌŐĞ ? ĂŶĚ ĚĂƚĞ ŽĨ ĚŝƐĐŚĂƌŐĞ/ date of death in 
hospital could be used to model all cause mortality. However, cause of death is not collected within 
the audit, and therefore it is not possible to distinguish between cardiovascular and non-
cardiovascular mortality. The collection of in-hospital death alone can limit the use of the audit to 
inform cost-effectiveness analysis. Nevertheless, it may be reasonable to assume that in-hospital 
death is procedure-related, especially if it occurs within a short period after the operation. The 
collection of data related to the occurrence of clinical events after index surgery in the NACSA 
ŝŶĐůƵĚĞƐ ĐŽŵƉůŝĐĂƚŝŽŶƐ ƌĞƋƵŝƌŝŶŐ ƌĞƚƵƌŶ ƚŽ ƐƵƌŐŝĐĂů ƚŚĞĂƚƌĞ  ? ‘Return to Theatre ? ? ƉƉĞŶĚŝǆ ? ĂŶĚ
cerebrovascular accidenƚƐ ? ‘New post-operative neurological dysfunction ? ?ƉƉĞŶĚŝǆ ? ?dŚĞ ‘Return to 
Theatre ? ĨŝĞůĚ ĐĂƉƚƵƌĞƐ ƌĞ-operation due to bleeding or tamponed, valvular problems, graft 
problems, other cardiac problems, sternum re-suturing and surgery for deep sternal wound 
infection. The collection of further events is limited to the period of hospitalisation following the 
initial surgery. 
 
The NACSA audit provides data on the type of surgical procedures (CABG, valve, major aortic, other 
cardiac procedures) and cardiac support devices used (intra-aortic balloon pump, impeller device 
use, ventricular assist device use, other support device), which would provide some of the 
information required to compare alternative treatments.  
 
Clinical events such as MI will not be captureĚ ďǇ ƚŚĞ ǀĂƌŝĂďůĞ  ‘Return to Theatre ? ĂƐ ƚŚĞƌĞ ŝƐ ŶŽ
specific entry for this type of cardiac problem and, furthermore, they may occur without requiring a 
ƌĞƚƵƌŶ ƚŽ ƚŚĞ ƚŚĞĂƚƌĞ ?  dŚĞ  ‘New post-operative neurological dysfunction ? ĨŝĞůĚ ƌĞĐŽƌĚƐ ƚŚĞ
occurrence of stroke-related events, as well as lower extremities paraplegia and paraparesis. 
However, it does not identify the type of stroke (other than distinguishing between transient and 
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permanent) and the level of disability following the cerebrovascular event (unless it causes paralysis 
or weakness of the legs). Furthermore, these two fields are not part of the completeness assessment 
dataset, which may negatively impact on their rate of completion compared to other fields. 
 
The NACSA collects a number of patient risk factors (identified in Table A15, Appendix) that allow 
the estimation of the EuroSCORE,(42) a risk stratification system to predict early mortality in cardiac 
surgical patients. This score can also be used to adjust mortality estimates based on patient 
characteristics to allow comparison of interventions across different patient case-mix. Furthermore, 
clinical measures collected for stable patients, such as the NYHA and ^ ƐĐŽƌĞƐ  ? ‘ŶŐŝŶĂ ƐƚĂƚƵƐ
pre-ƐƵƌŐĞƌǇ ?ĂŶĚ ‘Dyspnoea status pre-surgery ?ƌĞƐƉĞĐƚŝǀĞůǇ ?, number of previous MIs, and diabetes 
management, could also be used to case-mix patients when comparing performance or cost-
effectiveness of interventions. It is worth noting that these fields may be affected by issues 
regarding their rate of completion, as they are not part of the completeness assessment dataset 
(unlike the EuroSCORE fields). 
 
The NACSA audit does not currently collect patient related outcome measures.  The inclusion of a 
preference-based HRQoL questionnaire (preferably the EQ-5D), could improve the ability of the 
audit to inform cost-effectiveness analysis of interventions. Similarly to coronary angioplasty case, 
an alternative would be to apply values from the published literature to clinical events, as has been 
done in previous models. However, the audit does not collect all relevant clinical events, such as 
further ACS, and only collects data on those events that occur during the time spent in hospital 
following the initial PCI. As for coronary angioplasty, this approach may fail to capture the full impact 
on HRQoL by the interventions, as HRQoL may not be related to the occurrence of clinical events 
alone, or to any beneficial effect on symptoms. It is worth noting that in previous TAs, the focus was 
not on HRQoL differences driven by improvement in symptoms as they aimed to examine adjunctive 
therapies, rather than the surgical procedure. Furthermore, both TAs include CABG only, while the 
audit encompasses all major cardiac surgery procedures. Therefore, there may be other clinical 
events that were not identified as relevant to the assessment of interventions in cardiac surgery and 
would need to be collected in the audit too. The issues regarding the need to account for potential 
symptomatic differences between interventions that may be evident and are not fully accounted for 
by events would also apply in the case of cardiac surgery.  Although NYHA and CCSC scores are 
collected in the NACSA, which capture some of the symptomatic dimensions and can potentially be 
mapped onto HRQoL measures, the collection is limited to stable patients in the pre-operative stage, 
and therefore not very useful in this context. The collection of a PROM would allow HRQoL 
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considerations to be related to events, but also to symptomatic differences. As it is it may be difficult 
to demonstrate the full symptomatic benefits of an intervention over just the hospitalisation period 
following cardiac surgery, PROM collection should not be limited to this period. It would be 
preferable if HRQoL data was collected as for ablation patients in the NACRM, i.e. prior to the 
procedure, and at longer follow-up time points (6 and 12 months in this particular case), so as to 
ensure that any symptomatic impact of treatments that is not limited to the hospitalisation period is 
captured.  
 
Assuming that the audit fields in general have relatively high completion rates, with the exception of 
HRQoL, the information currently collected in the existing NACSA would provide a considerable 
amount of the information required to model the cost-effectiveness of interventions and policies in 
coronary angiography. Limitations on the collection of mortality data could be partially overcome by 
incorporating external data, namely by linkage to mortality registers, or by using estimates from the 
published literature. Linking the NACSA to other datasets could not only allow the determination of 
longer term mortality rates, but also the distribution of patients between cardiovascular and non-
cardiovascular. Even if mortality registers do not allow the identification of the cause of death, this 
can be ascertained through linkage to other audits or registers (e.g. Hospital Episode Statistics), as 
described for coronary angioplasty in Section 6.3. A potential alternative approach to overcome gaps 
in mortality data might be to use external evidence on the expected rate of non-cardiovascular 
mortality and remove this from the mortality estimates reported in the audit, and then to model 
non-cardiovascular mortality separately (e.g. using cause-exclusion life table data). Clinical events 
occurring after hospital discharge or not recorded in the audit (e.g. ACS, PCI, bleeding complications 
not resulting in cardiac surgical interventions) could also be sourced from the published literature. 
The occurrence of further cardiac surgery procedures could also be tracked ǀŝĂ ƉĂƚŝĞŶƚƐ ? E,^
number to check for further admissions. Similarly, the distribution of patients according to disability 
severity following cerebrovascular events could also be sourced from the published literature. An 
alternative to inform the occurrence of clinical events would be to use the NHS number to link the 
NACSA audit to other audits which collect data related to cardiovascular events (e.g. the MINAP for 
ACS, and the PCI audit for coronary angioplasty procedures).  These considerations apply mostly to 
the most frequent cardiac surgery procedure in the audit, i.e. CABG. Linkages to other audits and 
registers may be of relevance for less frequent cardiac surgery procedures, namely valve 
repair/replacement, aortic procedures and heart transplant, but identifying them would require 
further exploration of the clinical pathways following these procedures. 
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 7.4 Recommendations for cardiac surgery 
In summary, the EQ-5D appears to be appropriate in patients undergoing cardiac surgery, and the 
current NACSA collects some of the information required to conduct economic evaluations.  
Nevertheless, the audit does not collect any HRQoL data, and could be improved by including more 
fields and/or making some existing fields collection mandatory. The issues and corresponding PR and 
areas for FR are discussed below.  All suggested FR areas are indicative and would require a 
discussion and detailed proposal if required. 
 
As shown in Section 4.1.5 there is positive evidence of the validity of EQ-5D in cardiac surgery, most 
specifically for known-group and convergent validity, although no evidence was available on 
reliability and responsiveness. There was also some evidence that EQ-5D exhibits ceiling effects in 
this condition. Nevertheless, EQ-5D was considered an appropriate measure to estimate HRQoL in 
ĐĂƌĚŝĂĐ ƐƵƌŐĞƌǇ ? ĂŶĚ ŝƚƐ ŝŶĐůƵƐŝŽŶ ŝŶ ƚŚĞ E^ ǁŽƵůĚ ŝŵƉƌŽǀĞ ƚŚĞ ĂƵĚŝƚ ?Ɛ ĂďŝůŝƚǇ ƚŽ ŝŶĨŽƌŵ ĐŽƐƚ-
effectiveness analysis in cardiac surgery, especially if its collection also encompasses time points 
beyond the initial hospitalisation period.  To our best knowledge the collection of PROMs within the 
NACSA is not currently being considered, so it is recommended that EQ-5D (EQ-5D-5L) is collected 
within the audit. (PR.9) Furthermore, the use of the EQ-5D-5L, could potentially reduce any ceiling 
effect (86) in patients in less severe stages of cardiovascular disease. As no available evidence 
available on reliability and responsiveness of the EQ-5D, future research could aim to examine these 
properties in cardiac surgery patients using the NAPCI data (FR.5). 
 
The NACSA audit already collects considerable information of relevance for the economic evaluation 
of interventions in cardiac surgery (described in Section 7.3.3).  However, fields such as cause of 
death, type of stroke, severity of disability following stroke, and ACS and PCI on follow-up, are not 
ĐƵƌƌĞŶƚůǇ ĐŽůůĞĐƚĞĚ ? dŚĞƐĞ ĨŝĞůĚƐ ? ŝŵƉŽƌƚĂŶĐĞ ŚĂƐ ďĞĞŶ ŚŝŐŚůŝŐŚƚĞĚ ŝŶ ^ĞĐƚŝŽŶ 7.3.3, and should be 
considered for mandatory collection (PR.10).  Furthermore, it is also recommended that fields 
regarding pharmacological and surgical interventions in cardiac surgery patients (drug therapy, 
number and type of stents and type of arterial access), which are already collected in the audit, are 
considered for mandatory collection or inclusion in a Minimum Data Standard dataset to ensure high 
completion rates (PR.11). 
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Table 11: Recommendations and associated future research for cardiac surgery 
PR.9 Collect the EQ-5D (EQ-5D-5L) in the NCA prior to procedure, after procedure and at least at 
one longer follow-up time point. 
FR.5 Assess the psychometric properties of the EQ-5D-5L using data collected in the audit 
PR.10 Collect mandatory information on cause of death, type of stroke, severity of disability 
following stroke, and ACS and PCI on follow-up. 
PR.11 Depending on completion rates of completeness assessment dataset, consider making 
these fields mandatory 
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8. RESULTS FOR ACUTE CORONARY SYNDROME 
8.1 Evidence of appropriateness of EQ-5D in acute coronary syndrome (WP1.1) 
Five studies included in the updated review in CVD conditions (Section 4.14) assessed the 
psychometric properties of EQ-5D in ACS, and provided positive evidence of acceptability and 
construct (both convergent and known-group) validity, but showed poor reliability. Full details on 
the assessment of the appropriateness of EQ-5D in ACS are presented in Section 4.1.5. 
 
8.2 Routinely collected proxy measures in acute coronary syndrome (WP1.2) 
As the EQ-5D was found to be acceptable for CVD conditions, no additional searches for alternative 
measures were conducted. 
 
8.3 Evidence for economic evaluations in acute coronary syndrome (WP1.3) 
8.3.1 Cost-effectiveness modelling approach used in recent HTAs in acute coronary syndrome  
Five TAs relating to ACS were identified from the searches, one of these is currently in development 
with an anticipated issue date of July 2014, (35) and corresponds to the review of a previous TA.(36)  
Three of the TAs examined the clinical and cost-effectiveness of platelet aggregation inhibitors for 
the treatment of people who have suffered an ACS and are medically managed or underwent 
revascularisation procedures (PCI or CABG).(35-37)  Another TA examined the clinical and cost-
effectiveness of a direct thrombin inhibitor, bivalirudin, compared to heparin in addition to 
glycoprotein inhibitors for patients with STEMI intended for PCI.(38)  Another TA examined the 
clinical and cost-effectiveness of statins for the prevention of coronary heart disease (including 
ACS).(43)  
 
All TAs except one used two-part models to examine the cost-effectiveness of the interventions 
under appraisal.  The models comprised a short-term element that included a decision tree to model 
clinical events following an ACS (between three days to one year after the episode), and a long-term 
Markov model (15 months to lifetime) that modelled the subsequent clinical pathway and prognosis 
for those patients that survived within the short-term model.(35;37)  As mentioned in Section 14.3, 
the two-part model aimed to separately characterise the impact of treatments over the initial acute 
period and the post-acute period (or trial follow-up period vs. longer term). Often an assumption 
was made that the relative effectiveness of a particular treatment would be confined to the acute or 
trial period (e.g. TA182, TA236) (36;38) but that the longer term consequences associated with 
particular events experienced during this period would be different. The main clinical events 
incorporated in the models reflected the occurrence of further ACS (fatal and non-fatal), stroke 
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(fatal, and non-fatal, with different types and subsequent level of disability considered for the 
latter), revascularisation procedures (PCI and CABG), bleeding and other-cardiovascular and non-
cardiovascular mortality. Baseline risks and relative risks of clinical events in the short-term model 
were modelled based mostly on trial data (survival analysis), while risks and relative risls of clinical 
events on the longer-term element of the models were sourced from the published literature (35-
38) or from trial data.(37)  In one TA, observational data from the MINAP and General Practitioner 
Research Database was used to estimate risk of non-fatal events in the long-term Markov model. 
(37) Another TA applied a Markov model to examine the cost-effectiveness of statins in the primary 
and secondary prevention coronary heart disease (including ACS).(43)  In this model, the risk of 
events was sourced by UK observational studies and treatment effect of statins was applied as a 
relative risk reduction from a meta-analysis. The transition probabilities for secondary events (i.e. 
following one other cardiovascular event) could be different (depending on the type of event) for 
the first year, but remained constant in subsequent years. Other cause mortality risk estimated from 
national statistics for the overall population.(43)  
 
All studies quality adjusted survival by assigning mean utility values to the separate health states. 
The majority of utilities were derived from mean EQ-5D estimates sourced from external estimates 
reported in the published literature.(35-38;43)  One study used time trade-off elicited utility values 
to inform stable angina health states. (43)  In some models, utilities were gender and/or age 
specific,(35;36) and one model weighted utilities according to levels of disability in the stroke health 
states (although it was unclear what instrument or assumption was used to classify stroke 
severity).(35) 
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Table 12: Summary of existing models in acute coronary syndromes  
 Model approach Method used to model utilities  
MTA (ID:648): Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes 
(review of TA182); 2013 (35) 
 TAG two part model; short term trial-based 
model plus long-term extrapolation Markov 
model.   
Short-term model composed of decision tree 
for the first three days followed by a Markov 
model. Clinical events in the model are: 
primary endpoint events (non-fatal MI, non-
fatal stroke), bleed endpoint event, 
cardiovascular or bleed death, other death. 
Long-term de-novo Markov model: 
Ten initial health states defined by a 
combination of 1) worst event (none, MI, 
stroke), 2) Prior events (0, 1, 2, 3+) and 3) 
Disabled (yes or no).  
Further health states are defined by the 
occurrence of clinical events (and dependent 
on previous health state): Fatal MI, Nonfatal 
MI, Fatal HS, Nonfatal HS not disabling, 
Nonfatal HS disabling, Fatal ischaemic 
stroke/transient ischaemic, Nonfatal 
ischaemic stroke/transient ischaemic not 
disabling, Nonfatal ischaemic 
stroke/transient ischaemic disabling, other 
vascular death, non-vascular death. 
 
Effectiveness: Risk equations for primary 
endpoints and bleeding events (active 
treatment period) on short term model; 
gender specific event incidence risks and 
event fatality risks (age adjusted) for long-
term model; RR of MI, stroke, vascular and 
non-vascular death for patients with 
diabetes and vs. no diabetes were applied to 
reflect differences between populations. 
Source: clinical RCTs; published literature 
Utility: mean EQ-5D utility values (gender specific 
and disability weighted for stroke states) applied to 
separate health states; disutilities from clinical 
events applied as decrements for year following 
event.  
Source: clinical RCTs, assumptions. 
 
STA (TA236): Ticagrelor for the treatment of acute coronary syndromes; 2011 (37) 
 DĂŶƵĨĂĐƚƵƌĞƌ ?ƐƚǁŽ-part model: one-year 
decision tree plus long-term extrapolation 
Markov model.  
Decision tree: 4 separate health states (no 
further event, non-fatal MI, non-fatal stroke 
and death from any cause). 
Markov model: 6 separate health states; no 
further event, non-fatal MI, post MI, non-
fatal stroke, post stroke and dead. Non-fatal 
MI and non-fatal stroke health states are 
tunnel states that allow for a worse 
prognosis for patients in the year in which a 
non-fatal event occurs compared to 
subsequent years. 
Utility: mean EQ5D values assigned to each 
separate health state  
Source: clinical RCT, assumptions(Published 
literature utility estimates applied in sensitivity 
analysis) 
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Effectiveness: 
Survival analysis to estimate baseline risk 
and HR of clinical events on short term 
model. In the long-term model fatal events 
RRs are applied to UK life tables mortality 
estimates, and non-fatal event rates were 
estimated from an observational database. 
Sources: clinical RCTs, published literature, 
manufacturer study based on MINAP and 
General Practice Research Database.  
 
STA (TA230): Bivalirudin for the treatment of ST-segment elevation myocardial infarction; 2011 (38) 
 DĂŶƵĨĂĐƚƵƌĞƌ ?ƐƚǁŽ-part model: one-year 
decision tree plus long-term extrapolation 
Markov model.  
Decision tree: Initial angiography and 
reperfusion therapy, after which they can 
experience 7 possible subsequent events: no 
relevant complications, minor bleed, major 
bleed, stroke, repeat MI, repeat 
revascularisation and death. 
Markov model: 2 separate health states; 
alive and dead 
Effectiveness: RR of clinical events for 
patients treated with bivalirudin applied to 
baseline risks on the comparator arm, 
independent of index treatment (PCI, CABG 
or conservative treatment) in the short-term 
model; long term model assumes that life-
expectancy for those surviving the initial 
period was identical for both bivalirudin and 
heparin with GPI, and based on UK register 
data.  
Source: clinical RCT, published literature 
Utility: mean EQ-5D values from a single 
observational UK study were assigned to patients in 
the initial period (0.683) and in the long-term model 
(0.718), from a cohort study that followed up 
patients for 1-year after being diagnosed with acute 
MI. 
Source: Published literature 
 
STA (TA182): Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary 
intervention; 2009(36) 
 DĂŶƵĨĂĐƚƵƌĞƌ ?ƐƚǁŽ-part Markov model: 
short term trial-based model plus long-term 
extrapolation Markov model.   
Short-term model is composed of a decision 
tree for the first three days followed by a 
Markov model (15 months). Clinical events in 
the model are: primary endpoint events 
(non-fatal MI, non-fatal stroke), bleed 
endpoint event, cardiovascular or bleed 
death, other death. 
Long-term Markov model; same structure as 
for trial-based Markov model. 
 
Effectiveness: 
Risk equations for primary endpoints  and 
bleeding events (active treatment period) on 
short term model; mortality RRs in 
revascularised STEMI and unstable 
angina/NSTEMI compared to general 
Utility: 
Baseline utility (mean EQ-5D age and sex specific) 
taken from UK population norm;  ongoing utility EQ-
5D decrements for ACS and stroke/MI from single 
study; Major bleeding assumed to impose 25% 
utility decrement during 14 days. 
Source: Published literature; assumptions 
 
TAG critiqued the use of utility values as they were 
not directly measured on the population of interest 
(heart disease). The TAG applied a condition specific 
long-term utility decrement based on a US survey 
study. Limitations of this approach were recognised 
by the TAG. 
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coronary heart disease population, applied 
to UK age and gender adjusted life tables for 
long term model. 
Source: Clinical RCTs; published literature 
MTA (TA94):  Statins for the Prevention of Coronary Events; 2006 (43) 
 d' ?ƐDĂƌŬŽǀŵŽĚĞů: 24 separate health 
states;:  event free,  MI, stable angina, 
unstable angina, CHD death, TIA, stroke, 
cerebrovascular death, death other causes, 
post MI,  MI given CVD history, MI given CHD 
history, post stable angina, post unstable 
angina, post TIA, post stroke, post stroke 
given cerebrovascular disease history, post 
stroke given CHD history, fatal CHD event 
given CHD history, fatal CHD event given 
cerebrovascular disease history, fatal 
cerebrovascular event given CHD history, 
fatal cerebrovascular event given 
cerebrovascular disease history, death other 
causes following a first event. 
 
Effectiveness: 
CHD and cerebrovascular disease baseline 
risk of events modelled by age and gender 
from UK observational studies and 
treatment effect from statins applied as a 
relative risk reduction. Model allowed for 
differences in first year transition 
probabilities for secondary events, with 
these probabilities being constant in 
subsequent years. Other cause mortality risk 
estimated from national statistics for the 
overall population. 
Source: Observational studies, MA, 
published literature 
Utility: 
Mean EQ-5D utilities for baseline utility and most 
clinical events, although TTO-elicited utilities were 
applied to stable angina. It was assumed that there 
was no disutility due to the use of statins. 
Source: Reanalysis of UK population norm utilities; 
Published literature 
AE: Adverse Events; MTA: Multiple Technology Appraisal; CHD: Coronary heart disease; STA: Single 
Technology Appraisal; MI: Myocardial Infarction; HS: Haemorrhagic stroke; TAG: Technology Appraisal 
Group; TIA: Transient ischaemic attack; TA: Technology Appraisal; RCT: randomised controlled trial; RR: 
Relative risk. 
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In summary, the following evidence would be required to compare providers or the cost-
effectiveness of interventions for ACS: 
x Pharmaceutical interventions (type of intervention, treatment discontinuation, adverse 
events) 
x Underlying conditions and type of ACS 
x Procedure rates (type of intervention, success rate, peri and post-procedure complications)  
x Hospitalisation (rates, cause,  length of stay) 
x Further cardiovascular events (ACS, revascularisation, stroke, level of disability following 
stroke) 
x HRQoL data (at occurrence of index ACS and at follow-up) 
x Death rates (cardiac and procedure related, all cause) 
The majority of this evidence would need to be dated and linked through timings of collection. 
 
8.3.2 Fields collected in Myocardial Ischaemia National Audit  
The MINAP collects clinical data about patients that can present with either of the two types of MI  W
STEMI and non-ST elevation MI (NSTEMI)  W for which management of the condition differs.  As 
treatment of MI will also depend on the type of hospital in which the patient receives treatment, 
MINAP distinguishes between two types: interventional (providing emergency or primary PCI) and 
non-interventional hospital (does not have a facility to perform primary PCI). Therefore, the data 
collection form has been divided depending on the type of heart attack and the type of hospital.  
 
The fields in the MINAP are collected via a questionnaire, which includes four forms: main generic, 
reperfusion, interventional audit and Takotsubo cardiomyopathy form.  The questionnaire data are 
collected on an Excel spreadsheet (minap-dataset-v10.3.2). The Takotsubo cardiomyopathy is not 
formally part of MINAP dataset, and it is only completed if the discharge diagnosis is Takotsubo 
cardiomyopathy. For this reason, only items collected on the three remaining datasets were 
examined. Fields in the datasets have been classified as mandatory, expected to be completed for a 
useful overview of care, or for local use, with the classification varying depending on whether the 
patient suffered a STEMI or a NSTEMI. The mandatory and non mandatory fields are listed in the 
Appendix for STEMI and NSTEMI respectively.  For STEMI patients the data provide information on 
demographics (hospital identifier, NHS number, patient name (surname and forename), age, sex, 
postcode, General practitioner (GP) /Primary care trust (PCT) code); admission details (initial 
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diagnosis, procedure performed at the interventional hospital, date/time of symptom onset, 
date/time of call for help, ambulance job number, date/time arrival at hospital, admission method, 
referring hospital code); reperfusion (initial reperfusion treatment, electrocardiogram determining 
treatment location of initial reperfusion treatment, date/time of reperfusion treatment, delay 
before treatment, reason reperfusion treatment not given, additional reperfusion treatment , 
patient location at time of STEMI); examinations (systolic blood pressure, heart rate, Killip class); 
tests (serum glucose, creatinine, raised cardiac markers, peak troponin); drug therapy at discharge 
(beta blocker, angiotensin converting enzyme inhibitor or angiotensin receptor blocker, statin, 
aspirin, thienopyridine inhibitor, aldosterone antagonist, Ticagrelor); diabetes or hyperglycaemia 
management (as an inpatient); complications (death in hospital); cardiac arrest (location), 
investigations and interventions (daycase transfer date, interventional centre code); discharge 
details (date, diagnosis, destination); and interventional audit data in the case of interventional 
hospitals (date/time of arrival at non interventional hospital, assessment at non interventional 
hospital, assessment at interventional centre, intended reperfusion procedure, procedure 
performed, reason for no angiogram performed, reason for no intervention performed). Data 
mandatorily collected for NSTEMI patients is generally the same, with a few exceptions regarding 
which items are collected in admission details, reperfusion, previous medical history, drug therapy, 
complications, investigations and interventions, and discharge details. Interventional audit data is 
not collected for NSTEMI patients, and it is not applicable. 
 
8.3.3 Comparing fields in the Myocardial Ischaemia National Audit with variables used in existing 
HTAs 
The existing models used survival analysis to model mortality, and therefore the data collected in 
D/EW ƚŚƌŽƵŐŚ ƚŚĞ ǀĂƌŝĂďůĞ  ‘ĚĞĂƚŚ ŝŶ ŚŽƐƉŝƚĂů ?could be used to model the different types of 
mortality (all cause, cardiovascular, and non-cardiovascular). However, the MINAP will only provide 
data on death occurring at the hospital, which can be a limitation. There is some information in the 
MINAP on clinical interventions and type of care (procedure performed at the interventional 
hospital, admission method, and admission ward, drug therapy on discharge, coronary intervention) 
which would provide some of the information required to compare alternative treatments. The 
MINAP collects data on complications following ACS (bleeding, reinfarction), as well as reperfusion 
procedures (for STEMI patients) that can be used to inform the occurrence of further clinical events 
within the same hospital episode, but these items are not mandatory for all ACS classifications 
(STEMI and NSTEMI). Moreover, the audit does not provide data on the occurrence of stroke related 
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events, such as ischaemic and haemorrhagic stroke, and on disability resulting from these events 
which may have a non-negligible impact on HRQoL and costs.  
 
Previous models have defined patient subgroups or adjusted effectiveness and utility estimates 
based on sex, age, comorbidities (namely diabetes) and type of ACS (STEMI, NSTEMI, unstable 
angina). These data are collected in the audit and could be used to case-mix patients when 
comparing performance or cost-effectiveness of interventions. There is also a non-mandatory field in 
MINAP for previous clinical history that could be of interest in this context, as previous models have 
explicitly incorporated clinical history in their model structure.(43) 
 
MINAP does not currently collect patient-reported outcome measures.  The inclusion of a 
preference-based HRQoL questionnaire (preferably the EQ-5D-5L), could improve the ability of the 
audit to inform cost-effectiveness analysis of interventions. An alternative would be to apply values 
from the published literature to clinical events, as has been done in previous models. However, as it 
has been highlighted before, the MINAP does not collect all relevant data regarding clinical events, 
namely the occurrence of ischaemic and haemorrhagic strokes and level of disability following 
stroke. Even if the audit collected all relevant clinical events, applying utility weights to the clinical 
events alone may fail to capture the impact on HRQoL of the interventions if this extends beyond 
changing the frequency of the events and has an effect on symptoms too.  Similarly to the PCI audit, 
collection of a PROM would allow HRQoL considerations to be related to events, but also to 
symptomatic differences that may be evident and are not fully accounted for by events. The issue 
regarding duration of follow-up period for the collection of PROMs in the PCI audit also applies here, 
as it may be difficult to demonstrate the full symptomatic benefits of interventions over just the 
hospitalisation period following ACS. Therefore, the collection of PROMs beyond the initial 
hospitalisation episode would be useful to ensure that any longer term symptomatic impact of 
treatments is captured. 
 
Assuming the mandatory fields have relatively high completion rates, with the exception of HRQoL, 
the information currently collected in the existing MINAP would provide a considerable amount of 
information required to model the cost-effectiveness of interventions and policies in ACS.  Although 
mortality data is only collected for the period until discharge, external published data, linkage to 
other datasets (mortality registers, Hospital Episode Statistics, other audits) or longitudinal linkage 
across multiple MINAP entries (for patients that suffer further hospitalisations due to ACS) could be 
incorporated to overcome this limitation. Another alternative is to use risk scores, such as the Global 
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Registry of Acute Cardiac Events (GRACE), to estimate cardiovascular mortality, as well as the risk of 
future MI events, in hospital and at 6 months.(44)  All the variables required to estimate GRACE are 
already collected within the audit (age, Killip class, pulse rate, systolic blood pressure, serum 
creatinine, ST-segment deviation, cardiac arrest at admission, elevated cardiomarkers). Another risk 
score that can be used to predict all cause mortality, myocardial infarction, or urgent 
revascularisation is the Thrombolysis in Myocardial Infarction (TIMI).(45)  However, not all variables 
required to estimate this score are mandatory variables in MINAP, namely the place where aspirin 
was administered (allows assessment of whether it was administered within 7 days of the initial 
event), and TIMI only predicts short-term outcomes (at 14 days after index event). Another 
limitation of the MINAP to inform cost-effectiveness studies is that it provides incomplete coverage 
of other relevant clinical events that may occur during the initial episode. This limitation could 
potentially be addressed by linking data to other audits, such as the PCI audit for those patients 
undergoing coronary angioplasty (or coronary angiography, as this audit covers both procedures) to 
determine procedure related complications (e.g. cerebral, haemorrhagic stroke). However, the 
linkage to the NAPCI would in itself be affected by the same issues that were identified in that audit 
(Section 14.3), i.e. not all types of stroke are recorded, and level of disability following stroke is also 
not collected. Follow-up data which is limited to some complications (bleeding, reinfarction) and 
repeated revascularisation (reperfusion) occurring within the same hospital episode could be 
supplemented by risk estimates taken from the published literature. Clinical events occurring after 
the hospital episode for which the patient was initially admitted would also have to be sourced from 
ƚŚĞƉƵďůŝƐŚĞĚůŝƚĞƌĂƚƵƌĞǁŝƚŚƚŚĞĞǆĐĞƉƚŝŽŶŽĨĨƵƌƚŚĞƌ^ĞǀĞŶƚƐ ?ĂƐƉĂƚŝĞŶƚƐ ?E,^ŶƵŵďĞƌĐŽƵůĚďĞ
used to track readmissions. It is worth noting that it is unclear in the audit whether further events 
within the same hospital episode, such as reinfarction would generate a new entry on MINAP, or just 
ďĞ ĐŽůůĞĐƚĞĚ ŽŶ ƚŚĞ ĨŝĞůĚ  ‘ƌĞŝŶĨĂƌĐƚŝŽŶ ? ? ǁŚŝĐŚ ŝƐ ŶŽƚ ƉĂƌƚ ŽĨ ƚŚĞ ŵŝŶŝŵƵŵ ĚĂƚĂ ƐƚĂŶĚĂƌĚ ?
Furthermore, even by linking a patient longitudinally across multiple MINAP entries and to other 
relevant datasets, issues would remain regarding events that are not captured within the MINAP or 
NAPCI registries (e.g death outside hospitalisation, ischaemic stroke, non-ischaemic stroke unrelated 
to procedure, stroke disability and issues about symptoms more generally). 
 
8.4 Recommendations for acute coronary syndrome 
In summary, the EQ-5D appears to be appropriate in ACS patients, and the current MINAP collects 
some of the information required to conduct economic evaluations.  Nevertheless, the audit does 
not collect any HRQoL data, and could be improved by including more fields and/or making their 
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collection mandatory. The issues and corresponding PR and areas for FR are discussed below.  All 
suggested FR areas are indicative and would require a discussion and detailed proposal if required. 
 
As shown in Section 4.1, the validity of EQ-5D in ACS was demonstrated across all examined 
psychometric properties. There was no evidence regarding the responsiveness of this measure, and 
reliability examined at health dimension level was found to be poor in one study included in the 
review. There were also issues regarding the existence of potential ceiling effects in this condition. 
Nevertheless, the overall evidence was positive and EQ-5D is considered an appropriate measure to 
estimate ,ZYŽ> ŝŶ^ ?dŚĞ ŝŶĐůƵƐŝŽŶŽĨ ƚŚŝƐŵĞĂƐƵƌĞǁŽƵůĚ ŝŵƉƌŽǀĞ ƚŚĞĂƵĚŝƚ ?ƐĂďŝůŝƚǇ ƚŽ ŝŶĨŽƌŵ
cost-effectiveness analysis in this condition, especially if its collection also encompasses time points 
beyond the initial hospitalisation period. To our best knowledge the collection of PROMs within the 
NACSA is not currently being considered, so it is recommended that EQ-5D (EQ-5D-5L) is collected 
within the audit.(PR.12, FR.5) As mentioned in previous sections, the use of the EQ-5D-5L could 
potentially reduce any ceiling effect(86) in patients in less severe stages of cardiovascular disease. 
Alternatively and provided that all relevant clinical events could be collected or sourced from 
external sources, utility weights from the published literaturature could be applied to clinical events 
to generate quality adjusted life years (QALYs).  
 
The MINAP already collects the majority of relevant information for the economic evaluation of 
interventions in ACS (described in Section 8.3.3).  However, fields such as occurrence and type of 
stroke, severity of disability following stroke are not currently collected. These fields importance has 
been highlighted in Section 8.3.3, and should be considered for mandatory collection (PR.13).   
 
Table 13: Recommendations and associated future research for acute coronary syndrome 
PR.12 Collect the EQ-5D (EQ-5D-5L) in the NCA at admission and at least one longer-term follow-
up time point.  
FR.6 Assess the psychometric properties of the EQ-5D-5L using data collected in the audit 
PR.13 Collect mandatory information on occurrence and type of stroke, severity of disability 
following stroke. 
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9. SUMMARY 
9.1 Summary of evidence used to inform the conclusions for WP1.1  
Cardiovascular conditions: An existing review (3) was updated and a total of 12 primary studies 
were included in the update.  As there was substantial overlap between the study populations, and a 
very limited amount of evidence for some of the individual CVD conditions the evidence is 
summarised collectively.  Overal, the review provides evidence that the EQ-5D is adequate in CVD, 
being acceptable in the majority of studies and having good construct validity (known group and 
convergent).  There was some evidence of ceiling effects (although this is unlikely to be observed in 
the hospitalised patients within the CVD audits), and there was very little evidence on its reliability.  
Additional evidence was required on its sensitivity to detecting small changes in HRQoL over time. 
 
Table 14: Summary of evidence on EQ-5D for CVD conditions 
Measure (N) Acceptability Reliability Construct (KGV; 
Convergent) 
Responsiveness  
(Change over time; Ceiling 
effects) 
EQ-5D (12) Fair to good Poor (little 
evidence) 
Good Poor (mostly 
uncertain) 
Evidence of 
ceiling 
effects 
(more 
pronounced 
at health 
dimension 
level) 
 Adequate, with some uncertainty surrounding responsiveness.   
 
 
9.2 Summary of evidence required for use in economic evaluations (WP1.3) 
Cardiac arrhythmia: The NACRM currently collects the EQ-5D and the condition-specific AFTEQ in a 
patient questionnaire administered pre and post (6 month and 12 month) the ablation procedure.  
However, only patients undergoing ablation procedures complete the questionnaire and if this could 
be extended to all patients within the audit, this would increase the scope of the audit data in 
relation to performing economic evaluations and comparing providers.  Although there is currently 
insufficient information in the mandatory fields to conduct formal economic evaluations, the data 
standard subset has additional information that could be used, subject to completion levels.  In 
particular, the following information would ideally be required for informing economic models: 
normal sinus rhythm, permanent AF with uncontrolled symptoms, permanent AF with controlled 
symptoms, and death rates, type of intervention (CRT-P, CRT-D, dual-chamber or single chamber 
pace-makers, implantable cardioverter defibrillators) and associated success/complication rates, 
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cardiac resynchronisation therapy, anti-coagulant drugs and thromboembolic, ischaemic and 
bleeding events. 
 
Heart Failure: Although no PROMs are currently collected in the NHFA, it may be possible to utilise 
the NYHA breathless severity data to obtain proxy preference-based utility scores to generate QALYs 
in economic evaluations.  However, the NHFA data are only collected on admission and re-
admission.  To inform the benefits of interventions, they would also need to be collected post 
intervention and on discharge from hospital.  In addition, the collection of EQ-5D-5L directly within 
the audit would capture the benefits of interventions and procedures directly thus reduce the 
uncertainty inherent within mapping functions.  Excluding HRQoL information, the current NHFA 
collects much of the information required to conduct formal economic evaluations and to compare 
providers, and it is possible that the gaps identified (mortality and surgical complications) may be 
available in external datasets if these could be linked in some way.   
 
Coronary angioplasty: Although the PCI audit does not collect PROMs, due to the discrete nature of 
the health states in the typical clinical pathway, it would be possible to utilise evidence in the 
literature to populate HRQoL values in economic evaluations.  However, the inclusion of a PROM 
(preferably the EQ-5D-5L) within the audit would enable direct comparison of providers and 
interventions using the audit data.  In addition, depending on the timing of collection, EQ-5D-5L 
collected via the audit, could provide useful information on the longer-term effects (for example 6 
month and 12 month post discharge) on HRQoL associated with reductions in symptoms, rather than 
the immediate direct effect of specific interventions and procedures (i.e. during hospitalisation).  
Excluding HRQoL information, the NAPCI does collect much of the information required to conduct 
formal economic evaluations and to compare providers.  Again it may be possible to use external 
datasets to subsidise gaps in the evidence collected (e.g. mortality and surgical complication rates) 
for economic evaluations, but this would not be particularly informative when comparing providers. 
 
Cardiac surgery: The NACSA audit does not collect PROMs, and as discussed for the PCI audit, while 
it may be possible to utilise evidence from the literature when conducting economic evaluations of 
interventions, this form of information is not particularly informative when comparing providers and 
it is recommended that the EQ-5D-5L is collected within the audit with follow-up data to capture the 
longer-term HRQoL benefits of interventions.  Excluding the HRQoL information, the information 
collected within the audit would suffice to compare providers and would provide a substantial 
amount of the evidence required to conduct formal economic evaluations of interventions 
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(assuming a relatively high completion rate for all fields).  The exceptions are again the mortality 
information, surgical complications and longer term information on subsequent events.  The latter 
may be available from external datasets if these could be linked in some way. 
 
Acute coronary syndrome: The MINAP does not collect PROMs and as discussed for the PCI audit, 
while it may be possible to utilise evidence from the literature when conducting economic 
evaluations of interventions, this form of information is not particularly informative when comparing 
providers and it is recommended that the EQ-5D-5L is collected within the audit with follow-up data 
to capture the longer-term HRQoL benefits of interventions.  Excluding the HRQoL information, the 
information collected within the audit would provide a considerable amount of the information 
required to model the cost-effectiveness of interventions and policies in ACS assuming relatively 
high completion levels.   
 
In summary, while the evidence collected in the individual audits will allow comparison of providers 
in many cases, it is clear that the mandatory fields in most of the audits will not provide sufficient 
detailed information to perform formal economic evaluations.  The main omission is the lack of 
PROMs which limits the flexibility of the data in terms of comparing either providers or interventions 
used in routine clinical practice.  However, many of the audits contain optional fields which would be 
useful for economic evaluations and enforcing the collection of key variables is recommended in 
many of the audits.  A recurrent issue relates to the level of detail and the timing of the variables 
collected.  To be useful for economic evaluations, many of the variables used have to be 
synchronised in terms of timing of collection, and many need to be collected over periods of time to 
assess progression or relapse etc.   
 
Finally, subject to synchronising the fields collected, linking the CVD audits could produce a 
synergistic effect in terms of the evidence required to inform parameters within formal economic 
evaluations or to compare providers.  However, exploring this possibility is outside the scope and 
time restrictions of the current project. 
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APPENDIX: CARDIOVASCULAR CONDITIONS  
The tables in this Appendix provide additional information for the reviews (WP1.1, 1.2 and 1.3) conducted for CVD conditions.  
 
Table A1: Characteristics of included studies included in the systematic review for cardiovascular conditions (WP 1.1) 
Study ref 
Author, Year  
Country  Disease/treatment stage Treatment (if any) Study type (e.g. cross 
sectional, RCT, cohort) 
Study objective 
Schweikert, 
2006
a(
5) 
Germany Patients with acute coronary 
syndromes ACS (MI , coronary 
artery bypass, angina) 
No treatment, 
single cohort 
Questionnaires 
given at admission, 
at discharge and 
three months after 
discharge 
Consecutive patients 
attending inpatient cardiac 
rehabilitation following ACS 
To analyse the acceptance and 
feasibility, discriminative ability 
construct validity, criterion validity, 
reliability and responsiveness of the 
EQ-5D 
van Stel, 2006
a(
23) The Netherlands Patients with symptomatic 
coronary stenosis 
OctoPump 
standard on-pump 
CABG vs off-pump 
CABG 
OctoStent  
Off-pump CABG vs 
PTCA 
Questionnaires 
given prior to 
intervention, at 1, 
3, 6 and 12 months 
after the 
intervention. 
Two RCTs: OctoPump 
OctoStent  
 
To assess the equivalency of SF-6D and 
EQ-5D cross-sectionally, in domain 
content, in scoring distribution, and in 
the amount of change measured after 
intervention 
Nowels, 2005(25) United States Patients who suffered a MI (2 
to 25 months prior to study) 
No treatment, 
single cohort 
Questionnaires 
given before 
appointment. 
Cross-sectional study set at 
multi-site cardiology group 
practice 
To assess cross-sectional validity of EQ-
5D after MI. 
Eurich, 2006
a
(46) United States 
and Canada 
Patients with heart failure 
older than 30 years old and 
LVSD 
No treatment, 
single cohort 
Questionnaires 
given at baseline 
Cohort study Patients 
attending outpatient services 
Evaluate the relative responsiveness of 
selected disease-specific and generic 
HRQoL measures. 
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and at 6 weeks. 
Spertus, 2005
a
(47) North America Patients with heart failure 
older than 30 years old and 
LVSD 
No treatment, 
single cohort 
Questionnaires 
applied at baseline 
and at 6.7± 2.6 
weeks. 
Cohort study Patients 
attending outpatient services 
Compare the ability of selected 
disease-specific and generic HRQoL 
measures to reflect short-term changes 
in the clinical status of outpatients with 
heart failure. 
De Smedt, 
2013
b
(12) 
Europe (22 
countries) 
Patients hospitalised for 
CABG, PCI, acute MI or 
myocardial ischemia 
No treatment, 
single cohort 
Patients 
interviewed 6 
months to 3 years 
after index hospital 
admission 
Cross-sectional survey study  To investigate the validity and reliability 
of the EQ-5D, SF-12 and HADS 
Sut, 2011
b(
13) Turkey Patients with ACS (MI and 
unstable angina pectoris) 
No treatment, 
single cohort 
Patients 
interviewed at 
hospital 
Cross-sectional study To evaluate the construct validity of the 
Turkish version of the EQ-5D in patients 
with ACS 
Garster, 2009
b
(14) United States Population-based sample that 
included individuals without 
CHD, and with CHD of varying 
severity. 
Patients with heart failure 
older than 35 years old and 
LVSD 
No treatment. 
Patients 
interviewed over 
phone in first study 
(NHMS), and at the 
heart failure clinic 
on the parallel 
study (COMHS) 
Cross-sectional studies 
NHMS 
COMHS 
To compare HRQoL differences with 
CHD in generic indexes and a proxy 
specific score in a nationally 
representative sample of US adults 
Kontodimopoulos, 
2011
b(
15) 
Greece Patients with chronic heart 
failure admitted for elective 
cardiac surgery 
No treatment, 
single cohort. 
Patients 
interviewed at 
hospital 
Cross-sectional survey study 
Consecutive patients admitted 
for elective cardiac surgery 
To compare EQ-5D and SF-6D utilities 
across groups of chronic heart failure 
with varying disease severity 
Feeny, 2012
b
(16) United States Patients with congestive heart 
failure, older than 35 years old 
and LVSD 
(and patients undergoing 
No treatment. 
Questionnaires 
given at baseline 
and at 6 months 
Prospective cohort study To examine agreement in classifying 
patients as better, stable or worse.  
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cataract extraction surgery) follow-up 
De Smedt, 
2014
b
(19) 
Europe (20 
countries) 
Patients hospitalised for 
CABG, PCI, acute MI or 
myocardial ischemia 
No treatment, 
single cohort 
Patients 
interviewed 6 
months to 3 years 
after index hospital 
admission 
Cross-sectional survey study  To compare EQ5D and SF-6D utility 
scores in a large  European sample of 
patients with stable CHD 
Withers, 2014
b
(17) UK Cardiac arrhythmia patients 
treated with catheter ablation 
No treatment, 
single cohort 
Pre and post-
procedure 
questionnaires sent 
to patients at the 
same time. 
Reminders were 
sent to non-
responders within 
16-29 days of first 
contact. 
Retrospective audit data  
 
Consecutive patients treated 
with catheter ablation  
To assess the feasibility of 
administering PROMs in patients 
treated with ablation for cardiac 
arrhythmias, and to conduct the first 
stage of development and testing of a 
new PROM tool. 
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Table A2: Participant characteristics studies included in the systematic review for cardiovascular conditions (WP 1.1) 
Ref 
Man 
ID 
Study ref 
Author, Year 
Number of 
participants 
recruited 
Age in years 
mean (sd); 
range 
male %  Ethnicity 
(%) 
Other characteristics (%) Missing data (patients completing study) 
include reasons for non-completion if 
given 
        
 Schweikert, 2006
 
(24) 
114 55(7.6); 30-65  85 NR MI: 51 
Coronary artery bypass: 42 
Angina: 7 
NYHA class I: 83 
NYHA class II: 9 
NYHA class III: 3 
NYHA class IV: 0 
106 patients included in analysis 
8 patients excluded from analysis: 5 
withdrew and 3 had incomplete 
documentation for administrative 
reasons. Missing and invalid responses in 
the EQ-5D self-classifier ranged from 
0.6% (admission) to 2.9% (discharge). 
 van Stel, 2006(23) 560(281+280) 60.2 (9.3) 70.4 NR - % of missing data (BL and post-
intervention respectively): EQ-5D: 9.1%; 
15.9% 
5.9% (33) patients lost to follow-up 
4.6% (BL) and 4.1% (post-intervention) 
patients did not fill in the questionnaires 
 Nowels, 2005(25) 123 64 (NR) 69 NR One previous MI: 80 
Two previous MI: 17 
Three previous MI: 3 
Median time since last MI: 
176.5days (range 25-872 days) 
CCSC  I: 74 
CCSC II: 19 
CCSC III: 6 
CCSC IV: 1 
111 patients appeared for appointment 
20 patients of scheduled patients refused 
consent 
99 patients completed study 
 Eurich, 2006(46) 476 60(13) 75 Caucasian: 
73 
African-
American: 
23 
Other: 4 
NYHA class I: 11 
NYHA class II: 43 
NYHA class III: 41 
NYHA class IV: 5 
Only 298 who had complete data were 
included in the study. No other reason 
provided. 
 Spertus, 2005(47) 547 61(13) 75 White: 70 NYHA class I: 11NYHA class II: 41  
NYHA class III: 44 
NYHA class IV: 6 
Only 476 who had complete data were 
included in the study. No other reason 
provided. 
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5 patients died during the study 
 De Smedt, 
2013(18) 
8,966 63.2 (9.5) 74.6 NR Primary education: 25.3 
 Secondary education 56.7  
Higher education: 18.0 
8,745 were included in the analysis 
 Kahyaoglu, 
2011(48) 
138 63.9 (9.3) 72.1 NR MI : 45.1 
unstable angina pectoris: 54.9 
16 patients did not agree to respond to 
the scales 
122 patients were  included in the 
analysis 
 Garster, 2009(14) NHMS: 3,844  
COMHS: 154 
No CHD: 58.9 
(14.0)  
CHD only: 69.9 
(10.2) 
CHD + 
medication: 
68.9 (10.7) 
No CHD: 
41.2  
CHD only: 
57.0 
CHD + 
medication: 
49.1 
No CHD: 
66.2 
(White); 
28.8 (Black) 
CHD only: 
75.9(White); 
20.4 
CHD + 
medication: 
62.4 
(White); 
30.7 (Black) 
No CHD: 3,350 patients 
CHD only: 265 patients 
CHD + medication: 218 patients 
 
CHD only: 28.3 (CABG), 37.0 
(coronary angiography) 
CHD + medication: 33.0 (CABG), 
52.3 (coronary angiography) 
NHMS: 3,844 patients completed the 
study (46.% response rate) 
COMHS: 154 patients completed the 
study, no other information reported 
 Kontodimopoulos, 
2011(15) 
256 65.80 (71.7) 71.7 NR Self-assessed severity: 
Very severe: 17.1 
Severe: 35.9 
Medium: 21.5 
Mild: 15.5 
Very mild:10.0 
 
Comorbid conditions: 
Unstable angina: 23.5  
Diabetes: 21.9 
Hypertension: 61.8 
Acute MI: 32. 
251 patients included (98% response 
rate) 
 Kaplan, 2011(49) Heart failure 
cohort: 160 
NR 
Age reported 
by categories, 
rather than 
77 White: 79 
Black: 12 
Asian: 3 
Other: 1 
  
 
Patients completing EQ-5D at baseline, 1 
month and 6 months follow-up: 155; 136; 
110. 
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mean value. Missing: 5 
 Feeny, 2012(16) Heart failure 
cohort: 160 
NR 
Age reported 
by categories, 
rather than 
mean value. 
77 White: 79 
Black: 12 
Asian: 3 
Other: 1 
Missing:5 
  
 
Data available at baseline and 6 months 
follow-up for 110 patients  
 
Complete data for both time points for 86 
patients. 
 
Patients with missing data were older 
than those without (statistically 
significant difference) 
 
No other information reported 
 De Smedt, 
2013(18) 
8,966 63.1 (9.2) 75 NR Cardiac revascularisation as 
recruiting diagnosis: 60 
Reporting diabetes: 23.2 
History of stroke: 4.5 
Reported at least one recurrent 
coronary event since recruiting 
diagnosis: 13.3 
 
7,472 were included in the analysis (those 
that had complete data for both EQ-5D 
and SF-6D) 
 
 Withers, 2014(17) 800 57.8 (Range: 
17-88)) 
55 NR Atrial fibrillation:23.0 
 
791 were included in the analysis 
(patients were removed from the study 
as they were identified as duplicates (had 
moved houses or been retreated) or 
deceased  
 
SD, standard deviation; yr, year; NR, not reported; MI, Myocardial infarction; CHD, coronary heart disease; CABG, coronary artery bypass grafting;  NYHA, New York Heart 
Association; BL, baseline; CCSC, Canadian Cardiovascular Society Class; NHMS, National health measurement study; COMHS, Clinical outcomes and measurement of health 
study 
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Table A3: Valuation and descriptive methods used in studies included in the systematic review for cardiovascular conditions (WP 1.1) 
 GENERIC MEASURES OTHER MEASURES USED 
Study ref 
Author, Year 
Descriptive 
system  
Tariff used  Mean  (SD); 
95% CI 
Condition-specific 
HRQL measures  
Clinical 
measures  
Qualitative 
questions  
Missing data; completion rates of 
measures; etc.  
Schweikert, 
2006(24) 
EQ-5D European (0-
100)[Greiner, 2003] 
 MacNew  None None Acceptance of EQ-5D assessed by 
proportion of missing responses 
on EQ-5D SF-36   
van Stel, 2006(23) EQ-5D UK [Dolan, 1996] EQ-5D at 
baseline 
0.64 (SD NR; 
median 0.69) 
SF-6D at 
baseline 
0.62 (SD NR; 
median 0.60) 
 
 None None None % of missing data (BL and post-
intervention respectively): EQ-5D: 
9.1%, 15.9%; SF-6D:16.9%, 22.6%; 
SF-6D:16.9%, 22.6%; SF-6D after 
imputation of SF-36 missing 
items:10.9%, 16.8%; 
SF-6D   
Nowels, 2005(25) EQ-5D UK [Dolan, 1996] 0.73(SD NR)  QLMI CCSC None Only 99 patients completed the 
study 
SF-36  
Eurich, 2006(46) EQ-5D UK [Dolan, 1996] 
US [Shaw et al, 2005] 
EQ-5D at 
baseline, 
UK tariff: 
0.66 (SD 0.26) 
RAND12 at 
baseline: 
PCS: 35.0 (SD 
10.7) 
MCS: 48.4 (SD 
11.4) 
KCCQ None None Only 298 patients with complete 
data included in the study 
RAND12  
Spertus, 2005(47) EQ-5D UK [Dolan, 1996] 
 
EQ-5D at 
baseline: 
 KCCQ NYHA 
6-MW 
None Only 476 patients with complete 
data included in the study 
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SF-12  0.67 (SD 0.26) 
SF-12 at 
baseline: 
PCS: 35 (SD 11) 
MCS: 49 (SD 12) 
Physician 
global rate 
of change 
B-type 
natriuretic 
peptide 
 
De Smedt, 
2013(18) 
EQ-5D UK [Dolan, 1996] 
 
Means are 
reported by 
country and 
range between: 
EQ-5D: 0.76 (SD 
NR) 
SF-12: 
PCS: 42.14 (SD 
NR) 
MCS: 49.15 (SD 
NR) 
  None HADS None Only 8475 patients were included 
in the analysis 
 SF-12  
 Sut, 2011(13) EQ-5D 
Turkish 
version 
  
NR 
 
 0.79 (0.32)  MacNew None None 122 patients answered the 
questionnaires 
 Garster, 2009(14) EQ-5D  NR 
 
 EQ-5D;  
No CHD: 0.88 
(SD 0.15)  
CHD only: 0.82 
(SD 0.15) 
CHD + 
medication: 
0.74 (SD 0.21) 
 
 CVD-specific proxy 
score 
None None NHMS: 3,844 patients completed 
the study (46% response rate) 
COMHS: 154 patients completed 
the study, no other information 
reported 
SF-6D  
SF-36  
HUI2  
HUI3  
QWB-SA  
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 HALex  
 
Kontodimopoulos, 
2011(15) 
EQ-5D  UK [Dolan, 1996]  EQ-5D: 0.73(SD 
0.303; median 
0.796); 0.665  W 
0.741 
SF-6D: 0.710(SD 
0.136; median 
0.687); 0.693  W 
0.727 
  DASI 
 
None 251 patients included (98% 
response rate) 
 SF-6D SF-6D 
 Feeny, 2012(16) EQ-5D US [Shaw et al, 2005]  NR  MHLF None None Data available at baseline and 6 
months follow-up for 110 patients  
 
Complete data for both time 
points for 86 patients. 
 
SF-6D  
HUI2  
HUI3  
QWB-SA  
SRH  
 De Smedt, 
2014(19) 
EQ-5D UK [Dolan, 1996] 
 
 
Median EQ-5D : 
0.80 ( IQR:0.69-
1.00) 
Median SF-6D: 
0.70 (IQR: 0.62-
0.82) 
 
 
 None None None Only 7,472  patients were 
included in the analysis 
(complete data for both EQ-5D 
and SF-6D) 
 
 Withers, 2014(17) EQ-5D-5L Country not reported, 
refers to the EuroQoL 
crosswalk[EuroQoL 
group, 2013] 
NR 
 
 
Modified PPAQ 
 
Newly developed 
arrhythmia specific  
None None 791  patients were included in the 
analysis 
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questionnaire 
developed  
   
  
86 
 
Table A4: Acceptability, reliability and validity assessment in studies used studies included in the systematic review for cardiovascular conditions (WP 1.1) 
Author, Year Method of measuring validity 
Type of validity, how (e.g. known 
group/convergent)? 
Validity results 
Group A(n) vs. Group B(n)
Ƈ
 
Mean EQ-5D; mean difference in EQ-5D 
ƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ ?ŶŽƚĞƐ 
Schweikert, 2006(24) 
 
Acceptance and feasibility of EQ-5D 
assessed by proportion of missing and 
invalid responses 
EQ-5D questionnaire missing range: 0.6 to 
2.9% 
SF-36 missing range: 1.5 to 6.5% 
MacNew invalid answers range: 1.5 to 2.3% to 
4.8% 
Instrument well understood and accepted by 
patients with ACS 
 Construct validity, comparing subgroups:  
MI vs CABG patients: i.  % of patients citing 
no problems in each EQ-5D health 
dimensions at admission 
MI (% no; moderate; extreme problems) 
Mobility: 81.5; 18.5; 0 
Self-care: 100; 0; 0 
Usual activities: 55.8; 36.5;7.7 
Pain: 51.9; 48.1; 0 
Anxiety/depression: 50.0; 46.3.0; 3.7 
 
CABG (% no; moderate; extreme problems) 
Mobility: 61.4; 38.6; 0; p=0.03
a
 
Self-care: 77.3; 22.7; 0; p <0.001
b
 
Usual activities: 25.6; 51.2; 0; p=0.006
c
 
Pain: 15.9; 79.5; 4.6; p=0.002
a
 
Anxiety/depression: 52.3; 45.5; 2.3; p=0.822
a
 
 
% of patients citing no problems significantly 
higher among patients with MI than for 
patients after CABG, for all health dimensions 
except anxiety/depression. 
 
 
 Criterion validity: 
Association between EQ-5D self-classifier 
response level and median SF-36 subscale 
and McNew scores at admission. 
For all EQ-5D health dimensions , the median 
of the SF-36 and McNew subscales were 
ranked as expected and significantly different 
between groups (p<0.001) 
Reasonable criterion validity.  
 
EQ-5D correlates well with most subscales of 
SF-36, and MacNew questionnaire. 
 Reliability: 
Proportion of agreement between 
consecutive measures of EQ-5D self-
classifier for patients indicating unchanged 
HRQoL between time periods. 
Period 1: Health dimension (n): agreement 
(%), Kappa statistic 
 Mobility (n=11): 73%; k=0.24 
Self-care (n=11):  100%; k=1 
Usual activities (n=11): 55%; k=0.17 
Pain (n=11): 82%; k=0.62 
Anxiety/depression (n=11):: 65%; k=1 
 
Period 2 Health dimension (n): agreement 
EQ-5D has good test-retest validity, but may 
be due to ceiling effects. 
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(%), Kappa statistic  
Mobility (n=33): 88%; k=0.53 
Self-care (n=34): 70%; k=NA
e
 
Usual activities (n=33): 69%; k=0.43 
Pain (n=32): 82%; k=0.62 
Anxiety/depression (n=34): 65%; k=0.24 
 
van Stel, 2006(23) Acceptability: 
Not formally assessed, but the percentage 
of missing data by measure and time point 
was reported. 
% of missing data (BL and post-intervention 
respectively):  
EQ-5D: 9.1%, 15.9%;  
SF-6D:16.9%, 22.6%;  
 
Higher percentage of missing data for SF-6D 
on both periods 
 Discriminative validity: 
Tendency towards a single level response  
% patients reporting no problems at baseline 
for EQ-5D health dimensions: 
Mobility: 31.8% 
Self-care: 93.1% 
Usual activities: 30.5% 
Pain: 31.8% 
Anxiety/depression: 60% 
 
% reporting full-health at baseline for EQ-5D 
index: 
13.5% 
 
% patients reporting no problems at baseline 
for SF-6D health dimensions: 
Pain: 13.0% 
Mental health: 8.9% 
Physical functioning: 2.3% 
Social functioning: 20.1% 
Role limitations: 14.1% 
Vitality: 2.7% 
 
% patients reporting full-health at baseline for 
SF-6D score: 0.4% 
Evidence of ceiling effect for EQ-5D. 
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 Convergent validity: 
Spearman rank correlations between 
domains of SF-6D and EQ-5D  
 
ICC between utility scores of EQ-5D and SF-
6D 
Spearman correlations between like health 
dimensions of SF-6D and EQ-5D : 
Physical functioning and Mobility: 0.31
*
 
Physical functioning and Usual Activities: 0.42
* 
Role limitation and Usual Activities: 0.35
*
  
Social Functioning and Usual Activities: 0.41
* 
Pain and Pain/Discomfort:0.43
*
 
Mental Health and Anxiety/Depression: 0.47
*
 
 
Spearman correlations between remaining 
health dimensions of SF-6D and EQ-5D : 
Physical functioning and Self-care: 0.34
*
 
Physical functioning and Pain/Discomfort: 
0.24
*
 
Physical functioning and Anxiety/Depression: 
0.11
**
 
Role limitation and Mobility: 0.19
**
 
Role limitation and Self-care: 0.09 
Role limitation and Pain/Discomfort: 0.30
*
 
Role limitation and Anxiety/Depression: 0.21
*
 
Social Functioning and Mobility: 0.26
*
 
Social Functioning and Self-care: 0.20
**
 
Social Functioning and Pain/Discomfort: 0.36
* 
Social Functioning and Anxiety/Depression: 
0.34
* 
Pain and Mobility: 0.32
**
 
Pain and Self-care: 0.23
**
 
Pain and Usual Activities: 0.48
* 
 
Pain and Anxiety/Depression: 0.19
** 
Mental Health and Mobility: 0.04 
Mental Health and Self-care: 0.09 
Mental Health and Usual Activities: 0.09 
Mental Health and Pain: 0.17
** 
Vitality and Mobility: 0.20
*
 
Vitality and Self-care: 0.15
**
 
Vitality and Usual Activities: 0.27
*
 
Correlation structure was rather diffuse with 
only moderate correlations, which does not 
support construct validity. Only mood/mental 
health exhibited strong correlation with each 
other, and lower correlations with other 
health dimensions. 
 
Low ICC suggests lack of agreement. 
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Vitality and Pain/Discomfort: 0.26
*
 
Vitality and Anxiety/Depression: 0.27
*
 
 
ICC between EQ-5D and SF-6D scores:0.45 
Nowels, 2005(25) Convergent validity: 
Spearman rank correlations of EQ-5D 
domains with SF-36 and with QLMI. 
 
 
Spearman correlations between like domains 
of SF-36 and EQ-5D: 
Physical functioning and Mobility: 0.63 
Physical functioning and Usual Activities: 0.59 
Role limitation (physical) and Usual Activities: 
0.62 
Social Functioning and Usual Activities:0.50 
Pain and Pain/Discomfort: 0.68 
Mental Health and Anxiety/Depression: 0.75 
 
Spearman correlations between domains of 
QLMI and EQ-5D: 
Symptoms and Mobility: 0.47 
Symptoms and Self-care: 0.17 
Symptoms and Usual activities: 0.49 
Symptoms and Pain and Discomfort: 0.45 
Symptoms and Anxiety/Depression: 0.59 
Restriction and Mobility: 0.31 
Restriction and Self-care: 0.07 
Restriction and Usual activities: 0.45 
Restriction and Pain and Discomfort: 0.30 
Restriction and Anxiety/Depression: 0.53 
Confidence and Mobility: 0.34 
Confidence and Self-care: 0.07 
Confidence and Usual activities: 0.01 
Confidence and Pain and Discomfort: 0.38 
Confidence and Anxiety/Depression: 0.31 
Self-esteem and Mobility: 0.46 
Self-esteem and Self-care: 0.17 
Self-esteem and Usual activities: 0.56 
Self-esteem and Pain and Discomfort: 0.40 
Self-esteem and Anxiety/Depression: 0.48 
Authors state that convergent validity was 
demonstrated for the EQ-5D through 
moderate to high correlations with disease 
specific and general HRQoL instrument. 
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Emotion and Mobility: 0.41 
Emotion and Self-care: 0.31 
Emotion and Usual activities: 0.43 
Emotion and Pain and Discomfort: 0.31 
Emotion and Anxiety/Depression: 0.64 
 
Spearman correlations between EQ-5D index 
and QLMI total score: 0.57 
 Discriminative validity: 
Comparison of differences in EQ-5D index 
score between two groups based on their 
CCSC scores (I vs. II, III, or IV), using Mann-
Whitney rank-sum testing. 
 
Compared the means of EQ-5D index score 
between the CCSC class I and CCSC class II 
with a t-test and the respondents with 
Mann-Whitney rank-sum testing.  
EQ-5D index scores showed excellent 
discrimination (p<0.001) between patients 
with CCSC I compared to patients with either 
CCSC II, III or IV collectively. 
 
^ƉĞĂƌŵĂŶ ?ƐĐŽƌƌĞůĂƚŝŽŶĐŽĞĨĨŝĐŝĞŶƚďĞƚǁĞĞŶ
EQ-5D score and CCSC class grouping was 
0.36. 
 
Mean EQ-5D (SD) by CCSC: 
I: 0.78 (0.2) 
II: 0.72 (0.12) 
II, III, or III: 0.62 (NR) 
 
Non-parametric analysis showed significant 
differences in mean EQ-5D index scores 
(p<0.05, but t-test did not (p=0.1) 
Demonstrates that EQ-5D has discriminative 
validity.  
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De Smedt, 2013(18) 
 
Known-group validity:  
Assessment of the relationship of 
constructs with age, gender and education, 
using Kruskall-Wallis to test the hypothesis 
that quality of life would decrease with age, 
and lower education, and would be lower 
for females. 
EQ-5D mean by groups (Kruskall W allis p 
value<0.001 for all groups): 
 
Gender: 
Male: 0.78  
Female:0.69 
 
Age:  
< 50 years: 0.81 
50-59 years: 0.77 
60-69 years: 0.76 
 > 70 years: 0.72 
 
Education level: 
Primary education: 0.72 
Secondary education: 0.76 
High education: 0.80 
 
Discriminative validity was confirmed for all 
HRQoL measures including EQ-5D. 
 Convergent validity: 
^ƉĞĂƌŵĂŶ ?ƐĐŽƌƌĞůĂƚŝŽŶĨŽƌƚŚĞŽƌĞƚŝĐĂůůǇ
related constructs.  
Spearman correlations (CI 95%): 
EQ-5D index and HADS-A: -0.51 (-0.31;-0.61) 
EQ-5D index and HADS-D: -0.51 (-0.22;-0.63) 
EQ-5D index and SF-12 PCS: 0.64 (0.48;0.72) 
EQ-5D index and SF-12 MCS: 0.47 (0.20;0.61) 
EQ-5D index and SF-12 Q1: -0.51 (-0.33;-0.63) 
EQ-5D anx/dep and SF-12 Q6: -0.55(-0.47;-
0.66) 
Convergent validity was supported by the 
estimated correlations for all HRQoL measures 
including EQ-5D.  
Strong correlation between EQ-5D index and 
SF-12 Q1 confirmed good criterion validity. 
Sut, 2011(13) Construct validity: 
Defined as extent to which it correlates 
with criteria from an established measure, 
such as valid disease-specific instruments 
 
Spearman rank correlations between EQ-5D 
index and the macNew subscales and global 
scores  
Spearman rank correlations of EQ-5D index 
and: 
MacNew emotional subscale: 0.644
**
 
MacNew physical subscale: 0.721
**
 
MacNew social subscale: 0.557
**
 
MacNew global score: 0.688
**
 
 
Significant Spearman correlations between 
EQ-5D index scores and MacNew subscales 
shows the validity of the Turkish version of the 
EQ-5D (p<0.001).  
Garster, 2009(14) 
 
Discriminative validity:  
Comparison of adjusted and unadjusted 
Mean EQ-5D (SE) differences between: 
No CHD  W CHD only: -0.055(0.013); -
Little differences between generic indexes in 
their sensitivity to coronary heart disease 
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mean score differences scores between 
CHD group 
 
ES estimated between severity group 
 
0.047(0.013)
f
; -0.038(0.013)
g 
(p<0.001) 
No CHD  W CHD  with medication: -0.14(0.022); 
-0.12(0.023)
f
; -0.084(0.020)
g 
(p<0.001) 
P value by F-test across groups 
 
ES for proxy CVD score and EQ-5D, 
respectively: 
CHD only vs no CHD: 0.51; 0.32 
CHD  with medication vs CHD only: 0.62; 0.52 
CHD with medication  W no CHD: 1.13; 0.84 
related HRQoL. Effect sizes were in general of 
the same magnitude as for the CVD proxy 
score. 
 
Generic indexes can capture differences in 
HRQoL between populations with and without 
coronary heart disease. 
 Convergent validity:  
Correlations between proxy CVD scores and 
generic indexes, partial on age, sex, and 
race. 
Partial correlations between CVD proxy score 
and EQ-5D index: 
All NHMS sample:  -0.63 
NHMS all CHD sample: -0.65 
Partial correlations demonstrated that all of 
the generic indexes correlated highly with the 
CVD proxy score, in both the NHMS sample as 
a whole and in a subgroup of only those with 
CHD. 
Kontodimopoulos, 
2011(15) 
 
Convergent validity: 
Correlation and ICC between mean EQ-5D 
and SF-6D scores 
Pearson correlation: 0.647
**
 
 
ICC: 0.484, p<0.001 
Strong correlation between EQ-5D and SF-6D, 
despite level of agreement not being high. 
De Smedt, 2014(19) Convergent validity: 
Spearman rank correlations between utility 
scores of SF-6D and EQ-5D  
Spearman rank correlations between health 
dimensions of SF-6D and EQ-5D  
 
ICC between utility scores of SF-6D and EQ-
5D 
Spearman correlations between like SF-6D and 
EQ-5D utility scores: r=0.695
***
 
 
Spearman correlations between like health 
dimensions of SF-6D and EQ-5D
*
: 
Physical functioning and Mobility: 0.446 
Physical functioning and Usual Activities:0.504
 
Role limitation and Usual Activities: 0.390 
Social Functioning and Usual Activities: 0.403
 
Pain and Pain/Discomfort: 0.630 
Mental Health and Anxiety/Depression: 0.551 
 
Spearman correlations between remaining 
health dimensions of SF-6D and EQ-5D
***
 : 
Physical functioning and Self-care: 0.318 
Physical functioning and Pain/Discomfort: 
0.415 
Physical functioning and Anxiety/Depression: 
EQ-5D outcomes are significantly correlated 
with SF-6D values, with ICC indicating 
moderate agreement between instruments. 
 
Moderate correlations found between related 
health dimensions of the two instruments. 
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0.281 
Role limitation and Mobility: 0.338 
Role limitation and Self-care: 0.223 
Role limitation and Pain/Discomfort: 0.395 
Role limitation and Anxiety/Depression: 0.405 
Social Functioning and Mobility: 0.346 
Social Functioning and Self-care: 0.313 
Social Functioning and Pain/Discomfort: 0.390
 
Social Functioning and Anxiety/Depression: 
0.410
 
Pain and Mobility: 0.459 
Pain and Self-care: 0.321 
Pain and Usual Activities: 0.474
 
 
Pain and Anxiety/Depression: 0.338
 
Mental Health and Mobility: 0.268 
Mental Health and Self-care: 0.230 
Mental Health and Usual Activities: 0.321 
Mental Health and Pain: 0.354
 
Vitality and Mobility: 0.325 
Vitality and Self-care: 0.247 
Vitality and Usual Activities: 0.371 
Vitality and Pain/Discomfort: 0.343 
Vitality and Anxiety/Depression: 0.324 
 
ICC between utility scores of SF-6D and EQ-5D: 
0.536, p<0.01 
 Discriminative validity: 
Tendency towards a single level response 
Patients reporting full health: 
EQ-5D: 28.8% 
SF-6D: 4.2% 
Ceiling effect observed for EQ-5D instrument. 
Withers, 2014(17) 
 
Acceptability of EQ-5D assessed by 
proportion of complete responses for the 
overall PROM tool (3 instruments, for pre 
and post procedure) 
Response rate for following initial mailing 45-
50%, across centres 
Overall response rate for following reminders 
for non-responders: 
Across centres: 70-75% 
For all sample: 71.2% 
High response rates suggest that the PROM 
tool is acceptable. 
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Table A5: Responsiveness assessment studies included in the systematic review for cardiovascular conditions (WP 1.1) 
Author, Year 
 
Method of measuring 
responsiveness (e.g. effect 
sizes, statistical 
significance) 
Responsiveness results 
 
ƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ ?ŶŽƚĞƐ 
Spertus, 2005(47) 
 
Degree of clinical change 
assessed according 
validated rating of change 
assessment by cardiologist 
(7 categories: large (n=5), 
moderate (n=13), or small 
deterioration (n=35); no 
change (n=320); small 
(n=65), moderate (n=34), 
or large 
improvement(n=4)). 
 
t-tests to compare 
differences in mean change 
scores by change category 
for patients whose 
condition had changed as 
compared to stable 
patients 
c-statistics to compare 
responsiveness of EQ-5D 
with KCCQ,  SF-12, and 
NYHA by clinical change 
degree 
  
c-statistics represent % of 
the time that the measure 
correctly identified 
patients with clinical 
change for all possible 
EQ-5D (Index and VAS) and SF-12D did not show great sensitivity to 
changes in clinical condition, as measured by mean change scores.  
Differences were small and the majority was not statistically 
significant. Results were presented graphically. 
 
The EQ-5D Index c statistics ranged from approximately 0.56 (for 
small clinical improvements) to approximately 0.69 (for moderate to 
large clinical deterioration), performing worse than than the KCCQ 
and NYHA but similarly discriminative abilities to SF-12 PCS and MCS. 
Results are presented graphically. 
KCCQ and NHYA classification had a pattern 
consistent with the magnitude and direction of 
change. KCCQ was the most sensitive to clinical 
changes for groups of patients and for 
individual patients. 
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pairs of patients, one 
experiencing clinical 
change and one not. 
 
Eurich, 2006(46) 
 
Estimated mean changes in 
score and indices for all 
measures according to 
degree of change: 
ES
a
 
SRM
b
 
 
Clinical change defined 
according to three criteria: 
Change in NYHA:  
improving two NYHA 
classes, improving one 
NYHA class, no change in 
NYHA class, and 
deteriorating one NYHA 
class. 
Change global rating of 
change assessment (15 
points scale): substantially 
improved (+7, +6, +5), 
moderately improved 
(+4,+3,+2), no change (+1, 
0, -1), moderately 
deteriorated (-2, -3, -4), 
and substantially 
deteriorated (-5, -6, -7). 
Difference from baseline to 
6-weeks in distanced 
travelled in the 6 MW test: 
Substantially improved (A䠀 
+100 meters); moderately 
improved (+50 to +99 
Mean change in EQ-5D index (SD): 
 
NYHA change criteria: 
Improved +2 NYHA Classes (n=2): 0.04 (0.05) 
Improved +1 NYHA Classes (n=50): 0.02 (0.19) 
No Change in NHYA Class (n=206): 0.02 (0.20) 
Deteriorated -1 NYHA Classes (n=40): 0.00 (0.19) 
Deteriorated -2 NYHA Classes (n=0): - 
 
Change global rating of change assessment criteria: 
Substantially improved (n=7): 0.21 (0.26) 
Moderately improved (n=53): 0.03 (0.20) 
No change (n=206): 0.04 (0.19)  
Moderately deteriorated (n=30): -0.01 (0.19) 
Substantially deteriorated (n=2): -0.05 (0.07)  
 
Change in distance travelled in the 6-MW criteria: 
Substantially improved (n=28): 0.05 (0.16) 
Moderately improved (n=40): 0.08 (0.23) 
Small improvement (n=33): 0.05 (0.17) 
No change (n=114): 0.01 (0.17) 
Small deterioration (n=60): 0.06 (0.23) 
Moderately deteriorated (n=16): 0.03 (0.20) 
Substantially deteriorated (n=7): 0.00 (0.12) 
 
ES and SRM for EQ-5D index, respectively: 
 
NYHA change criteria: 
Improved +2 NYHA Classes (n=2): 0.20; 0.80 
Improved +1 NYHA Classes (n=50): 0.08; 0.11 
No Change in NHYA Class (n=206): 0.19; 0.25 
Deteriorated -1 NYHA Classes (n=40): 0.00; 0.00 
 
HRQoL measures more responsive to 
improvement than to deterioration in clinical 
status. 
 
Responsiveness will vary for the same generic 
HRQoL depending on responsiveness indices 
and external criterion used to identify clinical 
change. 
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meters), small 
improvement (+25 to +49 
meters), no change (+24 to 
-24 meters), small 
deterioration (-25 to -99 
meters), moderately 
deteriorated (- 100 to -199 
meters), and substantial 
deterioration (A䜀 -200 
meters). Substantially 
improved (A?A? ? ? ?ŵĞƚĞƌƐ ? ?
moderately improved (+50 
to +99 meters), small 
improvement (+25 to +49 
meters), no change (+24 to 
-24 meters), small 
deterioration 
(-25 to -99 meters), 
moderately deteriorated (- 
100 to -199 meters), and 
substantial dĞƚĞƌŝŽƌĂƚŝŽŶ ?A䜀 
-200 
meters). 
Deteriorated -2 NYHA Classes (n=0): - 
 
Change global rating of change assessment criteria: 
Substantially improved (n=7): 0.75;0.81 
Moderately improved (n=53): 0.13; 0.15 
No change (n=206): 0.15; 0.21  
Moderately deteriorated (n=30): -0.05; -0.05 
Substantially deteriorated (n=2): -0.15; -0.71  
 
Change in distance travelled in the 6-MW criteria: 
Substantially improved (n=28): 0.21; 0.31 
Moderately improved (n=40): 0.29; 0.35 
Small improvement (n=33): 0.22; 0.29 
No change (n=114): 0.04; 0.06 
Small deterioration (n=60): 0.23; 0.26 
Moderately deteriorated (n=16): 0.09; 0.15 
Substantially deteriorated (n=7): 0.00; 0.00 
 
 
KCCQ more responsive to clinical change than EQ-5D and RAND 12, 
across all responsiveness indices and criteria for change. 
EQ-5D appears to be more responsive for higher degrees of clinical 
improvement, than for smaller clinical changes, according to both 
NYHA and global rating of change. This is less evident for the 6 MW. 
. 
EQ-5D is slightly less responsive than RAND 12 (the difference is 
greater when compared to the mental component of RAND-12) 
Feeny, 2012(16) 
 
Agreement between the 
disease-targeted measure 
(MLHF) and each of the 
(EQ-5D, HUI2, HUI3, QWB-
SA, and SF-6D) preference-
based measures and SRH 
as to whether patients had 
improved, were stable, or 
got worse was assessed 
MLHF and EQ-5D (n=86): 
% agreement: 19% 
k-statistic: -0.25 (CI 95%: -0.37 to -0.13) 
Weighted k statistic: -0.30 (CI 95%: -0.45 to -0.15) 
Delta statistics not reported for individual measures but stated to 
range between -0.33 (QWB-SA) to 0.26 (self-reported health).  
 
  
Negligible agreement among measures on 
classification of patients as worse, stable or 
improved 
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using the of percentage 
agreement, k (unweighted 
and weighted), and  delta 
statistic. 
 
 Comparisons of number of 
patients experiencing 
change of HRQoL from 
baseline to 6 months 
according to MLHF and 
according to EQ-5D 
 
Patients who got worse according to MLHF (n=46): 
Got worse according to EQ-5D:11 
Stayed the same according to EQ-5D:16 
Showed improvement according to EQ-5D:19 
 
Patients who stayed the same according to MLHF (n=13): 
Got worse according to EQ-5D:6 
Stayed the same according to EQ-5D:2 
Showed improvement according to EQ-5D:5 
 
Patients who showed improvement according to MLHF (n=27): 
Got worse according to EQ-5D:16 
Stayed the same according to EQ-5D:8 
Showed improvement according to EQ-5D:3 
 
 
 
- 
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Table A6: Minimum Data Standard fields collected in the NACRM device dataset 
DEMOGRAPHICS 
 Hospital identifier, Patient case record number, NHS Number, Date Of birth, Sex, Postcode  
BASELINE DATA
 
 Date of first implant, Pre-device Aetiology, Pre-device Symptom, Electrocardiogram Indication for Device, 
Functional status (NYHA), LVEF , ICD Indication, PreDevice/Ablation QRS duration 
PROCEDURE
 
 Procedure Date, First operator (scrubbed) name, First operator (scrubbed) GMC number, Consultant 
Name, Consultant GMC number, Intervention category, Generator mode (Maximum system capability)  
PROCEDURE DETAILS - GENERATOR/DEVICE
 
  Generator/Device Procedure, Reason for generator change, Generator model, Generator serial number 
LEAD EXTRACTION
 
   Indication for Lead Extraction 
COMPLICATIONS  
  Acute complications 
 
Table A7: Non-Minimum Data Standard fields collected in the CRM device dataset  
DEMOGRAPHICS 
 Patient name (surname), Patient name (forename), Patient status 
BASELINE DATA
 
 Atrial rhythm at time of implant, Functional status (NYHA), QRS morphology (if greater than 120ms) 
PROCEDURE
 
 Second operator (scrubbed) name, Second operator (scrubbed) GMC number, Second operator grade, 
Consultant grade, Fluoroscopy time, Dose area product, Operation report/comment 
PROCEDURE DETAILS - GENERATOR/DEVICE
 
  Generator/Device implant site, Generator/Device manufacturer 
PROCEDURE DETAILS - LEAD
a 
  Lead intervention, Access, Pacing site, Indication for lead revision/change/removal, Lead manufacturer, 
Lead model, Lead serial number, Lead/Connector type  
LEAD EXTRACTION
 
  Methods used, Number of pacing leads removed completely, Number of pacing leads removed partially, 
Number of coronary sinus leads removed completely, Number of coronary sinus leads removed partially, 
Number of defibrillation (DF) leads removed completely, Number of DF leads removed partially 
COMPLICATIONS  
  Late complications 
FILE CLOSURE 
  Date of file closure, Device File Closure (reason) 
a
 Same set of fields for each type of lead: left ventricular lead (1,2); right ventricular lead (1,2); atrial lead (1,2); 
nonpacing defibrillation lead (1,2). 
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Table A8: Minimum Data Standard fields collected in the NACRM interventional procedures dataset 
DEMOGRAPHICS 
 Hospital identifier, Patient case record number, NHS Number, Date Of birth, Sex, Postcode  
BASELINE DATA
 
 Pre-procedure Aetiology (Underlying Heart Disease),  Pre-procedure Symptom (Ablation Indication),  
Other Documented Arrhythmia, Pre-procedure Arrhythmia 
PROCEDURE
 
 Procedure date, First operator name, First operator GMC number, Consultant name,  Consultant GMC 
number, Procedure type, Ablation procedure, Ablation attempted, Success, Acute complications 
ATRIAL FIBRILLATION ABLATION DETAILS
 
  Early Recurrence (within 24hrs)
a
,  European Heart Rhythm Association atrial fibrillation classification, 
NYHA functional status 
OUTCOME IN HOSPITAL
 
  No fields in the Minimum Data Standard 
FOLLOW-UP 
b 
  Complications (post discharge),  Outcomes: frequency of palpitations, Outcomes: duration of palpitations 
FOLLOW-UP QoL/PROMs 
  No fields in the Minimum Data Standard  
a
 This field has been deleted in the latest version of the dataset (version 3.05) 
b
 Only to be completed if the procedure was atrial fibrillation ablation 
Underlined fields are mandatory 
Table A10: Core mandatory fields collected in the National Heart Failure Audit  
PATIENT REGISTRATION 
 Hospital identifier Local patient identifier, Patient surname, Patient forename, Date Of birth, Sex, 
Postcode (of usual address) 
ADMISSION/READMISSION DETAILS
 
 Date of admission, Main place of care, Specialist input, Breathlessness
a
 (on admission), Peripheral 
oedema (on admission) 
MEDICAL HISTORY
 
 Ischaemic heart disease, Device therapy (prior to or during this admission), Valve disease, Hypertension, 
Diabetes, Asthma, Chronic obstructive pulmonary disease  
TREATMENT ON ADMISSION
 
  No mandatory fields 
PHYSICAL EXAMINATION
 
   Weight  (on admission/first recorded), Weight (on discharge /last recorded), Heart rate (on 
admission/first recorded),  Heart rate (on discharge /last recorded), Systolic blood pressure (on 
admission/first recorded), Systolic blood pressure (on discharge /last recorded) 
INVESTIGATIONS (all on discharge/last recorded) 
  Haemoglobin, Urea , Creatinine, Serum Sodium, Serum Potassium, Electrocardiogram, Echo (or other gold 
standard test e.g. MRI, nuclear scan or angiogram, recorded within 12 months of admission) 
TREATMENT ON DISCHARGE
b
 
  Angiotensin-converting-enzyme inhibitor, Angiotensin receptor blocker, Beta blocker, Loop diuretic, 
Thiazide or metolazone, Mineralocorticoid receptor antagonist, Digoxin 
DISCHARGE AND REFERRAL
b 
 Confirmed diagnosis of heart failure , Heart failure management plan, Stable on oral therapy after 
discharge planning, Review appointment with the heart failure multidisciplinary team, Date of review 
appointment, Referral to heart failure nurse follow-up, Referral to cardiac rehabilitation, Referral to 
cardiology follow-up, Date of discharge, , Death in hospital  
a 
corresponds to NYHA classification for heart failure severity 
b
if patient survived to discharge 
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Table A11: Non-mandatory (core and non-core) fields collected in National Heart Failure Audit 
PATIENT REGISTRATION 
 NHS number, Ethnic category, GP name 
ADMISSION/READMISSION DETAILS
 
 All fields are mandatory  
MEDICAL HISTORY
 
 Device mode (prior to or during this admission),  Congenital heart disease, Cerebral vascular accident , 
Alcohol (units/week), Smoking history 
TREATMENT ON ADMISSION
 
 Angiotensin-converting-enzyme(ACE) inhibitor, ACE inhibitor dose, ACE inhibitor contraindication, 
Angiotensin receptor blocker (ARB), ARB dose, Beta blocker, Beta blocker dose, Beta blocker 
contraindication, Loop diuretic, Loop diuretic dose, Thiazide or Metolazone, Thiazide dose, 
Mineralocorticoid receptor antagonist (MRA), MRA contraindication, MRA dose, Aspirin, Aspirin dose, 
Other oral anti-platelet, Digoxin, Digoxin dose, Calcium channel blocker (CCB), CCB dose, Statin, Statin 
dose, Warfarin, International normalized ratio (INR), Warfarin dose, Other oral anticoagulant, Other oral 
anticoagulant dose, Amiodarone, Amiodarone dose, Allopurinol, Allopurinol dose, Nonsteroidal anti-
inflammatory drug, Oral nitrates , Nitrate dose, Bronchodilators, Diabetes therapy, Ivabradine, Ivabradine 
dose, Hydralazine, Hydralazine dose 
PHYSICAL EXAMINATION
 
   All fields are mandatory  
INVESTIGATIONS (all on discharge/last recorded) 
  B-type Natriuretic Peptide (BNP), N-terminal prohormone of BNP, QRS duration,  MRI systolic dysfunction 
Chest x-ray cardiothoracic ratio, Chest  x-ray pulmonary oedema  
TREATMENT ON DISCHARGE
a
 
  ACE inhibitor dose, ACE inhibitor contraindication, ARB dose, Beta blocker dose, Beta blocker 
contraindication, Loop diuretic dose, Thiazide dose, MRA contraindication, MRA dose, Aspirin, Aspirin 
dose, Other oral anti-platelet, Digoxin dose, CCB, CCB dose, Statin, Statin dose, Warfarin, INR, Warfarin 
dose, Other oral anticoagulant, Other oral anticoagulant dose, Amiodarone, Amiodarone dose, 
Allopurinol, Allopurinol dose, NSAID, Oral nitrates, Nitrate dose, Bronchodilators, Diabetes therapy, 
Ivabradine, Ivabradine dose, Hydralazine, Hydralazine dose,  
DISCHARGE AND REFERRAL
a 
 Referral for cardiothoracic surgery, Referral for transplant, Referral to palliative care services 
a 
if patient survived to discharge 
Core fields are underlined 
 
 
 
Table A12: Minimum Data Standard fields collected in the PCI audit 
PATIENT DEMOGRAPHICS 
 NHS number, Birth date, Sex 
PRE-PROCEDURE DETAILS
 
 Indication for Intervention, Procedure Urgency, Cardiogenic shock (Pre-procedure), Date/time of 
symptom onset
a
, Date/Time arrival at First hospital
a
 , Date/Time arrival at PCI hospital
a
  
PROCEDURE DETAILS
 
 Vessels attempted, Date/Time of first balloon inflation
a
, PCI Hospital Outcome 
PREVIOUS MEDICAL HISTORY 
   Diabetes, Medical history, History of renal disease 
DISCHARGE DETAILS
 
  Status at discharge, Discharge Date 
a
 For primary PCI with symptom onset in community only 
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Table A13: Non Minimum Data Standard fields collected in the PCI audit 
PATIENT DEMOGRAPHICS 
 Patient Ethnic Group, Administrative category, Postcode of usual address 
PRE-PROCEDURE DETAILS
 
 Clinical Syndrome (requiring PCI), Indication for intervention, Canadian Cardiovascular Society  angina 
status (Pre-procedure; Stable only), NYHA Dyspnoea Status (Pre-procedure; Stable only), Admission route 
(ACS only), Presenting ECG (ACS only), Recent Lysis (ACS only), Cardiac Enzymes/Markers Raised, LVEF 
Category, LVEF, Number grafts present (Pre-operation), Number grafts patent (Pre-operation), Left main 
stem stenosis (Pre-PCI), Left anterior descending arteries (LAD) proximal stenosis (Pre-PCI), LAD  other 
stenosis (Pre-PCI), Right coronary arteries (RCA) stenosis (Pre-PCI), Circumflex coronary artery  (Cx) 
stenosis (Pre-PCI), Flow in IRA PreOp (ACS only), Ventilated PreOp, Drug therapy PreOp, Date/time of call 
for help (STEMI only), Referring Hospital, Date/time of ECG triggering primary PCI pathway (only for those 
developing STEMI while in hospital), Patient location at time of STEMI onset (for patients treated for 
acute STEMI only), PCI for stent thrombosis 
PROCEDURE DETAILS
 
 Date and time of operation, Consultant Responsible for Procedure, Primary Operator, Primary Operator 
status, Second Operator, Second Operator status, Third Operator, Third Operator status, Number of 
vessels attempted (not epicardial territories), Number of lesions attempted, Number of Chronic 
Occlusions attempted, Number Restenoses attempted, Number Instent stenoses attempted, Number 
Stents used, Number Drug-eluting stents used, Drug(s) eluted by stent(s) (drug based stents), 
Glycoproteins IIb/IIIa drug(s) used during procedure, Diagnostic device(s) used during procedure, 
Procedural device(s) used, Athero-thrombus removal device(s) used, Brachytherapy device(s) used, 
Emboli protection device(s) used, Circulatory support, Arterial management, Local Procedure Identifier, 
Follow on (Adhoc) procedure, Training procedure, Research procedure, Research title, Arterial access, 
Largest balloon/stent used, Longest stented / treated segment, Procedural Complication 
Arterial Complications, Time to bypass, Patient status during transfer to theatre 
Why no glycoproteins IIb/IIIA during procedure, Indication for stent, Surgical cover, Left Main Stem 
Protected, Consultant responsible for procedure GMC Number, Primary Operator GMC number 
Second Operator GMC number, Third Operator GMC number, PCI for stent thrombosis 
POST-PROCEDURE DETAILS
 
  Left Main Stem Stenosis (Post PCI), LAD Proximal Stenosis (Post PCI), LAD Other Stenosis (Post PCI), RCA 
Stenosis (PCI), Cx Stenosis (PCI), Number Lesions Successful, Number coronary grafts patent PostOp, Flow 
in infarct related artery PostOp (ACS), Operation report/comment, Device failure, Enzymes PostOp, 
Bleeding up to discharge 
PREVIOUS MEDICAL HISTORY
 
  Previous MI,  Previous CABG, Previous PCI, Family history of coronary artery disease, Smoking status 
INVESTIGATIONS AND INTERVENTIONS
 
  Height, Weight, Cholesterol, Creatinine, Q Wave on ECG, ECG ischaemia 
 CARDIAC ARREST AND CARDIOGENIC SHOCK 
  Out Of Hospital Cardiac Arrest, Presumed date / time of arrest, Ventilation, Arterial blood gas on arrival in 
cath lab: pH, Arterial blood gas on arrival in cath lab: Lactate, Arterial blood gas on arrival in cath lab: 
Base excess Glasgow Coma Scale on arrival in cath lab, Therapeutic Hypothermia, Other therapeutic 
hypothermia 
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Table A14: Mandatory and completeness assessment fields, collected in the NACSA 
PATIENT IDENTIFICATION AND DEMOGRAPHICS 
 Birth Date
a
, Sex
a
 
CARDIAC HISTORY
 
 Interval between surgery and last MI
a
 
PREVIOUS INTERVENTIONS 
   Previous cardiac surgery
a
 , Date of last cardiac operation 
ADDITIONAL MEDICAL HISTORY  AND RISK FACTORS
 
  Actual creatinine at time of Surgery
a
, Renal function/Dialysis
a
, History of pulmonary disease
a
, History of 
neurological dysfunction
a
, Extracardiac arteriopathy
a
, Pre-operative heart rhythm
a
 
CARDIAC INVESTIGATIONS
 
  Left ventricular function, Ejection fraction category
a
, Pulmonary artery systolic pressure
a
 
PRE-OPERATIVE STATUS AND SUPPORT
 
  Intravenous nitrates or any heparin
a
, Intravenous inotropes prior to anaesthesia
a
, Ventilated (Pre-
Operation)
a
, Cardiogenic shock (Pre-Operation)
 a
, Date and time of operation, Operative urgency
a
, 
Number of previous heart operations
a
, Responsible consultant surgeon, Responsible consultant 
Anaesthetist 
PROCEDURES CLASSIFIED BY GROUP
 
  CABG
a
, Valve
a
, Major Aortic
a
, Other Cardiac Procedures
a
 
OTHER CARDIAC PROCEDURES
 
  Other Actual Cardiac Procedures
a
 
VALVE SURGERY
 
  Reason for repeat aortic valve  operation
a
, Native mitral
 
valve pathology
a
, Reason for repeat mitral valve 
operation
a
, Native tricuspid valve pathology
a
, Reason for repeat tricuspid valve operation
a
, Native 
pulmonary valve pathology
a
, Reason for repeat pulmonary valve operation
a
,  
CARDIAC SUPPORT DEVICES - PRE-OPERATIVE
 
  Intra-aortic balloon pump used
a
, Impeller device used
a
, Ventricular assist device used
a
, Other support 
device used
a
 
CARDIAC SUPPORT DEVICES - INTRA-OPERATIVE
 
  Intra-aortic balloon pump used
a
, Impeller device used
a
, Ventricular assist device used
a
, Other support 
device used
a
 
CARDIAC SUPPORT DEVICES - POST-OPERATIVE
 
  Intra-aortic balloon pump used
a
,  Impeller device used
a
, Ventricular assist device used
a
, Other support 
device used
a
 
CARDIOPULMONARY BYPASS DATA
 
  Height, Weight 
POST-OPERATIVE COURSE
 
  Patient Status at discharge, Date of discharge / Date of death in hospital  
a 
Fields required for EuroSCORE risk adjustment of mortality estimates 
Underlined fields are mandatory 
 
 
Table A15: Other fields collected in the NACSA  
PATIENT IDENTIFICATION AND DEMOGRAPHICS 
 Hospital Identifier, NHS Number, Local Patient Identifier,  Patient Name (Surname), Patient Name 
(Forename),Postcode Of Usual Address 
ADMISSION DETAILS
 
 Admission Date, Administrative Category 
CARDIAC HISTORY
 
 Angina status pre-surgery, Dyspnoea status pre-surgery, Number of Previous MIs,  
PREVIOUS INTERVENTIONS 
  Previous PCI , Date of last cardiac operation 
RISK FACTORS FOR ACQUISITION OF CORONARY DISEASE
 
  Diabetes management, Cigarette smoking history, History of hypertension 
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ADDITIONAL MEDICAL HISTORY  AND RISK FACTORS
 
  History of neurological disease 
CARDIAC INVESTIGATIONS
 
  Left heart catheterisation, Date of last catheterisation, Extent of coronary vessel disease, Left main stem 
disease, Severity of Aortic Valve Stenosis (EOA in cm
2
), Severity of Aortic Valve Stenosis (Gradient mmHg), 
Category of aortic valve stenosis 
PRE-OPERATIVE STATUS AND SUPPORT
 
  First Operator, First operator grade, First operator - Calman year of trainee, First assistant, First assistant 
grade, First assistant - Calman year of trainee 
CORONARY ARTERY SURGERY
 
  Total number of distal coronary anastomoses, Graft Site, Graft Conduit, Graft Anastomosis 
VALVE SURGERY
 
  Number of valves replaced/repaired, Aortic valve haemodynamic pathology,  Aortic valve type, Native 
aortic valve pathology, Native aortic valve other pathology, Other reason for repeat aortic valve 
replacement, Aortic valve procedure, Aortic valve implant type, Aortic implant prosthesis name, Aortic 
implant prosthesis model, Aortic valve or ring serial number, Aortic valve or ring size (mm), Mitral valve 
haemodynamic pathology, Mitral valve type, Native mitral valve other pathology, Other reason for repeat 
mitral valve replacement, Mitral valve procedure, Mitral valve implant type, Mitral implant prosthesis 
name, Mitral implant prosthesis model, Mitral valve serial number, Mitral valve size, Tricuspid valve 
haemodynamic pathology, Tricuspid valve type, Native Tricuspid valve other pathology, Other reason for 
repeat tricuspid valve replacement, Tricuspid valve procedure, Tricuspid valve implant type, Tricuspid 
implant prosthesis name, Tricuspid implant prosthesis model, Tricuspid valve serial number, Tricuspid 
valve size, Pulmonary valve haemodynamic pathology, Pulmonary valve type, , Native pulmonary valve 
other pathology, Other reason for repeat pulmonary valve replacement, Pulmonary valve procedure, 
Pulmonary valve implant type, Pulmonary implant prosthesis name, Pulmonary implant prosthesis model, 
Pulmonary valve serial number, Pulmonary valve size 
Aorta procedure
 
  Number of aorta segments operated on, Presentation, Aetiology, Aortic pathology - Root Segment Code 
1, Aortic pathology - Ascending Segment Code 2, Aortic procedure  W Ascending Segment Code 2, 
Aortic pathology - Arch Segment Code 3, Aortic procedure  W Arch, Segment Code 3, Aortic pathology - 
Descending Aorta Segment Code 4, "Aortic procedure - Descending Aorta,  Segment Code 4", Aortic 
pathology - Abdomninal Segment Code 5, Aortic procedure - Abdominal Segment Code 5, 
Neuroprotection 
CARDIOPULMONARY BYPASS DATA
 
  Cardiopulmonary bypass, Predominant method of myocardial protection, Cardioplegia  W Solution, 
Cardioplegia  W Temperature, Cardioplegia - Infusion mode, Cardioplegia  W Timing, Non-cardioplegic 
myocardial protection 
CARDIAC SUPPORT DEVICES  - PRE-OPERATIVE
 
  Reason for Intra-aortic balloon pump use, Reason for impeller device use, Reason for Ventricular assist 
device use, Reason for use of Other Support device 
CARDIAC SUPPORT DEVICES  - INTRA-OPERATIVE
 
  Reason for Intra-aortic balloon pump use, Reason for impeller device use, Reason for Ventricular assist 
device use, Reason for use of Other Support device 
CARDIAC SUPPORT DEVICES  - POST-OPERATIVE
 
  Reason for Intra-aortic balloon pump use, Reason for impeller device use, Reason for Ventricular assist 
device use, Reason for use of Other Support device 
CPB DATA
 
  Height, Weight, Cumulative bypass time, Cumulative cross clamp time, Total circulatory arrest time 
POST-OPERATIVE COURSE
 
  Return to Theatre, Deep Sternal wound infection, Deep Sternal wound infection treatment, New post-
operative neurological dysfunction, New haemofiltration or dialysis post-operatively, Discharge 
destination from cardiothoracic ward 
GRAFT DATA
a
 
 Anastamosis contructed by (distal and proximal) 
AORTIC VALVE PROCEDURE DATA
a
 
 Aortotomy, Excision of valve, Decalcification of annulus, Implantation of valve, Closure of aortotomy, De-
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airing of heart 
MITRAL VALVE PROCEDURE DATA
a
 
 Bi-caval cannulation, Access to mitral valve, Assessment and repair, Excision of valve and annular 
debridement, Repair of valve, Ring, Implantation of valve, Atrial closure, De-airing of heart 
PREPARATION FOR BYPASS
a
 
 Sterntomy, Thoracotomy, Cannulation, Weaning, Sternal closure, Thoracotomy closure 
RISK SCORING
a
 
 Additive Euroscore, Logistic Euroscore 
CONDUIT HARVEST
a
 
 Left internal mammary artery, Right internal mammary artery, Lesser saphenous vein, Shorter saphenous 
vein, Radial, Other vein, Other artery, Sub-procedure 
a
 Fields that only are required for the trainee dataset, and that are filled in by the trainees.  
 
Table A16: Mandatory fields collected in the MINAP for STEMI 
DEMOGRAPHICS 
 Hospital identifier, NHS number, Patient surname, Patient forename, Date of birth, Sex, Postcode, GP/ 
PCT code 
ADMISSION DETAILS
 
 Initial diagnosis, Procedure performed at the interventional hospital, Date/time of symptom onset, 
Date/time of call for help, Ambulance Job Number, Date/time arrival at hospital, Admission method, 
Referring hospital code 
REPERFUSION
 
 Initial reperfusion treatment, Electrocardiogram determining treatment, Location of initial reperfusion 
treatment, Date/time of reperfusion treatment, Delay before treatment, Reason reperfusion treatment 
not given, Additional reperfusion treatment , Patient location at time of STEMI 
EXAMINATIONS
 
  Systolic blood pressure, Heart rate, Killip class 
TESTS
 
  Serum glucose, Creatinine, Raised cardiac markers, Peak troponin 
PREVIOUS MEDICAL HISTORY 
  No mandatory fields 
DRUG THERAPY 
  No mandatory fields 
DRUG THERAPY AT DISCHARGE
 
 Beta blocker, Angiotensin converting enzyme inhibitor or angiotensin receptor blocker, Statin, Aspirin, 
Thienopyridine inhibitor, Aldosterone antagonist, Ticagrelor  
DIABETES/HYPERGLYCAEMIA MANAGEMENT
 
 In patient management of hyperglycaemia/diabetes 
COMPLICATIONS
 
 Death in hospital 
CARDIAC ARREST
 
 Cardiac arrest location 
INVESTIGATIONS AND INTERVENTIONS
 
 Daycase transfer date, Interventional centre code 
DISCHARGE DETAILS
 
 Date of discharge, Discharge diagnosis, Discharge destination 
National Institute for Health and Care Excellence (NI) MI CRITERIA
 
 No mandatory fields  
INTERVENTIONAL AUDITa
 
 Date/time of arrival at non interventional hospital, Assessment at non interventional hospital, 
Assessment at interventional centre, Intended reperfusion procedure, Procedure performed, Reason for 
no angiogram performed, Reason for no intervention performed 
a 
only for interventional hospitals 
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Table A17: Mandatory fields collected in the MINAP for NSTEMI 
DEMOGRAPHICS 
 Hospital identifier, NHS number, Patient surname, Patient forename, Date of birth, Sex, Postcode, GP/ 
PCT code 
ADMISSION DETAILS
 
 Initial diagnosis, Ambulance Job Number, Date/time arrival at hospital, Admission method, Admission 
ward, Referring hospital code 
REPERFUSION
 
 Electrocardiogram determining treatment 
EXAMINATIONS
 
  Systolic blood pressure, Heart rate, Killip class 
TESTS
 
  Serum glucose, Creatinine raised cardiac markers , Peak troponin 
PREVIOUS MEDICAL HISTORY 
  Smoking status, Diabetes 
DRUG THERAPY 
  Previous statin use, Thienopyridine platelet inhibitor 
DRUG THERAPY AT DISCHARGE
 
 Beta blocker, Angiotensin converting enzyme inhibitor or angiotensin receptor blocker, Statin,  Aspirin, 
Thienopyridine inhibitor, Aldosterone antagonist, Ticagrelor  
DIABETES/HYPERGLYCAEMIA MANAGEMENT
 
 In patient management of hyperglycaemia/diabetes 
COMPLICATIONS
 
 Bleeding complications, Death in hospital 
CARDIAC ARREST
 
 Cardiac arrest location 
INVESTIGATIONS AND INTERVENTIONS
 
 Coronary angiography, Coronary intervention, Date/time of referral for investigation/intervention, Delay 
to performance of angiogram, Angio date/time, Local intervention date, Interventional centre code 
DISCHARGE DETAILS
 
 Date of discharge, Discharge diagnosis, Cardiological care during admission 
NICE MI CRITERIA
 
 No mandatory fields  
INTERVENTIONAL AUDIT
a 
 Not applicable 
a 
only for interventional hospitals 
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Table A18: Non-mandatory fields collected in the MINAP for STEMI 
DEMOGRAPHICS 
 Patient ethnicity 
ADMISSION DETAILS
 
 Date/time of arrival of first responder, Date/time of arrival of ambulance, Admission ward, Admitting 
consultant, Where was aspirin/other antiplatelet given?, Place first 12 lead electrocardiogram performed 
REPERFUSION
 
 Electrocardiogram QRS complex duration, Site of infarction 
EXAMINATIONS
 
  Weight, Height 
TESTS
 
  Serum cholesterol, Haemoglobin, Troponin assay, Exercise test, Echocardiography, Radionuclide study, 
Stress echo, Left ventricular ejection fraction 
PREVIOUS MEDICAL HISTORY 
  Previous MI, Previous angina, Hypertension, Hypercholesterolaemia, Peripheral vascular disease, 
Cerebrovascular disease, Asthma or COPD, Heart failure, Smoking status, Diabetes, Previous PCI, Previous 
CABG, Family history of CHD 
DRUG THERAPY 
  Previous beta blocker use, Previous angiotensin converting enzyme inhibitor (ACEI) or angiotensin 
receptor blocker (ARB),Previous statin use, Previous thienopyridine inhibitor use, Unfractionated heparin, 
Low molecular weight heparin, Thienopyridine platelet inhibitor, IV 2b/3a agent, IV beta blocker, Oral 
beta blocker, Calcium channel blocker, IV nitrate, Oral nitrate, Potassium channel modulator, Warfarin,  
ACEI or ARB, Thiazide diuretic, Loop diuretic, Thrombolytic drug, Aldosterone antagonist, Fondaparinux, 
Bivalirudin 
DRUG THERAPY AT DISCHARGE
 
 All fields mandatory 
DIABETES/HYPERGLYCAEMIA MANAGEMENT
 
 Diabetic therapy at discharge, Date/time of start of insulin infusion 
COMPLICATIONS
 
 Bleeding complications, Reinfarction 
CARDIAC ARREST
 
 Cardiac arrest date/time (first arrest only), Arrest presenting rhythm, Outcome of arrest 
INVESTIGATIONS AND INTERVENTIONS
 
 Date of return to referring hospital  
DISCHARGE DETAILS
 
 Followed up by, Cardiological care during admission, Cardiac rehabilitation 
NICE MI CRITERIA
 
 Smoking cessation advice given, Dietary advice given during this admission 
INTERVENTIONAL AUDIT
a 
 All fields mandatory 
a 
only for interventional hospitals 
 
Table A19: Non-mandatory fields collected in the MINAP for NSTEMI 
DEMOGRAPHICS 
 Patient ethnicity 
ADMISSION DETAILS
 
 Date/time of symptom onset, Date/time of call for help, Date/time of arrival of first responder, Date/time 
of arrival of ambulance, Admitting consultant, Where was aspirin/other antiplatelet given?, Place first 12 
lead electrocardiogram performed 
REPERFUSION
 
 Electrocardiogram QRS complex duration 
EXAMINATIONS
 
  Weight, Height 
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TESTS
 
  Serum cholesterol, Haemoglobin, Troponin assay, Exercise test, Echocardiography, Radionuclide study, 
Stress echo, Left ventricular ejection fraction 
PREVIOUS MEDICAL HISTORY 
  Previous MI, Previous angina, Hypertension, Hypercholesterolaemia, Peripheral vascular disease, 
Cerebrovascular disease, Asthma or COPD, Heart failure, Previous PCI, Previous CABG, Family history of 
CHD 
DRUG THERAPY 
  Previous beta blocker use, Previous ACEI or ARB, Previous thienopyridine inhibitor use, Unfractionated 
heparin, Low molecular weight heparin, IV 2b/3a agent, IV beta blocker, Oral beta blocker, Calcium 
channel blocker, IV nitrate, Oral nitrate, Potassium channel modulator, Warfarin,  ACEI or ARB, Thiazide 
diuretic, Loop diuretic, Aldosterone antagonist, Fondaparinux, Bivalirudin 
DRUG THERAPY AT DISCHARGE
 
 All fields mandatory 
DIABETES/HYPERGLYCAEMIA MANAGEMENT
 
 Diabetic therapy at discharge, Date/time of start of insulin infusion 
COMPLICATIONS
 
 Reinfarction 
CARDIAC ARREST
 
 Cardiac arrest date/time (first arrest only), Arrest presenting rhythm, Outcome of arrest 
INVESTIGATIONS AND INTERVENTIONS
 
 Daycase transfer date, Date of return to referring hospital  
DISCHARGE DETAILS
 
 Discharge destination, Followed up by, Cardiac rehabilitation 
NICE MI CRITERIA
 
 Smoking cessation advice given, Dietary advice given during this admission 
INTERVENTIONAL AUDIT
a 
 Not applicable 
a 
only for interventional hospitals 
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